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Abstract
Global tests are a key research endpoint in multivariate studies. They provide an
omnibus assessment of the overall effects across the multivariate outcomes. This
global evaluation is clearly of high practical value in the field of neuroimaging,
which has become increasingly important in recent years. Existing global testing
methodologies, however, fail to accommodate the demands of neuroimaging studies
that have typically small sample sizes and highly correlated local outcomes.
In this thesis a novel class of multivariate global tests is developed. The
proposed tests are based on a formal framework for using prior information and
accumulated data to learn the effect direction. This framework is used to construct
test statistics that target the estimated effect direction, rather than the whole multi-
variate space, for detecting global effects. Adaptive designs are employed to allow for
sequential modifications of the test statistics, based on accumulated data, without
inflating the type I error.
A major focus in our methodology is power performance. The proposed tests
are shown to be optimal in terms of predictive power. Furthermore, a power charac-
terisation allowing us to explain the behaviour of our tests and perform simple power
analysis is derived. An extensive power analysis, including comparisons to alterna-
tive global tests, is performed. Applications to neuroimaging studies are illustrated
through two real examples. Our results show that the developed methodology can
be particularly useful in cases where the sample sizes are small and prior information
about the effect direction is available.
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Chapter 1
Introduction
Multiple outcomes emerge in almost every area of scientific investigation. Natu-
rally, when performing a scientific study, researchers wish to monitor a number of
measures for each experimental unit. With more measures recorded and explored,
one can develop greater knowledge about the problem. This multiplicity, however,
does not solely arise from scientific curiosity and luxury to collect more information,
but often because of the nature of the problem which implies that a single isolated
measure is not sufficient to answer key experimental questions. Particularly, in med-
ical studies, to evaluate the effects of a treatment on subjects, multiple symptoms
and bodily functions need to be monitored. This situation occurs in many other
fields of statistical application including industry, economics, ecology, biology and
psychology, in cases where multiple events or phenomena are essential to evaluate
an effect of interest.
A fundamental question arising in experimental studies, regardless of whether
single or multiple outcomes are evaluated, is whether the results provide significant
evidence for the existence of the effect of interest or not. This is most often a
key question. In the presence of multiple outcomes, it is translated as whether the
results provide significant evidence for an overall effect. An omnibus assessment
throughout the multiple outcomes is then required. The global null hypothesis of
1
no treatment effect in any of the multiple outcomes is formed and suitable testing
procedures are constructed. These global tests, as opposed to being interested in
detecting “local” effects, as in effects on specific outcomes, simultaneously evaluate
multiple outcomes to provide a global statement for the presence of the treatment
effect.
Global testing is a classical field of statistical inference with several different
approaches being available. Multiple testing methods, such as Bonferroni correction,
can be used to evaluate global hypotheses. These are typically simple procedures,
usually constructed under weak modeling assumptions, but they become conserva-
tive if the multiple outcomes are highly correlated. In the latter case, it is often
useful to consider the multiple outcomes as multivariate observations and to incor-
porate correlations into the modeling assumptions. This multivariate approach is
especially appropriate when the multiple outcomes are biologically (or in some other
context) related. The classical multivariate global test, Hotelling’s T 2, can efficiently
detect effects in every direction of the multivariate space, when the sample size of
the study, n, is sufficiently large. However, in settings where n approaches or be-
comes smaller than the observation dimension K, the T 2 test becomes respectively
inefficient and inapplicable. This cost in efficiency, paid because of searching in ev-
ery direction of the alternative space, seems particularly wasteful if prior knowledge
about the direction of the effect is available.
The present thesis investigates global testing procedures in the presence of
multivariate observations. This work is motivated by an area which introduces new
challenges in global testing, highlighting some deficiencies of existing methodology
and necessitating the demand for novel methodology. This is the very exciting, and
rich in statistical applications, field of neuroimaging.
Neuroimaging uses powerful techniques, such as Magnetic Resonance Imag-
ing (MRI), to explore the anatomy, function and pharmacology of the normal and
abnormal brain. In neuroimaging studies, the global question whether the measures
2
of neural activity at various brain locations suggest a significant overall treatment
effect is fundamental. These local neural measures, even after substantial sum-
marisation, can have relatively large dimension. Furthermore, these measures are
typically highly correlated and the effects across them are often dispersed in the
sense that they are locally small, but, if combined, globally large. Another property
of neuroimaging studies is that the great amount of research in the area and the
spatial characterization of neural measures typically provide the researchers prior
information about various aspects of their investigation. Finally, the high cost of
neuroimaging equipment and expertise typically restricts sample size of neuroimag-
ing studies to small levels.
These properties are taken into consideration in the present thesis to develop
novel methodology for global testing. Multivariate assumptions are imposed on the
observation vectors enabling us to incorporate correlations and combine dispersed
local effects for a single global evaluation. The proposed tests are based on linear
combinations of the observation vectors. The crucial element in this approach is
the weighting vector reducing the observation vectors to scalar linear combinations.
This defines the direction in which we decide to search for effects, and it can sub-
stantially affect both type I and type II error rates of the tests. A formal framework
for selecting the weighting vector using prior information and pilot data without
inflating the type I error is developed. This enables the proposed tests to attain
high power levels for large sample sizes, but can be efficient even in situations where
the sample size is limited to relatively low values.
In a major development of our methodology, global testing procedures are
implemented within an adaptive design framework. Adaptive designs allow for in-
terim design modifications, based on the observed data, without inflating the type
I error rate. The use of adaptive design methodology increases the possible actions
of the proposed procedures and can potentially improve efficiency. The global test
statistics, initially constructed based on prior information, are sequential updated
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based on accumulated data at subsequent interim analyses. Early termination of
the study, due to early acceptance or rejection of the null hypothesis at interim
analyses, is also possible within the adaptive design framework.
While the developed tests are analytically proved to control type I error, a
major focus of our methodology is power performance. The test statistics of the
constructed procedures are derived to be optimal, within the class of linear com-
bination tests, with respect to predictive power given the information available at
interim analyses. Furthermore, a framework for performing power analysis of lin-
ear combination tests is derived. In this, we reduce the complexities in performing
power analysis of linear combination tests, by re-expressing the possibly high dimen-
sional design space as a lower dimensional easily interpretable space, that is, still
sufficient to determine power. These results provide wide understanding of the be-
haviour of linear combination tests and allow us to perform relatively simple power
analysis. The main results of an extensive power analysis, including comparisons to
alternative tests and application to neuroimaging studies, is provided in this thesis.
Finally, it is useful to note here that the methodology developed in this thesis
is motivated by neuroimaging studies, but our framework is rather more generic
and can be applied for multivariate global testing in many other fields. Biomedical
studies and particularly clinical trials would likely provide an area of application.
Clinical trials are studies undertaken to examine the effects of different medical
interventions on human subjects [Friedman et al., 2010]. The issues of multiple
outcomes, global testing, error rates control are often crucial in clinical trials and
this is addressed by the present thesis.
1.1 Outline of the thesis
The remainder of this thesis is structured as follows.
In chapter 2, the motivating application of neuroimaging studies is intro-
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duced. I briefly summarize the current state of the field, focusing on the two neu-
roimaging modalities, functional MRI (fMRI) and Electroencephalography (EEG),
which I target in this work. fMRI and EEG data analysis is then discussed with
special attention given to the types of preparatory analysis that generated the two
datasets used throughout this thesis to illustrate applications of various global tests.
In chapter 3, we discuss the problem of testing global hypotheses. Various
global tests available in the literature are discussed, with special attention given
to their strengths and weaknesses. We first briefly discuss p−value adjustment
methods, such as the Bonferroni global test. We then proceed to multivariate global
tests which are the broad focus of this thesis. We discuss the fully multivariate χ2
and Hotelling’s T 2 tests and briefly introduce one-sided multivariate tests. Finally,
we proceed to the class of linear combination tests which is the specific area of
focus in this thesis. Here, we describe the available approaches in the literature
and address the weaknesses which we attempt to mitigate using the methodology
developed in later chapters.
In chapter 4, we develop novel methodology for performing linear combi-
nation tests. The class of linear combination tests is first formally introduced.
Then, power-optimal linear combination tests are derived. Using this result, links
to O’Brien linear combination and Hotelling’s T 2 test are derived. The power-
optimal linear combination tests use weighting vectors which depend on unknown
model parameters. The weighting vectors which maximise predictive power given
prior information and preliminary data obtained from a pilot study are then derived.
The proposed z+ and t+ tests are discussed, while a comparison to the alternative
approach of a fully Bayesian test is also provided.
Adaptive designs provide the possibility of substantially improving the tests
developed in chapter 4. In chapter 5, the framework of adaptive design methodol-
ogy is introduced. Here sequential designs are also discussed as they are strongly
related, both conceptually and methodologically, to adaptive designs and they pro-
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vide the framework for various alternative global tests considered for comparison to
the developed methodology. The concepts that give rise to sequential and adaptive
designs are first discussed. Group sequential and adaptive testing is next developed
with the main attention given to the combination tests used in our methodology.
Finally, we briefly describe various types of applications of these designs available
in the literature, while the chapter is closed with a discussion for the current state,
challenges and potentials of the field.
In chapter 6, we develop a methodology for performing adaptive linear com-
bination tests. First, we formulate the J−stage tests with stage-wise statistics
obtained via linear combinations. The power-optimal J−stage linear combination
tests are then derived. The latter tests use weighting vectors which depend on
the unknown modelling parameters. For practical implementation, a framework for
sequentially updating the weighting vector, initially constructed based on prior in-
formation, using the data observed at interim analyses is constructed. Adaptation
rules maximising the predictive power given the interim results are derived. These
tests are analytically proved to control type I error.
The problem of performing power analysis of multivariate global tests and
particularly linear combination tests is discussed in chapter 7. We derive a power
characterisation of linear combination tests in terms of low-dimensional easily inter-
pretable parameter summaries. The implications of these results, with respect to
our understanding for linear combination tests and for performing power analysis,
are discussed.
In chapter 8, the main results of an extensive power analysis are presented.
We start by describing the effect of various design and model parameters on power
performance. Comparisons between various global tests, including the constructed
procedures, are next provided. Finally, application of various global tests on our
real examples of an fMRI and an EEG study are considered.
The thesis finishes with a discussion of the main results as well as possible
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future developments and extensions of the proposed methodology.
Appendix A provides some proofs of the results in chapter 6.
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Chapter 2
Neuroimaging studies
2.1 Introduction
In this chapter, we attempt to outline the enormously exciting field of neuroimaging
which has motivated the methodology developed in this thesis. Our target is to
establish our motivations and to provide the necessary background to understand
the examples to which we apply our methods.
We first briefly provide some background about neuroimaging and its current
state. We then provide some more details on the neuroimaging modalities, fMRI and
EEG, in which we are most interested. Here, we discuss fMRI and EEG data analysis
and particularly Regions of Interest (ROI) analysis of fMRI data and frequency
analysis of EEG data from which our real datasets are derived. We also introduce our
real examples arising from a fMRI drug development study and an EEG depression
study.
2.2 Neuroimaging
The study of the human brain has a long history tracing back at least to the father
of western medicine Hippocrates. Since then, scientists from many disciplines in-
cluding mathematics, physics, chemistry, biology, medicine and psychology studied
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different aspects of the nervous system. In the late 1960s, scientists of all these
disciplines decided to merge their knowledge under an interdisciplinary field coined
neuroscience. The Society of Neuroscience, formed in 1971, set a common principal
target for neuroscientists: to understand the structure and function of the normal
and abnormal brain. This initiated an era of revolutionary achievements and great
public interest with neuroscience being one of the leading areas of science today
and the Society of Neuroscience being, according to Bear et al. [2007], the “largest
and fastest-growing association of professional scientists in all experimental biology”
[Bear et al., 2007; Squire et al., 2008].
Neuroimaging is the branch of neuroscience that uses various techniques to
create images of the structure, function and/or pharmacology of the brain. Struc-
tural neuroimaging targets the description of brain anatomy, while functional neu-
roimaging attempts to describe the functional organization of the brain [Squire et al.,
2008]. Technological development enabled the invention of various neuroimaging
techniques over the 20th century [Raichle, 2000]. The consecutive discoveries of
Positron Emission Tomography (PET) in 1980s and especially fMRI [Ogawa et al.,
1992] in early 1990s led to an explosion of interest in functional neuroimaging over
the last decades (see for example Friston [2009]).
Neuroimaging is now the predominant technique in behavioral and cogni-
tive neuroscience [Cabeza et al., 2001; Friston, 2009] and it has a fast-growing role
in psychiatry [Phillips, 2012], evidence-based neurology [Burneo et al., 2011] and
image-guided neurosurgery [Aquilina et al., 2005]. An emerging application of neu-
roimaging is in the discovery and development of drugs for the treatment of disorders
of the Central Nervous System (CNS). This is regarded by many authors as a great
opportunity to respond to the increasing burden of CNS disorders by improving
the efficiency of current practice in CNS drug development [Matthews et al., 2011;
Wong et al., 2008].
Neuroimaging provides non-invasive and safe methods for rapid data acqui-
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sition. Using the various modalities of neuroimaging, the living human brain can be
studied with great spatio-temporal resolution while activated and possibly engaged
to symptom-related tasks. Many authors have argued that neuroimaging can play
an important role in early stages of drug development by providing objective mark-
ers of brain activity. Imaging biomarkers can replace subjective behavioral measures
especially to support proof-of-concept studies and go/no-go decision making. At the
current time, neuroimaging techniques are (strictly) not validated for drug develop-
ment, but most major pharmaceutical companies are embracing this technology by
establishing it in-house or via academic collaborations [Borsook et al., 2011; Wise
and Tracey, 2006].
Nevertheless, there are several challenges to be overcome before these tech-
niques become further established. The signal of various important neuroimaging
modalities needs to be better understood and neuroimaging traits of CNS diseases
need to be established. The high cost of the equipment and the need for trained
individuals to run the experiments most often limits the sample size of the studies,
while the pressure for efficiency remains high. Hence, there is a need for standard-
ized statistical methodologies specialized to neuroimaging data analysis [Borsook
et al., 2011; Whitcher and Matthews, 2006]. We respond to the latter problems,
as we explain later, by providing methodology which uses the special properties of
neuroimaging to achieve high efficiency even in settings with small sample sizes.
The modalities of functional neuroimaging can be broadly separated into two
categories. The first, which mainly consists of Electroencephalography (EEG) and
Magnetoencephalography (MEG), directly measures brain activity by capturing the
electrical or magnetic signals produced by neurons during activation. The second,
which is currently dominated by functional Magnetic Resonance Imaging (fMRI)
and Positron Emission Tomography (PET), indirectly measures brain activity by
capturing changes in local blood flow linked with neuronal activation. The nature
of the various neuroimaging methods affect their spatial and temporal resolution
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which along with their invasiveness and their cost are important properties in terms
of application (see table 2.1).
Table 2.1: Properties of various neuroimaging modalities. Source: Lystad and Pol-
lard [2009]
PET fMRI EEG MEG
Measure indirect indirect direct direct
Response haemodynamic haemodynamic neuroelectrical neuromagnetic
Invasive yes no no no
- confined yes yes no yes
- radiation yes none none none
Device cost $8,000,000 $2,000,000 $100,000 $2,000,000
Operating cost $1,500 $800 $150 $600
Temporal res 1-2 min 4-5 s < 1 ms < 1 ms
Spatial res 4 mm 2 mm 10 mm 5 mm
In the following, we discuss further two important neuroimaging techniques, fMRI
and EEG, which motivate the methodology developed in this thesis.
2.3 fMRI
The most prominent form of fMRI is based on the so-called Blood Oxygenation
Level Dependent (BOLD) contrast. BOLD fMRI (often simply called fMRI) uses
the strong magnetic fields generated by MRI scanners to capture the local changes
in blood oxygenation level that accompany neural activation. These local haemo-
dynamic responses of the brain are recorded in 3−dimensional images with great
spatial resolution (around 1−4 millimeters). The temporal resolution (around 1−4
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seconds) of the scanner is restricted by various issues including the delay of the
haemodynamic response to neural activation [Huettel et al., 2008].
Figure 2.1: Schematic representation of a subject in a fMRI scan. Image by Duff
Hendrickson, U.W., Copyright Hunter Hoffman, U.W.
The key properties of fMRI are the non-invasive, unharmful nature of the
technique and the very high spatial resolution allowing for a study of the brain
at the systems level. fMRI is currently one of the main drivers in understanding
brain function. The potential of further application to drug development studies is
discussed in a number of review publications (see Iannetti andWise [2007]; Matthews
et al. [2011]; Whitcher and Matthews [2006]; Wise and Tracey [2006] for overviews).
fMRI is currently used to study the function and pharmacology of the brain under
several pathologies, such as Alzheimer’s disease [Pihlajama¨ki and Sperling, 2008] and
drug addiction [Smith et al., 2010]). Honey and Bullmore [2004] report more than
50 published articles on psychopharmacological studies using fMRI while Schwarz
et al. [2011a,b] provide guidelines for good imaging practice in pharmacological fMRI
studies.
2.3.1 FMRI data analysis
The typical fMRI dataset produced by a single scanning session consists of BOLD
recordings acquired from a small number of subjects (often around 15) during a
relatively short period of time (few hundreds time points) at around 104 − 105
voxels1 throughout the brain.
1voxel: a three-dimensional volume element, with rectangular cuboid shape, analogous to the
two-dimensional pixel.
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The raw fMRI data is preprocessed using several techniques of signal process-
ing, image processing and statistics. This typically involves realignment and spatial
normalization using suitable transformations to register the raw data to a com-
mon reference image. Spatial smoothing and temporal filtering are also employed
to eliminate the most common experimental artifacts (such as motion and scanner
artifacts) and increase the signal-to-noise ratio [Poldrack et al., 2011]. The typical
approach to model the preprocessed fMRI data is to apply mass-univariate Gen-
eral Linear Models (GLMs) to the time-series of each voxel separately. Normality
is a common and generally acceptable assumption for the preprocessed fMRI data
[Friston et al., 2007; Lindquist, 2008; Poldrack et al., 2011]. The default approach
for statistical inference is based on maps of the brain, called Statistical Parametric
Maps (SPMs), depicting the value of the t-statistics for each voxel. Parametric (for
example random field theory) or non-parametric (for example permutation tests)
approaches are then widely used to handle the huge multiple-testing problem of
detecting activated voxels throughout the brain while controlling for false positives
[Friston et al., 2007; Poldrack et al., 2011].
The burden of this multiple-testing problem can be alleviated by restricting
the search for activated voxels only to specific brain areas. In the following, we
briefly describe one method of data reduction. This is the ROI analysis applied to
the fMRI study of the example in section 2.3.2.
ROI analysis
In fMRI data analysis, investigators often primarily target selected brain locations
called regions of interest (ROI). ROI analysis is also very often reported as supple-
mentary to the standard mass-univariate voxel-by-voxel analysis in fMRI studies.
Compared with the voxel-by-voxel approach, ROI analysis provides a number of key
benefits. First, in data exploration, it enables the investigator to take advantage of
and find links with important findings that are currently available in the literature
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regarding the anatomy and function of a great number of brain ROI. For similar rea-
sons, ROI analysis is more suitable than voxel-by-voxel analysis for studying specific
regional hypotheses about the drug action [Wise and Tracey, 2006]. Such hypothe-
ses are more strict and therefore potentially more conformable to the regulations of
drug authorities. Finally, ROI analysis results in a drastic reduction of data dimen-
sion and this is expected to substantially increase statistical power [Mitsis et al.,
2007; Poldrack et al., 2011].
The first step in ROI analysis is to define the exact location of the ROI
to be analyzed. This can be performed based on structural or functional features.
Structural or anatomical ROI can be defined based on anatomical landmarks of
the brain. These are described by standard brain atlases, such as the Talairach
atlas [Talairach and Tournoux, 1988], which are widely available. In some cases,
brain atlases can even be specific to the area of investigation. For example, Mitsis
et al. [2007] use a “pain-atlas” for a pain treatment study. Based on such atlases,
investigators define the detailed location of ROI in each subject either in terms of
the subject’s brain anatomy, derived using high-resolution structural MRI, or using
“probabilistic atlases” reflecting the anatomical variability between subjects. On
the other hand, functional ROI are often derived using an independent “localizer”
scan to identify voxels in particular brain areas that show a characteristic response
of interest. Finally, ROI can be defined based on previous studies, preferably from
a meta-analysis on the domain of interest. It is important to note that to control
the type I error, the ROI locations need to be defined prior to analyzing the data
of the main study [Poldrack et al., 2011].
The next step in ROI analysis is to quantify the measure to be extracted
from each ROI. One method is to count the activated voxels within the defined
ROI. However, this approach, used mainly in early fMRI studies, is very sensi-
tive to the specified activation threshold. More commonly, voxel-wise estimates, βˆ,
of a chosen parameter, β, expressing an effect of interest, are extracted from the
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mass-univariate GLM. These βˆ-values are often standardized to the design of the
experiment by appropriate scaling. Summaries of the βˆ-values across the voxels of
each ROI of each subject are then derived using either weighted (for example first
Principal Component [Friston et al., 2007]) or un-weighted averages. These averages
of the estimated effects constitute the ROI data which are used to derive statistical
inference for the brain action at, between or across the selected ROI [Poldrack et al.,
2011]. The main steps for deriving ROI data are also described in figure 2.2.
Figure 2.2: Typical steps of ROI analysis producing the multivariate outcome used
in our real example in section 2.3.2. The preprocessed series of fMRI images are
modelled at voxel-by-voxel resolution using mass univariate General Linear Models
(GLMs). Suitable estimates of parameter values (β) expressing the treatment effect
in each voxel are first extracted from the GLM and then averaged across the pre-
defined ROI to produce a multivariate outcome where each component corresponds
to a measure of the treatment effect in a specific ROI.
2.3.2 Example: fMRI drug development study
For the purposes of drug development, a fMRI study was conducted by Glaxo-
SmithKline plc. A total of 13 subjects participated in the study. At the planning
stage, the following anatomical ROI (see figure 2.3) were defined: 1. Anterior Cin-
gulate (AC), 2. Atlas Amygdala (A), 3. Caudate (C), 4. Dorsolateral Prefrontal
Cortex (DL), 5. Globus Pallidus (GP), 6. Insula (I), 7. Orbitofrontal cortex (OF),
8. Putamen (P), 9. Substantia Nigra (SN), 10. Thalamus (T), 11. Ventral Striatum
(VS).
ROI summary data was extracted from the mass-univariate GLM applied to
preprocessed fMRI data. For this, the voxel-wise βˆ parameter estimates were aver-
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aged across the voxels of each ROI for each subject. The available data represents
the difference between paired treatment-placebo observations across ROI for each
subject.
Figure 2.3: Approximate locations of ROI used in the fMRI study example. Each of
the following ROI are indicated by a different colour and abbreviation: Anterior Cin-
gulate (AC-pink), Atlas Amygdala (A-red), Caudate (C-red/yellow), Dorsolateral
Prefrontal Cortex (DL-copper), Globus Pallidus (GP-magenta), Insula (I-purple),
Orbitofrontal cortex (OF-blue), Putamen (P-green), Substantia Nigra (SN-cyan),
Thalamus (T-yellow), Ventral Striatum (VS-blue/lightblue)
The means, standard deviations and correlations matrix of this ROI dataset
are presented in table 2.2. As we can see, effect sizes differ across ROI, the standard
deviations are relatively large and generally high correlations are observed.
Using this data, the investigators wished to address a fundamental question
arising in neuroimaging studies. This concerns the existence of global treatment
effects across ROI. The term global is used here to stress the difference to being
interested in local effects, as in effects at specific ROI. The null hypothesis to be
evaluated is then whether the treatment-placebo differences provide no statistically
significant evidence for treatment effects across the selected ROI. To answer this
global question, within this setting but also more generally, we employ various test-
ing procedures introduced in the next chapters. We now turn our interest to another
neuroimaging modality: electroencephalography (EEG).
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Table 2.2: Means, standard deviations and correlations of ROI data (nT = 13) of
the fMRI study.
ROI (k) AC A C DL GP I OF P SA T VS
x¯k 0.01 -0.06 0.08 0.08 0.14 0.02 0.08 0.06 0.10 0.10 0.13
sk 0.33 0.33 0.17 0.22 0.33 0.28 0.36 0.39 0.32 0.33 0.32
rAC,k 1 0.70 0.87 0.88 0.73 0.89 0.66 0.81 0.26 0.95 0.70
rA,k 1 0.55 0.61 0.72 0.77 0.65 0.68 0.59 0.68 0.66
rC,k 1 0.89 0.72 0.87 0.47 0.80 0.27 0.90 0.74
rDL,k 1 0.71 0.76 0.73 0.77 0.27 0.87 0.62
rGP,k 1 0.86 0.51 0.90 0.54 0.70 0.90
rI,k 1 0.45 0.85 0.46 0.86 0.84
rOF,k 1 0.44 0.09 0.65 0.39
rP,k 1 0.49 0.82 0.89
rSA,k 1 0.30 0.55
rT,k 1 0.74
rV S,k 1
2.4 EEG
EEG records the electrical activity of the brain. Specifically, EEG captures the
summed electrical potential generated by synchronously activated neurons (tens
of thousands). This activity is captured by electrodes typically placed at various
locations of the scalp. EEG has unrivalled temporal resolution (around 1-10 mil-
liseconds) with recordings regarded as “real-time” measures. On the other hand,
spatial resolution has fundamental physical limits with up to a number of sites,
often called channels, sampled in routine studies. For clinical studies, typically 19
channels are used, but if necessary 32, 64 or even more than 100 channels can be
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used [Gevins, 2002].
The high temporal resolution, the relatively low cost compared to other neu-
roimaging techniques, as well as the non-invasive, safe, portable equipment are the
main advantages of EEG. During the last decade, neuroscientists have shown great
interest in combining EEG with fMRI to achieve high spatial and temporal resolu-
tion [Mulert and Lemieux, 2010]. There is also interest in the so-called event-related
potentials (ERPs) which employ EEG to record brain response to specific stimuli
[Handy, 2005]. EEG has made great contribution in studying the effects and phar-
macology of various CNS-related disorders (see [Bauer and Bauer, 2005]), particu-
larly epilepsy [Thompson and Ebersole, 1999] and depression [Steiger and Kimura,
2010]. An example of the latter application is described in section 2.4.2.
Figure 2.4: Schematic representation of the EEG electrodes placed on the scalp.
Image source: www.riversideonline.com
2.4.1 EEG data analysis
EEG raw data of a single subject consists of multiple time-series recorded at a num-
ber of different location or channels. They are typically preprocessed by applying
high- and low-pass filters to eliminate experimental artifacts and possibly signals of
no interest for the study. Baseline correction is also applied by subtracting a “mean
signal” from all time points to eliminate slow level shifts produced by experimental
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artifacts such as sweating and muscle tension [Hauk, 2013; Sanei and Chambers,
2007].
EEG data can be analyzed as observed in the time-domain, but they are of-
ten transformed to the frequency-domain to perform data analysis. Frequency data
analysis is particularly important in EEG. The rhythms that characterize normal
and abnormal brain activity in EEG are categorized in four major frequency ranges.
These are (from low to high frequency): delta (0.5 − 4 Hertz), theta (4− 8 Hertz),
alpha (8− 13 Hertz) and beta (13− 30 Hertz). In terms of cognition states, delta is
associated with deep sleep and theta with creative inspiration and deep meditation.
Alpha frequency is associated with relaxed awareness and beta is observed during
active thinking, focus and creation. Abnormal EEG signal in alpha and beta fre-
quency ranges is associated with various CNS related disorders (for example epilepsy
[Sanei and Chambers, 2007]).
The Discrete Fourier Transformation (DFT) is typically used to transform
the time-series of each channel to the frequency domain. Formally, the DFT is
defined as
y(f) =
N∑
t=1
x(t) exp−i2πft,
where x(t) the response at time t and y(f) the amplitude of the spectrum at fre-
quency f . The square of the amplitude, (y(f))2, named the power spectrum, or
more commonly its logarithm, log
(
y(f)2
)
, is then used in data analysis [Rao, 2010].
In practice, EEG data is typically segmented into short time intervals before ap-
plying the DFT. These epochs are defined by the clinicians, by taking into account
the experimental design, to ensure that they have similar characteristics. To avoid
discontinuities at the epoch edges, overlapping between them and suitable window
functions (such as the Hanning or Gaussian window) are often used. DFT is then
applied to the time-series of each epoch (after windowing and overlapping) to derive
their power spectrum function. To increase the low signal-to-noise ratio of EEG
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data, the power spectra are typically averaged across these epochs to derive a sum-
mary aggregate power spectrum (stationarity assumptions are made here) for each
subject. This average power spectrum function, or the average power spectrum at
specific frequencies, are then often used for data analysis [Kropotov, 2009; Sanei
and Chambers, 2007]. Gaussianity is the typical assumption for the logarithms and
other transformations of the average power spectra [Collura et al., 2009; Lopes da
Silva, 2005; Sanei and Chambers, 2007].
2.4.2 Example: EEG depression study
La¨uter et al. [1996] published frequency data from an EEG study. As they describe,
the data is collected from n = 19 depressive patients at the beginning and at the end
of a six week therapy. The published data represent the changes on the absolute2
theta power of channels 3, 4, 5, 6, 7, 8, 17, 19 (K = 9 locations, see figure 2.5) during
the therapy of each patient.
Figure 2.5: Schematic presentation of the position of the channels used in the EEG
depression study
In table 2.3 we present the means, standard deviations and correlation matrix
of the data. Note that the correlations especially of nearby locations are high.
Furthermore, an increase in theta power is indicated in all channels, but the standard
deviations are generally high.
2The term absolute is used in EEG data analysis to distinguish from the relative power where,
in the latter, the absolute power is divided by the total power in all frequencies
20
Similarly to the fMRI study in section 2.3.2, the investigators were primar-
ily interested in the global treatment effects. That is, they wished to investigate
whether the differences in the absolute theta power suggest a statistically signifi-
cant treatment effect across the selected channels. This question can be expressed
in terms of a global hypothesis.
Table 2.3: Means, standard deviations and correlations for the EEG depression
study presented in La¨uter et al. [1996].
ch. (k) 3 4 5 6 7 8 17 18 19
x¯k 0.87 1.59 1.04 1.15 0.85 0.85 1.42 0.75 1.00
sk 2.95 3.51 2.36 2.25 2.28 2.07 3.26 2.64 2.36
r3,k 1 0.93 0.81 0.80 0.58 0.49 0.93 0.49 0.53
r4,k 1 0.63 0.78 0.34 0.45 0.93 0.28 0.49
r5,k 1 0.79 0.85 0.71 0.73 0.71 0.76
r6,k 1 0.60 0.79 0.82 0.63 0.78
r7,k 1 0.62 0.46 0.68 0.60
r8,k 1 0.52 0.60 0.78
r17,k 1 0.40 0.57
r18,k 1 0.44
r19,k 1
2.5 Conclusions
Neuroimaging is a very important and exciting field of neuroscience. Neuroimaging
studies can provide great insight into the normal and abnormal brain anatomy and
function. However, for these studies to become further established, particularly in a
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clinical trials setting, a number of challenges remain outstanding and some of them
regard statistical methodology.
Some of these challenges are illustrated by the real examples of the fMRI and
EEG study. These studies share common properties which are typical in neuroimag-
ing studies. Firstly, high correlations are observed especially but not exclusively be-
tween nearby locations. Secondly, the observed effects are dispersed across different
locations, in the sense that they are locally small but, as we show in section 3.3.1,
globally large. This suggests combining the local outcomes, rather than treating
them separately, to detect global effects. In addition, due to the high cost of these
studies, the sample size is small and even after the reduction in data dimensionality
(for example using ROI or frequency analysis) remains close to the observations’
dimension. Furthermore, for these studies but also more generally in neuroimaging,
there are opportunities to elicit prior information from earlier results. In section
8.4 we provide some examples of such prior information which may arise from the
spatial characterization of the signal and from the nature of the study. Lastly, as
our examples illustrate, effects are often expressed in different directions between
brain locations with hyperactivation simultaneously occurring with deactivation.
These properties of neuroimaging studies are taken into consideration in the
methods introduced in later chapters. The deficiencies of existing global tests in
application to neuroimaging are discussed and novel methodology is developed.
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Chapter 3
Global testing
3.1 Introduction
As we discussed in the previous chapter, in neuroimaging studies the neural ac-
tivity is simultaneously investigated at multiple brain locations. More generally,
in biomedical studies but also in experiments performed in many other fields (for
example industry, ecology and psychology), investigators are often interested in a
number of outcomes and only rarely focus on a single measure. This situation often
becomes necessary due to the nature of the research questions. For example, in order
to evaluate the treatment effect on patients, multiple symptoms and relevant body
functions need to be monitored and hence multiple outcomes need to be evaluated
[D’Agostino and Russell, 2005; Dmitrienko et al., 2010].
In this chapter, we consider methods that can be used to evaluate treat-
ment effects in settings where multiple outcomes are studied. Specifically, we are
interested in testing procedures which can be used to evaluate global effects ob-
served across these outcomes. That is, as opposed to focusing on local effects on
specific outcomes, we consider methodology which evaluates multiple outcomes si-
multaneously to provide an omnibus assessment of the effects over all the outcomes.
These methods address the fundamental question of whether or not, overall, the
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observed outcomes suggest a significant treatment effect. [D’Agostino and Russell,
2005; O’Brien, 1984; Pocock, 1997; Sankoh et al., 1997]. This methodology can be
used to evaluate the question posed by the examples of neuroimaging studies, as
seen in sections 2.3.2 and 2.4.2, regarding global treatment effects across multiple
brain locations.
In the following, we consider various testing procedures, focusing mainly on
the essence of their methodology and discussing when they are appropriate. We
discuss p−value adjustment methods and multivariate tests, including “fully” mul-
tivariate tests and the class of linear combination tests which is the main method-
ological focus in this thesis. We begin with a general formulation of the global
testing problem.
Formulation
The K−dimensional observation vectors, xi = (xi1, xi2, . . . , xiK)T , of subjects i =
1, 2, . . . , n, are assumed to be independent with common mean vector E(x) =
µ = (µ1, . . . , µK)
T and covariance matrix (the symmetric positive definite) Σ =
(σkk′)
K
k,k′=1. The mean vector µ is often interpreted as the effect of interest or the
treatment effect. We wish to test the global null hypothesis of no treatment effect
against the two-sided alternative. That is,
H0 : µ = 0K = (0, 0, . . . , 0)
T versus H1 : µ 6= 0K . (3.1)
In global testing, and more generally in statistical hypothesis testing, we are inter-
ested in controlling or minimising the potential incorrect decisions, called errors, of
the test. Specifically, we focus on controlling the type I error rate as in ensuring
that
Pr( reject H0 | µ = 0K) ≤ α, (3.2)
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and minimising the type II error rate
1− β = Pr( not reject H0 | µ = µ1), (µ1 6= 0K) (3.3)
or, equivalently, maximising the power of the test
β = Pr( reject H0 | µ = µ1). (3.4)
If the type I error is equal to the significance level α, that is, the equality in (3.2)
is satisfied, we say that the test controls/maintains the type I error exactly or,
simply, the test is exact. The target of maximising power is sometimes replaced by
minimising the sample size of the test (or other design parameters) while controlling
power at a fixed level. We stress that in this thesis power is denoted by the letter β
rather than the (more common) expression 1− β, to simplify notation.
Note that the testing procedures which follow equally apply to the two-
sample setting with common covariance matrix. This can be formulated in terms
of two independent samples, xAi, xBi, i = 1, 2, . . . , n from groups A and B, with
E(xAi) = µA, E(xBi) = µB , var(xAi) = var(xBi) = Σ which are used to test
the null hypothesis H0 : µA − µB = 0K against the two-sided alternative H0 :
µA −µB 6= 0K . Furthermore, the setting of paired multivariate observations (as in
observations before and after a treatment), where the multivariate outcomes are set
equal to di = xAi−xBi, i = 1, 2, . . . , n, can also be accommodated by the methods
which follow. Finally, with a few trivial changes in the procedures to follow, the
situation where the hypotheses of interest are H ′0 : µ = µ0 and H
′
1 : µ 6= µ0, with
µ0 6= 0K can also be accommodated. However, to simplify notation we continue
with the above one-sample presentation.
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3.2 P−value adjustment methods
The above global hypotheses can be evaluated using p−value adjustment methods,
such as the Bonferroni test. In the well-known Bonferroni correction test, the local
outcomes, x1, x2, . . . , xK , are used to construct the statistics t1, t2, . . . , tK , with
corresponding p−values p1, p2, . . . , pK , to test the local null hypotheses
H0k : µk = 0, k = 1, 2, . . . ,K.
The Bonferroni test rejects the k−th local null hypothesis H0k if and only if pk ≤
α/K. Note that the global null hypothesis H0 in (3.1) can be written as the inter-
section of the local null hypotheses, formally
H0 =
K⋂
k=1
H0k, (3.5)
and thus rejection of a local null hypothesis implies rejection of the global null
hypothesis.
Thus, by ordering the p−values as p(1) ≤ p(2) ≤ · · · ≤ p(K), we can write the
global Bonferroni test as
reject H0 iff p(1) ≤ α/K. (3.6)
Due to the first-order Bonferroni inequality (Boole’s inequality) this procedure con-
trols the type I error at the nominal α level [D’Agostino and Russell, 2005].
The global Bonferroni test is easy and convenient to apply and it does not
require any distributional assumption to control the type I error. It can even be
used if the observations of each dimension are measured at a different scale. On
the other hand, the Bonferroni method relies entirely on the smallest p−value and
can often be conservative (that is, type I error rate substantially lower than the
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nominal α level) and inefficient (that is, power at unexpectedly low levels). This is
the case when, as in our motivating example, high correlations exist between the
local outcomes. The problem becomes worse as the dimension, K, of the observation
vectors increases. Pocock et al. [1987] and Dmitrienko et al. [2010] found, through
simulation studies, that for large positive correlations, especially when these are
higher than 0.5, the type I error rate of the Bonferroni method is substantially
lower than the nominal level. The results in Dmitrienko et al. [2010] show that the
conservatism is considerably larger if the observation dimension is increased even
from K = 2 to K = 5. We next consider the application of the global Bonferroni
test to the examples in sections 2.3.2 and 2.4.2.
Example: Global Bonferroni test for fMRI and EEG study data
We compute the values of the t test statistics and the corresponding two-sided
p−values (12 degrees of freedom) at each of the 11 ROI.
Table 3.1: The local t− and p−values for the observations collected at each ROI
used in the fMRI study.
ROI AC A C DL GP I OFC P SA T VS
tk 0.03 -0.72 1.80 1.28 1.55 0.21 0.76 0.59 1.14 1.10 1.46
pk 0.98 0.48 0.10 0.23 0.15 0.84 0.46 0.57 0.28 0.29 0.17
The smallest p−value p(1) = p3 = 0.10 is clearly larger than α/K ≈ 0.0045 for
α = 0.05, K = 11 and thus the Bonferroni method fails to reject H0.
Similarly, in the next table, we present the t− and p−values of the theta
frequency observations recorded at each channel used in the EEG depression study.
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Table 3.2: The local t− and p−values for the observations collected at each channel
used in the EEG depression study.
ch. 3 4 5 6 7 8 17 18 19
tk 1.29 1.97 1.92 2.22 1.63 1.80 1.90 1.24 1.84
pk 0.22 0.06 0.07 0.04 0.12 0.09 0.07 0.23 0.08
The smallest p−value is p(1) = p4 = 0.04 > α/K ∼= 0.0055 for α = 0.05, K = 9 and
thus the Bonferroni method fails to reject H0.
A number of modifications of the Bonferroni method exist in the literature.
Simes [1986] global test rejects H0 if and only if p(k) ≤ kα/K, for at least one k,
k = 1, 2, . . . ,K. This test does not rely heavily on the smallest p−value and it is less
conservative and more efficient than the Bonferroni method. Further, despite the
slight increase in computation, it is still very easy and convenient to apply. However,
Simes’ global test does not always control the type I error. Simes [1986] analytically
proved that his test controls type I error for independent outcomes, while, through
simulations, he showed that the type I error is also controlled for specific correlation
structures under various distributions including the multivariate normal. Hommel
[1988] also proposed two p−value adjustment methods, which control the type I
error and are less conservative than Bonferroni method but more conservative than
Simes global test [D’Agostino and Russell, 2005].
The above methods completely ignore correlations and thus they all become
conservative when correlations are high. Some p−value adjustment methods ac-
counting for correlations exist in the literature (for example James [1991], random
field theory [Friston et al., 2007] and non-parametric [Westfall and Young, 1993]
methods), but these tend to require complex calculations and they often rely on
assumptions for specific observation structures in order to be efficient and/or to
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maintain the type I error.
More generally, any multiple testing method can be re-written as a global
test, because rejection of a single local null hypothesis implies rejection of the global
null hypothesis. However, multiple testing methods treat local outcomes as indepen-
dent entities rather than as components of a multivariate observation and they focus
on detecting one or some few distinct local effects. Hence, they are more appropriate
when we are interested in assessing local rather than global effects [D’Agostino and
Russell, 2005; Dmitrienko et al., 2010]. Since these characteristics do not fit with
our motivating application, we are driven to multivariate tests considered next.
3.3 Multivariate tests
There are various reasons why a multivariate test might be more appropriate than
p−value adjustment methods for evaluating global hypotheses. First, multivariate
global tests control type I error without the burden of multiplicity adjustments.
Secondly, multivariate tests make direct use of, rather than ignore, correlations by
incorporating them into the multivariate assumptions used to construct global test
statistics. This is particularly important in studies, such as those arising in neu-
roimaging, where high correlations between local responses are typically observed.
Further, rather than evaluating local effects separately, multivariate tests
combine the effects from the correlated outcomes to obtain omnibus assessment of
treatment effects. This is particularly meaningful in cases where the multiple out-
comes are biologically related and especially if they are replications of the same
measure at different locations, as in neuroimaging. In terms of efficiency, multi-
variate methods can be advantageous compared to p−value adjustment methods, if
the effects are locally small but globally large if combined. The latter situation is
illustrated by our neuroimaging examples.
Finally, these multivariate global tests are often constructed based on dis-
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tances between multivariate observations and linear combinations of the multiple
outcomes are fundamental [D’Agostino and Russell, 2005]. As Rencher [2002] nicely
put it, the construction of these linear combinations “reveal more (compared to mul-
tiple univariate tests) about how the variables unite to reject the null hypothesis”.
Multivariate normality assumption
The multivariate tests to follow are based on the assumption of multivariate nor-
mality. That is, the K−dimensional observation vectors xi = (xi1, . . . , xiK)T of
subjects i = 1, 2, . . . , n, are assumed to be independent and identically distributed
multivariate normal random variables,
xi ∼ NK (µ,Σ) , i = 1, 2, . . . , n, independent (3.7)
with mean µ and covariance matrix Σ (as above).
Multivariate normality is the central assumption for many multivariate sta-
tistical methods and there are various reasons for this [Anderson, 2003; Mardia
et al., 1979; Rencher, 2002]. A practical advantage of this assumption is the mathe-
matical tractability of the multivariate normal distribution. The probability density
function of a random variable x ∼ NK (µ,Σ),
f(x) = (2pi)−k/2 |Σ|−1/2 exp
(
−1
2
(x− µ)T Σ−1(x− µ)
)
, (3.8)
is a direct generalisation of its univariate counterpart and is completely determined
by its first two moments, µ and Σ. Several useful results can be easily proved for the
multivariate normal distribution, including that the linear combinations y = wTx,
with w 6= 0K , is also normally distributed with
y ∼ N(wTµ,wTΣw) (3.9)
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and that uncorrelated normal random variables are independent. Another reason
for the dominance of normality in multivariate statistics is that, in contrast to the
univariate case, there are considerably fewer established alternatives with general-
izations of non-normal univariate distributions, such as Gamma and Poisson, not
being widely accepted. Last, but not least, the central limit theorem for multivariate
random variables asymptotically links, under some restrictions, any other multivari-
ate distribution to the multivariate normal. Therefore, multivariate normality can
often be considered as an approximation of other multivariate distributions [Mardia
et al., 1979].
These reasons contribute in establishing multivariate normality as the typical
assumption for modelling continuous observations in various multivariate settings.
These include our motivating neuroimaging applications of fMRI [Friston et al.,
2007; Lindquist, 2008; Poldrack et al., 2011] and EEG [Collura et al., 2009; Lopes da
Silva, 2005; Sanei and Chambers, 2007]. In the methods to follow, multivariate
normality assumption is used almost universally.
3.3.1 Fully multivariate tests
We now consider the fully multivariate global tests which, as opposed to p−value
adjustment methods, are constructed by considering the multiple outcomes as mul-
tivariate observations.
The likelihood-ratio test for multivariate normally distributed observations
as in (3.7) and Σ known is based on the statistic,
χ2 = nx¯TΣ−1x¯, (3.10)
where
x¯ = n−1
n∑
i=1
xi (3.11)
is the sample mean of the observation vector x. The χ2 statistic follows the non-
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central χ2K(∆
2) distribution with K degrees of freedom, and non-centrality param-
eter
∆2 = (µ− µ0)TΣ−1(µ− µ0), here µ0 = 0K , (3.12)
where ∆ is called the Mahalanobis distance of the vector µ from µ0 for covariance
matrix Σ [Mahalanobis, 1930]. This measures expresses the standardized, with
respect to Σ, distance between a value, µ, of the mean vector and the hypothetical
null mean vector, µ0. Mahalanobis is the central distance in multivariate statistics.
It generalizes the univariate signal to noise ratio µ/σ and can be interpreted as a
measure of deviation from the null hypothesis. In the medical setting, it is a well
known global measure of the strength of the treatment effect.
Under H0, ∆ = 0 and χ
2 is (centrally) χ2K distributed with K degrees of
freedom. The χ2 test rejects H0 if and only if
χ2 > χ2K,α, (3.13)
where χ2K,α is the 100(1 − α) percentile of the null χ2K distribution. The χ2 test
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Figure 3.1: The ellipsoids χ2 = χ2K,α of the two-dimensional (K = 2) χ
2 test for
various Σ. The outside area of the ellipsoids represents the rejection region of the
χ2 test. The direction in which the null hypothesis H0 is rejected more easily, i.e.
for smaller x¯, changes for different Σ.
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controls the type I error exactly. As we show in figure 3.1, the rejection region of the
χ2 test is the region outside the ellipsoid nx¯Σ−1x¯ = χ2K,α with the zero vector as
the center. The size and shape of the ellipsoid is sensitive to the covariance structure
in Σ. As we can easily understand from figure 3.1, not only the size, but also the
direction of the effect determines the value of the test statistic and thus whether H0
is rejected or accepted (not rejected).
The main issue with the χ2 test is that it requires the Σ matrix to be known.
As the latter is most often not true, Hotelling’s T 2 test, which takes Σ as unknown,
is of much greater practical use. This is based on the statistic
T 2 = nx¯TS−1x x¯, (3.14)
where Sx is the sample covariance matrix of x, that is,
Sx =
1
n− 1
n∑
i=1
(xi − x¯)(xi − x¯)T . (3.15)
The test statistic T 2 is the generalisation of the (squared) univariate t test. It is the
product of the sample size and the squared sample Mahalanobis distance
x¯S−1x x¯,
which estimates the size of the global treatment effect.
Hotelling [1931] computed the distribution of T 2, the non-central T 2K,n−1(∆
2)
distribution with non-centrality parameter ∆2. The distribution is indexed by the
dimension K and the degrees of freedom n − 1. Under H0, the non-centrality
parameter is equal to 0 and T 2 follows the T 2K,n (central) distribution. The T
2
test rejects H0 if and only if
T 2 > T 2K,n−1,α (3.16)
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where T 2K,n−1,α is the 100(1 − α) percentile of the null T 2K,n−1 distribution.
Hotelling’s T 2 is the likelihood-ratio test for multivariate normal samples. It
is invariant to affine transformations, X˜ = CX + b, of the observation matrix X,
where C is a non-singular constant K ×K matrix and b a constant K × 1 vector.
It is also admissible for testing H0 under the multivariate normality assumption
[Anderson, 2003]. It provides exact control over type I error and it is found to
be robust against non-normality and heterogeneity between covariance matrices in
two-sample tests [Rencher and Christensen, 2012].
A few more important properties of T 2 test arise from the critical values
of T 2. First, T 2 requires n − 1 > K to be applicable (otherwise Sx is singular).
Further, the T 2 distribution relates to the F distribution by the following equation
T 2K,n−1(∆
2) =
(n− 1)K
n−K FK,n−K(∆
2). (3.17)
In the univariate case (K = 1), t2n−1 = F1,n−1 = T
2
1,n−1, while asymptotically, as
n → ∞, T 2K,∞ = χ2K . As K increases, larger sample sizes are required for T 2 to
approach χ2. As shown in figure 3.2, for fixed sample sizes n, the critical value
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Figure 3.2: The critical values of the χ2 and T 2 tests versus the dimension K (left
panel) and sample size n (right). The critical values of T 2 can be much larger than
χ2 test for K approaching n. Here, α = 0.05, n = 100 (left), K = 20 (right).
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T 2K,n−1,α increase exponentially with K. In particular, the critical values are ex-
tremely high for n close to K, a situation which is common in our motivating field
of neuroimaging.
Example: Hotelling’s T 2 test for the fMRI and EEG study data
For both the ROI data of the fMRI study and the theta frequency data of the EEG
study, the sample Mahalanobis distance
Dx =
(
x¯S−1x x¯
)1/2
is relatively large. Specifically, the sample Mahalanobis distance for the ROI data
is DxROI = 2.7657 and for the frequency data DxTHETA = 1.1537. This suggests a
large global treatment effect, contrary to the small local treatment effects, in both
studies, which resulted in a failure to reject H0 using the global Bonferroni test.
The T 2 statistic in (3.14) takes the value T 2ROI = 99.4413, for the ROI data,
and T 2THETA = 25.2881 for the theta frequency data. Despite the large Maha-
lanobis distance, the T 2 test fails to reject H0 in both studies (pT 2ROI
= 0.4656,
pT 2THETA
= 0.2486), since the critical values are very high T 211,12,0.05 = 1280.7,
T 29,18,0.05 = 48.9302.
The χ2 and Hotelling’s T 2 tests are designed to detect deviations from the
null hypothesis in any direction. Before we proceed to our main focus which are
the linear combination tests, to provide a more complete picture of global testing,
we briefly discuss in the next section another class of global tests, which target
the detection of effects restricted to be positive in every dimension. Note that, as
Rencher and Christensen [2012] suggests, the methodology for turning univariate
two-sided tests to one-sided tests does not readily generalize to the multivariate
setting, mainly due to the complexities introduced by the dependencies between the
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multiple outcomes.
3.3.2 One-sided tests
One-sided tests evaluate the global null hypothesis against one-side alternatives,
typically expressed as
H+1 : µk ≥ 0, k = 1, 2, . . . ,K, (strict inequality for at least one k). (3.18)
In clinical trials, the alternative H+1 is often found appropriate to describe improve-
ments expressed by increased treatment effects [Tang et al., 1993]. For evaluating
H0 against H
+
1 , Kudo [1963] and Perlman [1969] derive the likelihood ratio tests
(under multivariate normality) for covariance matrix assumed known and unknown,
respectively. However, both of these tests require extremely challenging computa-
tions with their critical values depending on the covariance structure. The latter
feature makes them practically infeasible even for small K. Their computational
complexity arises from their test statistics’ construction. For Σ known, this re-
quires deriving an optimal projection, x¯∗+, of the sample mean vector, x¯, in the
positive orthant RK+ = {v = (v1, v2, . . . , vK)T ∈ RK |vk ≥ 0, k = 1, 2, . . . ,K} of
real numbers. Here optimality is defined in terms of maximisation of the sample
Mahalanobis distance, x¯T+Σ
−1x¯+, of the projection, x¯+. This optimization problem
is substantially complicated by the dependencies across the multivariate outcomes.
Under independence, the latter optimal projection is derived by simply set-
ting the negative entries of x¯ to zero. Tang et al. [1989a] use the latter result,
by applying the one-sided likelihood ratio tests to observation vectors which are
previously transformed using a matrix A, such that AAT = Σ−1, to correct for cor-
relations. This Approximate Likelihood Ratio test makes computations less complex
and allows for critical values tabulation. However, it relies heavily on the non-unique
definition of the matrixA which can be challenging, especially for unknownΣ. Tang
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et al. [1993, 1989a] proposed methods for deriving appropriate choices of matrix A,
but this requires intensive computations, particularly when the number of outcomes
is high [D’Agostino and Russell, 2005].
Follmann [1996] proposes a simple test which also targets the one-sided prob-
lem. Follmann’s test, often called T 2+, rejects H0 in favor of H
+
1 if both the sum of
the mean vector is positive, that is,
∑K
k=1 x¯k > 0, and Hotelling’s T
2 test rejects
H0 at twice the value of the significance level, 2α. Follmann [1996] proves type I
error control of this test and showed its power robustness under various positive
directions of the mean vector. Although, the dependence of T 2+ to Hotelling’s T
2
test implies that the former preserves the restriction for n ≫ K and therefore T 2+,
as T 2, is also often inappropriate for neuroimaging applications.
3.3.3 Linear Combination Tests
The fully multivariate tests considered in the previous section “look” in every di-
rection of the two-sided or one-sided alternative space. Effects in every direction of
the alternative space can be efficiently detected in settings where the sample size is
sufficiently large. However, in settings where the sample size is restricted to be close
to K, these methods become inefficient, while if the sample size is smaller than K
fully multivariate tests are inapplicable. This efficiency cost from looking in every
direction, seems avoidable and wasteful if prior knowledge about the direction of the
effect is available. In this case, it seems more appropriate to construct a suitable
test which targets this specific direction.
This statistical motivation leads to the development of “directional” or “lin-
ear combination” tests. The latter characterization addresses the construction of
these tests, which are based on the linear combination y = wTx, combining the
observation vector, x, using the weighting vector w = (w1, w2, ..., wK)
T 6= 0K . In
other words, the multivariate observation, x, is reduced to the scalar linear com-
bination, y, using the weighting vector w. The geometrical interpretation of y is
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particularly useful as we emphasize in chapter 7. The linear combination y can be
seen as the magnitude of the projection of the observation vector x into the direction
w.
Figure 3.3: The observation vector x, the weighting vector w and the projection
vector yw with magnitude the linear combination y.
The linear combinations, yi = w
Txi, i = 1, 2, . . . , n, of each subject’s obser-
vation vector are treated as univariate outcomes to construct the standard z and t
statistics
z =
y¯
σ/
√
n
, t =
y¯
s/
√
n
,
for testing the null hypothesis H0, when Σ is either known or unknown, respectively.
Here, σ2 = wTΣw is the variance and
y¯ =
1
n
n∑
i=1
yi, s
2 =
1
n− 1
n∑
i=1
(yi − y¯)2 (3.19)
the sample mean and sample variance of the linear combination y, respectively.
The z and t statistics are scale invariant with respect to w, that is, zw = zcw,
tw = tcw for any c 6= 0. Also, the distributions of both test statistics are invariant
to scale transformations x→ cx (c 6= 0) of the observation vector x. However, these
tests are not generally invariant to affine transformation of the weighting vector or
the responses. The latter properties emphasize the importance of the direction of
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the weighting vector which is the crucial element in linear combination tests defining
the region in which we search for treatment effects.
The selection of the weighting vector can substantially affect both type II
and, if chosen based on observed data, type I error rate of the z and t test. This
becomes clear if we consider the distribution of the z and t statistics. Under H0, for
fixed weighting vector w, the z and t statistics are respectively standard normally
N(0, 1) and Student’s t distributed tn−1 with n − 1 degrees of freedom. Thus the
decision rules which reject H0 if and only if
|z| > zα/2, |t| > tn−1,α/2,
where zα/2 and tn−1,α/2 are respectively the 100(1−α/2) percentiles of the standard
normal and of the Student’s tn−1 distribution, specify hypothesis tests of size α.
However, if the weighting vector depends on the observations (see examples below),
the z and t statistics are not necessarily normally and t distributed and thus the
type I error of the above tests can be inflated.
Furthermore, to see how crucial the weighting vector is for the power of
the test, consider the distribution of the z and t statistics under H1. Under H1,
the z and t statistics are normally and non-centrally t distributed with location
parameter
√
nµ/σ, where µ = wTµ. The location parameter of the test statistics
and thus power is largely affected by the direction of w. For example, if w is fixed
orthogonally to µ, the location parameter is zero and the power of the test is equal
to α. It is thus important to ensure that w is not far from the effect direction and
in particular not orthogonal to µ. These crucial issues are discussed next, but they
are also thoroughly studied in chapters 4, 6, 7 and 8.
Here we attempt to outline the existing methodology in the class of linear
combination tests. This can be partitioned into two main approaches. The first ap-
proach stems from the seminal work of O’Brien [1984] while the latter from La¨uter
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[1996]. We describe the methodology of these tests as well as some of their modifi-
cations and discuss their strengths and weaknesses. The latter discussion introduces
the motivations behind the methodology described in later chapters.
O’Brien tests
O’Brien’s [1984] seminal paper, as Dmitrienko et al. [2010] suggest, was a turning
point, not only for linear combination tests, but for multiple testing procedures in
general. In this paper, O’Brien derived several parametric and non-parametric tests
for multiple endpoints settings in clinical trials. The parametric tests, developed
under multivariate normality, are based on the assumption that the treatment effect
is of equal strength across the multiple outcomes. That is, the mean vector µ is
assumed to be proportional to the uniform vector 1K = (1, 1, . . . , 1)
T . Based on this
assumption, O’Brien derived global tests using Ordinary Least Squares (OLS) and
Generalized Least Squares (GLS) methods. These can be expressed as linear com-
bination tests with weighting vectors wOLS = 1K , wGLS,1 = (σ
−1
11 , σ
−1
22 , . . . , σ
−1
KK)
and wGLS,2 = Σ
−11K , respectively.
O’Brien’s tests are easily interpretable. The linear combination in OLS test
is simply the sum of the multiple outcomes. In the first GLS test, the multiple
outcomes are standardized to their standard deviation while in the second GLS test
the weights are the column sums of the matrix Σ−1 and therefore outcomes that
are less variant and less correlated (to other) outcomes receive greater weights.
The OLS z and t tests have fixed weighting vector and therefore, under
multivariate normality, they exactly control the type I error. The GLS z test also
control type I error, but for Σ unknown, O’Brien [1984] suggests replacing it with
its sample estimate Sx and therefore the t statistic is no longer t distributed. Frick
[1997] and Logan and Tamhane [2004] show that the type I error of the GLS tests
can be inflated especially for small sample sizes and they obtain empirical critical
values for type I error control.
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O’Brien’s tests, as we show in later chapters, are power optimal as in they at-
tain maximum power, within the class of linear combination tests, if the assumption
of uniform mean vector holds (additional assumptions are necessary for the OLS and
the first GLS test). However, if the effect slips from the uniform direction, they can
lose great amounts of power. D’Agostino and Russell [2005] suggest that O’Brien’s
tests are inefficient in situations where nonzero treatment effects are expected to
occur in only a few endpoints. Furthermore, Tang et al. [1993] suggest that it might
be difficult to know in advance whether the effect direction is close to the uniform
direction.
O’Brien’s methodology has been extended in many directions, including com-
bination with the closure principle [Marcus et al., 1976] to provide multiple testing
procedures [Lehmacher et al., 1991] and to develop consonant procedures [Bittman
et al., 2009]. Practical application in various settings have also been considered
[Dallow et al., 2008; Hemmelmann et al., 2004; Leroux et al., 2005]. Pocock et al.
[1987] and Tang et al. [1993, 1989b] provide a useful discussion on O’Brien tests and
extend their use respectively to asymptotically normal test statistics (for example
survival and binary data) and group sequential designs. The wider class of group
sequential linear combination tests with fixed weighting vectors is studied in later
chapters.
Lau¨ter exact tests
La¨uter [1996] introduce a class of linear combination tests which targets high-
dimensional settings being applicable even in situations where n < K. The proposed
tests allow for determining the weighting vector based on the observed data without
inflating the type I error. In particular, La¨uter [1996] proves that, if the weighting
vector is uniquely determined from the K ×K sums of the products matrix XXT ,
where X = [x1x2 . . .xn], the type I error of the linear combination t test is exactly
controlled. Note that, as La¨uter [1996] confirms, the sample covariance matrix Sx
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cannot be used instead of XXT = Sx + nx¯x¯
T , since this may substantially inflate
the type I error.
The type I error control under this weighting selection rule is proved using
the theory of spherical matrix distributions [Fang and Zhang, 1990]. It is based on
the invariance of the matrix XXT and the null distribution of X to orthogonal
transformations. These invariance properties imply right-sphericity, under H0, of
both X and the linear combinations with weighting vector selected under the above
rule which in turn implies that the linear combination t−statistic is exactly Student’s
t−distributed. Using these results and the theory of spherical matrix distributions,
exact control of the type I error of the linear combination t test is deduced [La¨uter
et al., 1996].
La¨uter et al. [1996] propose two methods for deriving the weighting vector
from the matrix XXT . The Standardized Sum (SS) test has weights equal to the
inverse square root of the diagonal entries ofXXT , that is, wSS,k =
(∑n
i=1 x
2
ik
)−1/2
,
k = 1, ...,K. Note that
∑n
i=1 x
2
ik is an unbiased estimator of n(σ
2
k + µ
2
k). Thus,
correlations between the components of the response are not taken into account and
components with larger means are down-weighted which contradicts the intuition
for selecting weights. On the other hand, components with smaller variance receive
larger weights which intuitively is a desirable property. As La¨uter et al. [1996]
suggest, the SS test is efficient “if the expected deviations from the hypothesis H0
have the same direction for all K variables”. In this case, µ = 1K , and thus wSS is
expected to avoid down-weighting of outcomes with higher µk’s. It might be useful
to note the similarities with O’Brien’s tests which are also powerful under the same
restrictions.
The second test proposed by La¨uter et al. [1996] is the Principal Component
(PC) test which has weighting vector wPC equal to the solution of the eigenvalue
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problem
(XXT )w = λDiag(XXT )w, wTDiag(XXT )w = 1,
corresponding to the largest eigenvalue λ. Here, Diag(XXT ) is a diagonal matrix
with main diagonal entries as in XXT . The weighting vector wPC can be alterna-
tively written as wPC = Diag(XX
T )−1/2w˜, where w˜ = (w˜1, w˜2, . . . , w˜K)T is the
solution of the eigenvalue problem
Diag(XXT )−1/2XXTDiag(XXT )−1/2w˜ = λw˜.
The latter presentation shows that the weighting vector wPC is the standardized,
with respect to Diag(XXT )−1/2, first eigenvector of the matrix
Diag(XXT )−1/2XXTDiag(XXT )−1/2.
This also implies the connection between the weights of the SS and PC tests, that
is, wPC,k = w˜kwSS,k, k = 1, 2, ...,K, which indicates that under certain conditions
they have similar behaviour. The PC tests, similarly to the SS test, is appropriate if
uniform effects are expected across the multiple outcomes. La¨uter et al. [1996] argue
that the PC test can be useful under the one factorial structure between the mean
vector and the covariance matrix, as in Σ = Ψ + c2µµT , with Ψ being a diagonal
matrix of nuisance variances and c is a constant. However, the task of deriving
analytical or empirical results supporting these arguments remain outstanding and
this is partly due to the complex construction and thus interpretation of the wPC
vector.
Despite these difficulties, La¨uter’s methodology is appealing mainly for two
reasons. The first is that it remains applicable for sample sizes smaller than K. The
second is that it provides a framework for deriving the weights using the observed
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data without inflating the type I error. The proposed class of tests can be used for
purposes beyond global testing (see for example La¨uter et al. [2009]) and they have
been applied in various high-dimensional settings [Adolf et al., 2011; Almeida and
Ledberg, 2002].
Example: OLS, SS and PC t tests for fMRI and EEG study data
We apply O’Brien’s OLS and La¨uter’s SS and PC t tests to the fMRI and EEG
data. The GLS t tests are not considered since they do not control the type I error
for small sample sizes. The OLS statistic is equal to tROI,OLS = 0.9329, for the
ROI data, and tTHETA,OLS = 2.1118, for the theta frequency data. For the ROI
data, tROI,OLS is smaller to the critical value t12,0.05/2 = 2.1788 and thus OLS does
not reject H0 (pROI,OLS = 0.3693). In comparison, for the theta frequency data,
tTHETA,OLS = 2.1118 which is larger than the critical value t18,0.05/2 = 2.1009 and
thus OLS (narrowly) rejects H0 (pTHETA,OLS = 0.0489).
For the SS and PC t tests, we obtain tROI,SS = 0.9552 and tROI,PC = 0.9421
which are both smaller than t12,0.05/2 = 2.1788 and thus the SS and PC do not reject
H0 (pROI,SS = 0.3583, pROI,PC = 0.3647). This is in contrast to the tests for the
theta frequency data where, as with the OLS test, the t−values, tTHETA,SS = 2.112
and tTHETA,PC = 2.114, are both larger than the critical value t18,0.05/2 = 2.1009
and thus they also (narrowly) reject H0 (pSS = 0.0489, pPC = 0.0487). Note that
OLS, SS and PC tests have similar t− and p−values.
3.4 Conclusions
It is clear that no universally optimal solution can be found for global testing.
Bonferroni-type methods can be more appropriate in the presence of one or few
significant independent outcomes. Multivariate tests are more appropriate when
the multiple outcomes are highly correlated and the effects are locally small but
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globally large. Driven by our motivating application of neuroimaging studies, we
mainly focus on multivariate tests.
If the sample size is sufficiently large, particularly substantially larger than
the observations’ dimension, Hotelling’s T 2 test is very efficient. However, if the
sample size is small and prior knowledge about the direction of the effect is available,
linear combination tests provide an appealing alternative solution.
D’Agostino and Russell [2005] address three issues arising with O’Brien-
type linear combination tests. The first considers the inflation of type I error in
GLS tests. The second issue regards the inappropriateness of these tests in cases
where the prior knowledge about the direction of the effect is either not reliable or it
indicates a non-uniform effect direction. The third issue is concerned with situations
where the second GLS test gives negative weights, but also more generally with the
interpretability of results derived under O’Brien-type tests.
Except from the first issue regarding type I error control, which is addressed
by La¨uter’s exact tests, the latter two issues remain outstanding. As we discuss
later, the methodology developed in later chapters attempts to address these issues
and provide satisfactory solutions.
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Chapter 4
Optimal linear combination
tests
4.1 Introduction
As we discussed in the previous chapter, D’Agostino and Russell [2005] raise three
issues regarding O’Brien-type linear combination tests. These are in fact directly
connected to the most important targets not only for O’Brien-type linear combina-
tion tests, but generally every testing procedure.
The first target is type I error control. This is the main target in hypothesis
testing, especially within the context of clinical trials, in order to provide credibil-
ity to “positive” outcomes, that is, rejection of H0. The second is type II error
minimisation or equivalently power maximisation. This is required to ensure that
“negative” outcomes, i.e. not rejection of H0, are not derived simply because the
study has insufficient power (for example insufficient sample size), but also to ensure
that sufficient power is attained efficiently, i.e. without excessive use of the human or
monetary resources. The third target is interpretability of the derived conclusions.
This is often required because investigators are not satisfied by a single statement
whether the null hypothesis is rejected or not, but they wish to be able to explain
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the outcome. The linear combination tests developed in this chapter attempt to
provide methodology satisfying these targets.
The proposed linear combination tests explicitly use prior knowledge to select
the weighting vector w. The use of prior knowledge for selecting the weighting vec-
tor has been suggested earlier by various authors. Specifically, La¨uter et al. [1996];
Pocock et al. [1987] and Tang et al. [1993, 1989b] addressed that O’Brien’s approach
to select w, under the assumption of uniform effect structure, reflects the investiga-
tors prior knowledge about the direction of the effect. They suggested that, if prior
knowledge suggests a different structure due to different clinical or effect importance
across outcomes, this should be expressed in the weighting vector. Furthermore, in
our motivating application of neuroimaging studies, there is typically at least some
vague prior knowledge about the effect structure. This can arise, for instance, from
the spatial structure of the multivariate outcome. The methods developed next
provide a formal framework for optimally incorporating such prior information into
weighting vector selection. However, prior information is used only to select the
weighting vectors and not for the final data evaluation.
For selecting the weighting vector, in addition to prior information, we also
suggest using data from a preliminary sample obtained from a pilot study. Pilot
studies are often performed prior to the main study to derive information, such
as estimates of nuisance parameters, which is then used to decide various aspects
of the design of the main study [Lancaster et al., 2004]. Birkett and Day [1994]
and Shih et al. [2004] discuss the use of pilot studies for determining the sample
size of the main study. Gupta and Perlman [1974] use a preliminary sample to
decide whether to include additional, possibly costly or time-consuming, variables
to perform a Hotelling’s T 2 test. Westfall et al. [1998] use pilot data to select the
component-wise significance levels in multiple testing. The use of pilot data, in
our methods, allows the possibility of re-assessing prior information for the effect
direction and potentially correcting the weighting vector.
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The weighting vectors are optimally selected to maximise the predictive
power of the test based on prior information and the pilot data. Predictive power
is the chance to reject the null hypothesis H0, at the final analysis, given the infor-
mation available at a certain stage. Specifically, predictive power is defined as the
probability to reject H0 given an information set I,
b = Pr( reject H0 | I).
The information set I may include prior information and/or observed data. Note
that predictive power is a probability defined in the Bayesian context. It can be
derived by averaging the rejection probability over the distribution of the parameters
given the information set I and for this reason it is often called expected or average
power.
Predictive power has been used for sample size calculation [Huson, 2009;
Lan and Wittes, 2012; O’Hagan and Stevens, 2001; Spiegelhalter and Freedman,
1986], monitoring clinical trials and stochastic curtailment [Spiegelhalter et al.,
1986], treatment selection [Kimani et al., 2009], population selection [Brannath
et al., 2009] and to select the component-wise significance levels in multiple testing
[Westfall et al., 1998]. The use of predictive power for sample size calculation and
stochastic curtailment has been criticised for incorporating the whole distribution
of the parameters imposing probabilities for even extreme values. Thus, if investiga-
tors consider predictive power in the same scale with the power of the test, this may
unnecessarily lead to large sample sizes and early stopping [Jennison and Turnbull,
1990]. However, as becomes clearer in later sections, these issues do not apply to
our methods. In our methods, predictive power is used to allow for incorporating,
in a natural and plausible way, prior information and pilot data in determining the
weighting vector. By selecting the weighting vectors that maximise predictive power,
our selection becomes power-optimal with respect to the collected information.
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This chapter is organised as follows. We start by formulating linear com-
bination tests and discussing some of their principal characteristics. We stress the
importance of the weighting vector and proceed to derive the weighting vector max-
imising the power of the test. We then derive corollaries of the latter result which
provide links to alternative global tests. The optimal weighting vector depends on
the unknown model parameters and thus we then proceed to derive the predictive
power-optimal weighting vectors used in the proposed tests. The chapter is closed
with discussion of some of the properties of the latter tests.
4.2 Formulation
We now formally set-up the problem of evaluating the global hypotheses using lin-
ear combination tests of multivariate observations. Linear combination tests have
already been briefly formulated and discussed in the previous section, however, to
ensure clarity of our results, the problem is considered again from the beginning.
Let the K−dimensional response vectors xi = (xi1, xi2, . . . , xiK)T for sub-
jects i = 1, 2, . . . , n be independent Gaussian random variables
xi ∼ NK (µ,Σ) , (4.1)
with mean µ = (µ1, µ2, . . . , µK)
′ and covariance matrix Σ = (σkk′)
K
k,k′=1. Here, the
diagonal entries of the positive definite matrix Σ are the variances, σkk = σ
2
k, of the
local outcomes and the off-diagonal entries the covariances, σkk′ = σkσk′ρkk′, where
ρkk′ the correlations between the outcomes xk and xk′ , k, k
′ = 1, 2, . . . ,K, k 6= k′.
We wish to test the global null hypothesis of no treatment effect against the
two-sided alternative
H0 : µ = 0K = (0, 0, . . . , 0)
T versus H1 : µ 6= 0K . (4.2)
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The multivariate observations are reduced to the scalar linear combinations
yi = w
Txi =
K∑
k=1
wkxik, i = 1, 2, . . . , n, (4.3)
with non-zero fixed weighting vector w = (w1, w2, ..., wK)
T 6= 0K . The linear com-
binations yi for subjects i = 1, 2, . . . , n, are independent Gaussian random variables
yi ∼ N(µ, σ2), (4.4)
where µ = wTµ and σ2 = wTΣw. Note that, under H0, yi ∼ N(0, σ2), i =
1, 2, . . . , n.
The likelihood-ratio z and t statistics for testing H0 against H1 on the basis
of the random sample yi, i = 1, ..., n are
z =
y¯
σ/
√
n
, t =
y¯
s/
√
n
, (4.5)
for σ known and unknown, respectively. Here,
y¯ =
1
n
n∑
i=1
yi, s
2 =
1
n− 1
n∑
i=1
(yi − y¯)2 (4.6)
are the sample mean and sample variance of the linear combinations.
Under H0, the z and t statistics are standard normal, z ∼ N(0, 1), and
Student’s t distributed with n− 1 degrees of freedom, t ∼ tn−1. Thus, the decision
rule to reject the null hypothesis H0 if and only if respectively
|z| > zα/2, |t| > tn−1,α/2, (4.7)
specify hypothesis tests of size α. It might be useful to stress that the latter tests,
henceforth called linear combination z and t tests or simply z and t tests, exactly
control the type I error at the nominal α level.
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For any arbitrary value of µ, the z and t statistics are respectively normally
and non-centrally t distributed, z ∼ N(θ¯, 1) and t ∼ tn−1(θ¯) with location parameter
θ¯ = θ
√
n, θ = µ/σ =
wTµ
(wTΣw)
1/2
. (4.8)
The latter parameter θ, often interpreted as the signal-to-noise ratio, is central in
the methods to follow. The power of these tests, for given values µ 6= 0K and Σ,
are respectively
βz = Pr
(|z| > zα/2) , βt = Pr (|t| > tn−1,α/2) . (4.9)
Note that, unlike Hotelling’s T 2 test, the linear combination z and t statistic do
not depend on the dimension of the response K and hence they are applicable even
for n < K. However, as we explained in the previous chapter, this is attained
by restricting our search for treatment effects to a single direction defined by the
weighting vector. In what follows, we focus on deriving an optimal weighting vector
maximizing the power of the herein described linear combination z and t tests.
4.3 The power-optimal z∗ and t∗ tests
Power maximisation is one of the most important targets in hypothesis testing. It
is an intuitively correct approach since it targets maximization of the probability
to detect a treatment effect. We wish to derive the weighting vector maximizing
the power of linear combination z and t tests. The next lemma is the first step for
computing this power-optimal weighting vector.
Lemma 4.3.1. Under (4.1), the power, βz, of the single-stage z test is non-decreasing
in the absolute value of θ in (4.8).
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Proof. The power of the single-stage z test can be written as
βz = Pr
(
|z| > zα/2
)
= 1− Φ
(
zα/2 − θ¯
)
+Φ
(
−zα/2 − θ¯
)
,
where Φ(·) the cumulative distribution functions of the standard normal distribution
N(0, 1). Its derivative with respect to θ is
dβz
dθ
=
√
n
(
φ
(
zα/2 − θ¯
)
− φ
(
−zα/2 − θ¯
))
,
where φ(·) the density of the standard normal distribution. The latter derivative is
non-negative for θ ≥ 0 and negative for θ < 0. Therefore, βz is non-decreasing in
|θ|.
The above result can be generalized to the t test. For this we use the well-
known representation of the cumulative distribution function, Ψθ,ν(·), of the non-
central tν(θ) distribution (see for example Johnson et al. [1995])
Ψθ,ν(t) =
∫ ∞
0
Φ
(
xt√
ν
− θ
)
hν(x) dx, (4.10)
where hν(x) the density of the χν distribution with ν degrees of freedom.
The following result is proved by showing that for every fixed value in the
support of the χν distribution (ν = n − 1), similar results to the z test can be
obtained.
Lemma 4.3.2. Under (4.1), the power, βt, of the single-stage t test is non-decreasing
in the absolute value of θ in (4.8).
Proof. The power, βt, of the single-stage t test can be written as
βt = Pr
(|t| > tν,α/2) = 1−Ψθ¯,ν (tν,α/2)+Ψθ¯,ν (−tν,α/2) .
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Using equation (4.10), we derive that
dβt
dθ
=
∫ ∞
0
√
ν
(
φ
(
xtν,α/2√
ν
− θ¯
)
− φ
(
xtν,α/2√
ν
+ θ¯
))
hν(x)dx.
For any x ≥ 0, the quantity φ
(
xtν,α/2√
ν
− θ¯
)
− φ
(
xtν,α/2√
ν
+ θ¯
)
is nonnegative for
θ ≥ 0 and negative for θ < 0. Thus, the derivative dβtdθ is nonnegative for θ ≥ 0 and
negative for θ < 0, which implies that βt is non-decreasing in |θ|.
Lemma 4.3.1 and 4.3.2 imply that the power of the single-stage z and t tests
is maximized if and only if the value of θ is maximized. These results, in addition to
being crucial for deriving theorem 4.3.1 below, can also be useful for more general
settings, as for instance in linear regression, to construct power-optimal procedures.
Considering the linear combination z and t tests, lemma 4.3.1 and 4.3.2 imply
that in order to maximize the power of these tests with respect to the weighting
vectors w, it is sufficient to maximize the value of θ. Using this result, we next
derive the power-optimal weighting vector.
Theorem 4.3.1. Under (4.1), the power of the single-stage z and t tests is maxi-
mized with respect to w if and only if w is proportional to
ω∗ = Σ−1µ. (4.11)
Proof. The Generalized Cauchy-Schwarz inequality (see page 178 [Anderson, 2003])
states that
θ2 =
(w′µ)2
wTΣw
≤ µΣ−1µ,
with equality obtained if w = ω∗ in (4.11). The results then follow by lemmas 4.3.1
and 4.3.2.
The optimal weighting vector, ω∗, in (4.11) is a standardization of the treat-
ment effect µ, with respect to Σ. The form of ω∗ implies that larger local effects µk,
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smaller local variances σ2k and lower correlation values ρkk′ , k
′ 6= k, all contribute
to larger ω∗k. We write z
∗ and t∗ the optimal z and t tests with weighting vector
w = ω∗ and their power functions β∗z and β∗t .
Using theorem 4.3.1, we can derive simple results describing mean and co-
variance structures for which O’Brien’s OLS and GLS tests [O’Brien, 1984] are
power-optimal.
Corollary 4.3.1. The power-optimal ω∗ in (4.11) is equal to
1. the weighting vector wGLS,2 = Σ
−11K , if µ ∝ 1K ,
2. the weighting vector wGLS,1 = (σ
−1
1 , σ
−1
2 , . . . , σ
−1
K )
T , if µ ∝ 1K and Σ is a
diagonal matrix, as in the correlations ρkk′ = 0, ∀ k, k′ = 1, 2, . . . ,K, k 6= k′,
3. the weighting vector wOLS = 1K , if µ ∝ 1K and Σ−11K = c1K , c constant,
that is, 1K is an eigenvector of Σ
−1 with c the corresponding eigenvalue.
Proof. The result is proved by applying the appropriate values of µ andΣ at ω∗.
From theorem 4.3.1, we can also derive the following result allowing us to
compare the optimal power, β∗t , of the t test to the power of Hotelling’s T
2 test βT 2 .
Corollary 4.3.2. For fixed values of the parameters µ, Σ and sample size n ∈
(K,∞), where K > 1,
β∗t > βT 2 .
Proof. Under (4.1), the t∗ statistic follows the non-central t distribution with n− 1
degrees of freedom and non-centrality parameter θ∗
√
n. Here,
θ∗ =
ω∗Tµ(
ω∗TΣω∗
)1/2 = µTΣ−1µ(µTΣ−1ΣΣ−1µ) = (µTΣ−1µ)1/2 = ∆,
where ∆ is the Mahalanobis distance. Hence, the square of the t∗ statistic, t∗2,
follows the non-central F−distribution with non-centrality parameter ∆2 and (1, n−
54
1) degrees of freedom, that is, t∗2 ∼ F1,n−1(∆2). Thus, the power of the t∗ test can
be written as
β∗t = Pr
(
t∗2 > t2n−1,α/2
)
= Pr
(
F1,n−1(∆2) > F1,n−1,α
)
,
where F1,n−1,α is the 100(1 − α) percentile of the F1,n−1 distribution. Further, the
power of Hotelling’s T 2, using the relation between the T 2 and F distributions in
(3.17), can be written as
βT 2 = Pr
(
FK,n−K(∆2) > FK,n−K,α
)
.
The result then follows by corollary 2.1 in Gupta and Perlman [1974] which implies
the inequality
β∗t = Pr
(
F1,n−1(∆2) > F1,n−1,α
)
> Pr
(
FK,n−K(∆2) > FK,n−K,α
)
= βT 2 .
Note that the sample size restriction, in corollary 4.3.2, is required only to
ensure that Hotelling’s T 2 test is applicable. For smaller sample sizes, the T 2 test
is not applicable. The above result stress the scope for improvement to the power
of Hotelling’s T 2 test by using linear combination tests. It shows that the power of
the t∗ test is strictly larger than the power of T 2, while, as we can see in Figure 4.1,
the difference between the two power functions can be considerably high, especially
for small sample sizes.
Although these results are promising, it still remains that the optimal weight-
ing vector ω∗ depends on the unknown modelling parameters. Therefore, the opti-
mal weighting vector is unknown and cannot be used in practice. We next propose
a method to optimally select the weighting vector in practice.
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Figure 4.1: The power of T 2 and t∗ tests versus the sample size n. The power of
t∗ is substantially larger than power of T 2 for small sample sizes, while for large
sample sizes both power functions reach β = 1. Here α = 0.05, K = 10.
4.4 The z+ and t+ tests
Since the optimal weighting vector ω∗ depends on the unknown model parameters
µ and Σ, suitable estimates must be derived to select the weighting vector. In this
work, we propose estimating the weighting vector using prior information and data
collected from a pilot study conducted prior to the main study. Here, we assume
that the pilot and main study observations, xp and x, respectively, are sampled
under the same conditions. That is, we let the K−dimensional pilot observations,
xpi, be independent multivariate normal random variables
xpi ∼ NK (µ,Σ) , i = 1, 2, ..., np (np ≥ 0), (4.12)
with mean µ and covariance matrix Σ.
Prior information, I0, elicited from previous studies and expert clinical opin-
ion is used to inform standard conjugate multivariate priors for the response mean
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and covariance matrix. For the mean response we use the prior
(µ | Σ, I0) ∼ NK (m0, Σ/n0) , (4.13)
where m0 represents a prior estimate of the value of µ and n0 corresponds to the
number of observations on which this prior estimate is based. When Σ is unknown,
we use the inverse-Wishart K ×K prior
(Σ | I0) ∼ IWK×K
(
ν0, S
−1
0
)
, (4.14)
where ν0 and S0 respectively represent the degrees of freedom and the (positive
definite) scale matrix of the inverse-Wishart prior.
Under this standard Bayesian model (for example see [Gelman et al., 2004]),
the posterior distribution of µ given the information set, I = {I0,Xp}, and condi-
tional on Σ, is K−dimensional Gaussian with covariance matrix Σ/(n0 + np) and
mean
m =
n0
n0 + np
m0 +
np
n0 + np
x¯p, (4.15)
where x¯p = (np)
−1∑np
i=1 xpi is the multivariate sample mean of the pilot data.
The posterior distribution of the covariance matrix (Σ|I) is inverse-Wishart with
ν = n0 + np − 1 degrees of freedom and scale matrix
S = S0 + (np − 1)Sxp +
n0np
n0 + np
(x¯p −m0)(x¯p −m0)T , (4.16)
where Sxp = (np−1)−1
∑np
i=1 (xpi − x¯p) (xpi − x¯p)T is the sample covariance matrix
of the pilot data.
In particular, the modeling assumptions (4.12), (4.13) and (4.14) encompass
the following special cases: (i) no prior information is available or n0, ν0 → 0, (ii)
no pilot data is used to select the weighting vector or np = 0. In case (i) we require
np−1 > K to obtain a positive definite S. However, it should be stressed that these
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methods rely on prior information for the effect direction and if no prior information
is available the investigators may find it more appropriate to use the non-directional
Hotelling’s T 2 test.
We wish to use this information to select the weighting vectors wj optimally.
Optimality here is expressed in terms of predictive power of the test. The predictive
power of the z and t test given the information set I is defined as
bz = Pr
(|z| > zα/2| I ) , (4.17)
bt = Pr
(|t| > tn−1,α/2| I ) . (4.18)
The following theorem provides the weighting vectors maximising the pre-
dictive power of the z and t tests given the information set I.
Theorem 4.4.1. Under (4.1), (4.12) and (4.13), the predictive power, bz, of the z
test in (4.17) is maximized with respect to the weighting vector w if and only if w
is proportional to
wz+ = Σ
−1m, (4.19)
where m as in (4.15).
For np → ∞, the predictive power, bt, of the t test in (4.17) is maximized
with respect to the weighting vector w if and only if w is proportional to
wt+ = S
−1m, (4.20)
where m, S define as in (4.15) and (4.16), respectively.
Proof. The z statistic can be written as
z = θ
√
n+ e, e ∼ N(0, 1),
where θ is defined in (4.8). Under (4.1), (4.13), (θ | I) is normally distributed with
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variance (n0 + np)
−1 and mean
θˆ = wTm/σ.
Thus, (z | I) ∼ N
(
θˆ
√
n, 1 + n/(n0 + np)
)
. The result is then proved using the
same steps as in theorem 4.3.1 where θ is replaced by θˆ.
For the t test, we compute the asymptotic distribution of t | I as np → ∞.
By Bayes’ rule, under (4.1), (4.13), (4.14), we have that,
(xi | I) ∼ tK (ν0 + np −K + 1,m, cS) , i = 1, 2, . . . , n
where
c =
n0 + np + 1
(n0 + np)(ν0 + np −K + 1) .
Hence for np →∞,
(xi | I) ∼ NK (m,S) , i = 1, 2, . . . , n
Using the last result and corollary 7.2.3 in Anderson [1984] we have, for y¯ = wT x¯,
that
(y¯|I) ∼ N (wTm,wTSw/n) . (4.21)
Using the same result we have that for Sx = (n − 1)−1
∑n
i=1(xi − x¯)(xi − x¯)T ,
(Sx|I) ∼WK×K (n− 1,S/(n − 1))
and hence, for s2 = wTSxw, by proposition 3.4.2 in Mardia et al. [1979] that
(
s2
wTSw/(n− 1) |I
)
∼ χ2n−1, independent of y¯. (4.22)
From (4.21) and (4.22), it follows that the asymptotic distribution of the t statistic
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in (4.5) given I and for np →∞ can be written as
t | I = z + ϑˆ
√
n√
x2/(n− 1) ,
where z ∼ N(0, 1) and x2 ∼ χ2n−1, that is, t | I, for np → ∞, is approximately
non-central t distributed with non-centrality parameter
ϑˆ
√
n =
wTm√
wTSw
√
n
and n− 1 degrees of freedom. The result follows by replacing θ with ϑˆ in the proof
of theorem 4.3.1.
In the weighting vectors wz+ and wt+ , compared to ω
∗, the unknown model
parameters are replaced by their posterior estimates. Hence, outcomes which based
on the elicited prior knowledge and the observed pilot data are expected to have
larger effects, smaller variances and smaller correlations, they receive greater weights.
It is important to stress that the above information is collected and the
weighting vectors are fixed prior to the start of the main study. The pilot data is
only used for selecting the weighting vector and possibly for selecting other aspects
of the design of the study (for example the sample size n). Herein we will refer
to z+ and t+ as representing the linear combination z and t test statistics with
weighting vectors wz+ and wt+ , respectively. The fact that the weighting vectors
wz+ and wt+ are chosen before the initiation of the main study implies that the z
+
and t+ tests control the false positive rate at their nominal significance level. We
next consider an alternative approach to our problem. Note that in the next section
we use a slightly different notation than the rest of the thesis to suit better Bayesian
methodology.
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4.5 Bayesian multivariate tests
For purposes of comparison, it might be interesting to consider an alternative fully
Bayesian approach. First, it is useful to make clear the reasons why in this thesis
we focus on hybrid methods which use prior information to select design parameters
such as the sample size or, in our problem, the weighting vector, but derive statistical
inference using classical frequentist methodology.
The primary reason is that in our motivating applications, that is, neu-
roimaging but more generally biomedical studies and clinical trials, the control of
the frequentist or long-run type I error is of paramount importance. In Bayesian
methodology, frequentist or long-run probabilities are conceptually irrelevant and
their computation is often complicated and dependant on prior specification. Fur-
thermore, control of these probabilities is often not attained. Another reason for
not following a fully Bayesian methodology is that, in our motivating examples, the
use of prior distribution for statistical inference is often controversial and in clinical
trials is typically prohibited. In contrast, the use of prior information for the design
of the study, as in our methods, is widely acceptable. Finally, Bayesian tests and es-
pecially those performed using Bayes Factors tend to be complicated and unfamiliar
to practitioners and the latter introduces further complexities in implementation.
However, in cases where these concerns are less important, one may wish
to follow a Bayesian methodology as this allows a more natural way to synthesize
information from various sources and to assess the data evidence against or in favour
of the null hypotheses based on posterior probabilities.
There are several ways to derive a Bayesian test. First, one may use the pos-
terior probabilities Pr(H0|x) and Pr(H1|x). This results, for Σ known, to rejecting
H0 for large values of the posterior Mahalanobis distance (n0 + n)m
′Σ−1m where
m the posterior mean of µ. As [Berger,1985] comments “posterior probabilities of
hypotheses are the primary Bayesian measures in testing problems”.
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Bayesian tests are also often derived using Bayes Factors,
BF =
posterior odds ratio
prior odds ratio
=
Pr(H0|x)/Pr(H1|x)
Pr(H0)/Pr(H1)
.
expressing the odds for H0 to H1 given by the data (but in most cases also affected
by the prior). The Bayes Factor can be re-written in the more convenient form,
BF01 =
Pr(x|H0)
Pr(x|H1)
which shows the connections of BF with the likelihood ratio. In our setting,
BF01 =
f(x;µ = 0K)∫
µ 6=0 f(x;µ)f(µ|I0)dµ
=
L(µ = 0K ;x)∫
L(µ;x)f(µ)dµ
where f(x;µ) and L(µ;x) the density of the data x and the likelihood function of
the parameter value µ while f(µ) the prior density of µ1. We consider here the case
of known Σ and we set the prior
f(µ) =


p0, for µ = 0K ,
(1− p0)φm0,T0(µ), for µ 6= 0K ,
where φm0,T0(·) the density of multivariate normal distribution with mean m0 and
covariance matrix T0. The latter ensures a non-zero value for the prior (and poste-
rior) probability of H0. Under this prior, we compute
BF01 =
∣∣∣∣T0T1
∣∣∣∣
1/2
exp
[
−n
2
{
x¯TΣ−1x¯− (x¯−m0)T
(
Σ−1T1T−10
)
(x¯−m0)
}]
,
1The restriction µ 6= 0 is omitted in the last equation as the value of the integral is unchanged
with the addition of a single point of a continuous function in the integration area.
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where
T1 =
(
T−10 + nΣ
−1)−1
the covariance matrix of the posterior distribution of µ. Note that if we take
T0 = Σ/n0
then the form of the Bayes Factor simplifies to
BF01 =
(
n1
n0
)1/2
exp
[
−n
2
{
x¯TΣ−1x¯− n0
n1
(x¯−m0)T Σ−1 (x¯−m0)
}]
,
where n1 = n0 + n.
In order to get a better idea of how the Bayes Factor approach compares
with our methodology we next provide a short empirical study. Here we fix the
observation dimension K = 5, the pilot sample size np = 8, the main study sample
size n = 12 (total sample size nT = np + n = 20) and T0 = Σ/n0 with the prior
sample size n0 = 5. We approximate the power of z
+, βz+ , and the power of the
Bayes Factor test, βBF , by the rate of rejections in R = 20000 iterations. For the
Bayes Factor test, the null hypothesis H0 is rejected for BF10 = BF
−1
01 > b = 8. The
latter is a very conservative boundary, since typically b > 3 is considered significant
evidence against H0 [Kass,1995].
In table 4.1 we provide the power of the above tests for various values of
the model parameters µ and Σ and the prior m0. The mean parameter µ is taken
under both H0 (µ = 0K) and H1 (µ = 1K/
√
K), while in both cases the priors
m0 = 0K ,1K/
√
K are applied. As we can see, the Bayes Factor test, even for
the conservative boundary b = 8, can seriously inflate the type I error rate (see
βBF for µ = 0K). The latter rate depends strongly on the prior specification and
the covariance structure for the Bayes Factor test, in contrast to the z+ test which
controls type I error. Higher power is achieved by the Bayes Factor test (although
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this must be considered in the light of a higher type I error rate).
Table 4.1: Power of z+ and Bayes Factor test for various values of the model param-
eters µ and Σ and the prior m0. Here, K = 5, np = 8, n = 12 (nT = np + n = 20),
T0 = Σ/n0, n0 = 5, b = 8.
Σ µ m0 βz+ βBF
IK 0K 0K 0.05 0.21
1K/
√
K 0.05 0.06
1K/
√
K 0K 0.77 0.99
1K/
√
K 0.88 0.99
block diagonal 0K 0K 0.05 0.20
with blocks I2, I3/2 1K/
√
K 0.05 0.03
1K/
√
K 0K 0.95 0.99
1K/
√
K 0.98 0.99
The case of unknown Σ is more complicated and it is not considered here.
4.6 Discussion
The proposed methodology attempts to provide solutions satisfying the three main
targets of hypothesis testing as discussed in section 4.1. Firstly, we believe that
connecting the weighting vector to the prior knowledge and pilot data using a for-
mal framework improves the interpretability of the conclusions. The investigators
along with the outcome of rejection or acceptance of the null hypothesis, can easily
understand why an outcome is more or less heavily weighted to derive the conclusion.
Furthermore, the type I error of these tests is controlled by simply fixing
the weighting vector prior to the beginning of the main study. It is important to
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acknowledge that prior information is used only to select the weighting vector and
not for the final data evaluation. This procedure can be readily extended to allow
for further design parameters to be decided using the prior information and the pilot
data without inflating the type I error. The power performance of the z+ and t+,
including comparisons to alternative global tests, will be studied in chapter 8. In
section 8.4, we also consider applications to the neuroimaging examples described
in sections 2.3.2 and 2.4.2.
In situations where the sample size is limited, conducting a pilot study ex-
ternal to the main study, using a part of the available sample, has some crucial
disadvantages. The main disadvantage of these external pilot studies is that they
introduce a trade-off with often no satisfactory solution. On the one hand, per-
forming a small pilot study allows for a sufficient sized sample to be used in the
main study, but may not provide sufficient information to design the latter. On the
other hand, relatively large pilot studies, reduce substantially the sample size for
the main study and raise ethical concerns for not directly using a substantial part
of the observations for the final conclusions [Bauer and Ko¨hne, 1994; Jennison and
Turnbull, 2000].
In chapter 6 we develop methodology to replace the external pilot study with
an internal pilot study. This internal pilot study can be seen as the first stage of
a two-stage or, generally, a multi-stage study. Here the pilot data is used for both
testing and to select the weighting vector of the second stage. Adaptive designs,
which are considered in the next chapter, allow for such testing procedures to be
performed without inflating the type I error.
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Chapter 5
Adaptive designs
5.1 Introduction
All the global tests considered in chapters 3 and 4 assume a simple standard design.
Specifically, they assume that the multivariate outcome, x, is randomly sampled
from a study conducted under the classical single-stage design (SSD). This is the
textbook approach [Armitage et al., 2002; Friedman et al., 2010; Matthews and
Farewell, 2007; Peacock and Peacock, 2011] for the design of experiments inclusive
of those performed in biomedical research (for example clinical trials, epidemiological
studies). Under SSD, the investigators define all aspects of the design (for example
target population, sample size, statistical methodology) at the planning stage. The
study is then conducted, the full dataset is collected and conclusions are lastly
derived following every step of the a priori fixed design. Any intervention to the
design is strictly prohibited to avoid bias of the final results.
There are various concerns arising under SSD, particularly in biomedical re-
search. These mainly ethical and economical issues necessitate the monitoring of
data acquisition with the possibility of early termination and interim design mod-
ifications. Sequential designs [Armitage, 1954; Wald, 1945] and later on adaptive
designs [Bauer and Ko¨hne, 1994; Proschan and Hunsberger, 1995] were developed
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to address these issues and allow for several actions to be taken at an interim point,
without contaminating the validity of the conclusions.
In this chapter, we provide background on sequential and adaptive designs
attempting to outline important issues and developments in the field. Our main
focus is the methodology underpinning the adaptive linear combination tests devel-
oped in later chapters, but also the group sequential global tests used mainly for
comparison. We begin with the concept of sequential and adapting designs and then
we describe the methodology for performing group-sequential and adaptive testing
procedures. Finally, we briefly summarize applications of these designs and discuss
their potential and the challenges to be overcome.
5.2 Early stopping and design adaptation
We next discuss the concepts that give rise to early stopping and interim design
adaptations. As we explain next, the latter motivate the development of sequential
and adaptive designs.
5.2.1 Early stopping
For studies, such as those performed in agriculture, where typically all the results
are made simultaneously available after a certain period of time, it is reasonable to
analyse data and derive conclusions only after the full dataset is collected. However,
in biomedical studies, as well as in industrial applications, where data is accumulated
gradually over a period of time, it is more natural to monitor results as observed
[Jennison and Turnbull, 2000; Whitehead, 1997].
Especially for clinical trials, not only it is natural, but several administrative,
economic and ethical reasons necessitate data monitoring. In this setting, it is im-
portant to check that the study is being conducted as planned (for example eligibility
criteria are satisfied), while it is also crucial to ensure the safety of the administrated
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treatments. Furthermore, for ethical and economic reasons, it is important to take
full advantage of the available human and monetary resources. Therefore, it is often
advantageous to terminate the study earlier than planned, if this is suggested by
interim results. Such early stopping allows the remaining resources to be allocated
to another study. Furthermore, if the new treatment is proved unsafe or ineffective,
early termination ensures that the remaining subjects can switch to a better treat-
ment, while if the new treatment is proved safe and more effective, the time for the
treatment to become publicly available is shortened [Jennison and Turnbull, 2000].
The latter ethical and economical issues were the main motivations for ex-
tending sequential design methodology initially developed for industrial applications
[Wald, 1945] to the medical field [Armitage, 1954, 1958]. However, the use of early
sequential designs in medical studies was initially restrained by their demand to
analyze data and decide for early stopping continuously, that is, after every ob-
servation. Group-sequential design (GSD) methodology developed later by Pocock
[1977] and O’Brien and Fleming [1979] enhanced application of sequential designs,
particularly in clinical trials. In group-sequential designs, interim analyses are per-
formed only after every time a number of observations (group) is collected. This
makes them practically less demanding, while most of the benefits of continuous
sequential designs are retained [Jennison and Turnbull, 2000].
Interim analysis and early stopping are also permitted under adaptive design
methodology. However, as we explain next, the main motivation for the adaptive
designs, developed after the work of Bauer and Ko¨hne [1994] and Proschan and
Hunsberger [1995], was to permit for interim design modifications.
5.2.2 Design modifications
As we briefly discussed above, in the standard fixed single-stage studies, the investi-
gators rely entirely on the information available at the planning stage to select the
experimental design. The latter defines how the study is to be conducted as well
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as how to analyze the results and derive statistical inference. Regarding the study
conduct, amongst other things, the investigators define the target population, the
number of participating subjects (sample size), the rule for allocating subjects to
different treatment groups and the measurements to be taken. Considering statis-
tical inference, the primary and secondary hypotheses to be studied are defined as
well as the corresponding measures (often called endpoints) and statistical method-
ology to be used for their evaluation. For the conclusions of the study to remain
valid under the traditional SSD, the study and the subsequent data analysis needs
to be conducted following in every step the initially specified design [Armitage et al.,
2002; Friedman et al., 2010].
However, in some cases, the information available at the planning stage is not
sufficiently precise and reliable to define all aspects of the design. This is a problem
arising even when primary design parameters, such as the sample size of the study,
are to be determined. For example, to compute the sample size of a clinical trial with
normally distributed responses, investigators are typically required to provide an
estimate of the response variance as well as the value of the treatment effect described
by regulatory authorities as the “minimal effect which has clinical relevance” [ICH,
1998]. However, in some cases, these values cannot be precisely defined, even after
the imperative careful planning. A similar problem is also confronted in linear
combination tests, in cases where the effect direction is not precisely known at the
planning stage. In such circumstances, investigators may be reluctant to design the
whole study based on imprecise estimates, as this might be considered as unethical
and can proved to be inefficient [Bauer and Ko¨hne, 1994; Kirby and Chuang-Stein,
2010].
One approach to this problem is to first perform a small external pilot study.
This pilot study can be used to obtain information for various aspects of the design
of the main study. In the tests developed in chapter 4, we follow this approach
for performing linear combination tests. However, as discussed in section 4.6, this
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approach has obvious limitations, especially in cases where only a restricted sample
size is available.
A more satisfying solution is provided by adaptive designs as well as various
developments of the classical group-sequential designs [Denne and Jennison, 2000;
Jennison and Turnbull, 2003; Wittes and Brittain, 1990]. This can potentially miti-
gate the ethical and economic issues arising with external pilot studies and provide
type I error control under certain design modifications. To deal with the issue of
insufficient information at the planning stage, these designs suggest performing an
internal rather than an external pilot study. That is, to consider the pilot study as
the first stage of a two-stage or, generally, a multi-stage study. The pilot or first-
stage data are then used for deriving interim decisions (for example early stopping
with rejection/acceptance of the null hypothesis), but they can also be used for
re-assessing and possibly modifying various aspects of the design. In a multi-stage
design, interim analysis and design modifications can be performed sequentially each
time a number of observations are collected.
Such designs can be seen as a method of allowing for modification, at interim
analyses, of the initially planned design. Various authors suggest interim design
modifications, under the above framework, to deal with new or unexpected results
becoming available during the study conduction [Chi et al., 1999; Proschan and
Hunsberger, 1995]. Such results may originate from other studies, but it can also
arise from the collected data. For example, Chi et al. [1999] describe a single-stage
study where at an interim analysis the observed treatment effects were substantially
lower than expected but still clinically significant. This suggested an increase in the
initially planned sample size as the latter was most likely not sufficient to derive a
statistically significant outcome. However, if such a sample size re-calculation was
not initially planned, it can be controversial and as various authors have shown
(for example Chi et al. [1999]; Proschan and Hunsberger [1995]), if ignored in the
final analysis, may substantially inflate the type I error. On the other hand, if the
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observed results are ignored and the study continues as planned, the resources of
the study might be wasted without reaching a convincing outcome. In the example
provided by Chi et al. [1999], the study progressed as originally planned and the final
analysis led to a statistically insignificant outcome. The above design framework
which permits for interim design modifications provides a solution to these issues.
Note that this design framework conceptually consists of two sequential parts
[Brannath et al., 2007]. The design of the first part is fixed, while the design of the
second part can be changed based on the information that becomes available at the
interim analysis, that is, interim data and possibly external information. Each part
may consist of a single-stage study, as in a single group of observations, but, it is
not unusual to conduct more than a single stage in the second part.
As we mentioned earlier, several authors proposed methodologies for per-
forming interim design modifications within the group-sequential design framework.
These approaches are typically characterized by a pre-planned adaptivity, that is,
adaptation rules are completely pre-specified at the planning stage. These pre-
planned adaptation rules are restricted to ensure that the form of the test statistics
remains as in SSD. For example, modifications are often required to be indepen-
dent of effect estimates and based solely on nuisance parameter estimates. If design
modifications are more flexible, often using the observed effects estimates, adaptive
design methodology is required to ensure type I error control.
In the next section, we describe the methodology for performing testing pro-
cedures within group-sequential and adaptive designs. We mainly focus on the issues
related to the methodology developed in later chapters. Special attention is given
to type I error control while power analysis of group sequential and adaptive tests
is conducted in chapter 8.
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5.3 Group-sequential testing
In group-sequential designs (GSD), interim analyses are performed after each group
of a (typically pre-specified) number of observations is collected. At these interim
analyses, a test is performed to decide whether to stop the study and either accept
or reject the (primary) null hypothesis, H0, or continue to the next stage. In the
standard GSD, the maximum number of analyses is pre-specified and if the final
analysis is reached, the study is terminated and a test is performed to either accept
or reject H0. The tests in these interim and final analyses are typically performed
using the same (often likelihood-ratio) statistics used in SSD applied to all the
collected observations.
We next illustrate this methodology with the group-sequential global tests
also considered in later chapters.
5.3.1 Group-sequential global tests
Suppose that we wish to evaluate the global null hypothesis of no treatment effect
H0 : µ = 0K using a group-sequential test. We use a GSD where up to J analyses
are sequentially performed after collecting n(1), n(2), . . . , n(J) observations, where
n(j) = n1+n2+ · · ·+nj, j = 1, 2, . . . , J . At the j−th interim analysis, we compute
the value of a pre-specified global test statistic and this is compared to suitable
rejection and acceptance stage-wise critical values to decide whether to continue the
study or stop the study and either accept or reject the global null hypothesis. The
test statistics are based on all the collected observations up to the interim analysis,
while the stage-wise critical values, as we explain in the next section, are derived to
control the overall error rates of the test.
The j−th stage linear combination z and t statistics are
z(j) =
y¯(j)
σ/
√
n(j)
, t(j) =
y¯(j)
s(j)/
√
n(j)
, (5.1)
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where σ is the (population) variance of the linear combination y = wTx, (w 6= 0)
and y¯(j), s(j) are the sample mean and sample variance of the linear combinations
collected up to the j−th interim analysis. Henceforth, we call the group-sequential
tests with stage-wise statistics as in (5.1) linear combination zGS and tGS or simply
zGS and tGS tests.
Furthermore, the group-sequential multivariate χ2GS and Hotelling’s T
2
GS
tests have stage-wise statistics
χ2(j) = n(j)x¯
T
(j)Σ
−1x¯(j), T
2
(j) = n(j)x¯
T
(j)S
−1
x(j)
x¯(j), j = 1, 2, . . . , J (5.2)
where x¯(j), Sx(j) are respectively the sample mean and sample covariance matrix of
all the collected observations up to the j−th interim analysis.
Critical values
The repeated multiple testing performed in GSDs, if ignored, may produce substan-
tial inflation of the type I error. This problem can be solved by considering the
multivariate joint distribution of the interim test statistics [Jennison and Turnbull,
2000]. Various forms of stage-wise critical values, controlling the tests’ error rates,
are proposed in the literature. Pocock [1977] and O’Brien and Fleming [1979] pro-
vide the classical fixed critical values, while Lan and DeMets [1983] propose the
error spending method in which critical values are derived, or the α rate is “spent”,
based on the observed information levels. Eales and Jennison [1992], Eales [1995]
and Barber and Jennison [2002] provide methods for optimally deriving critical val-
ues to minimize the average sample size used in the study, while controlling the
error rates of the test. In chapter 8, we use critical values of the class developed by
Wang and Tsiatis [1987] which include as special cases those obtained by Pocock
[1977] and O’Brien and Fleming [1979].
Calculating the group sequential critical values often requires numerical com-
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putation and, for this, various computer software (for example R, SPLUS, SAS,
FORTRAN) provide appropriate packages, such as the gsDesign implemented in R
[Anderson, 2013].
5.4 Adaptive testing
As in group-sequential tests, adaptive testing procedures perform interim analysis
to decide whether to terminate the study and reject or accept H0 after every time a
group of observations is collected, that is, a stage of the study is completed. How-
ever, adaptive tests are constructed to permit for interim adaptations and for this
a suitable framework ensuring type I error control is developed. Adaptive testing
procedures are often expressed in terms of combination functions which are used to
combine the stage-wise test statistics at each interim analysis. As explained in the
following sections, adaptive combination tests that adhere to the conditional invari-
ance principle (CIP) attain type I error control. Alternatively, adaptive tests are
expressed in terms of conditional error functions (CEF) in which case the conditional
error principle is often used to prove type I error control [Bretz et al., 2009].
5.4.1 Combination tests
We next describe the adaptive combination tests and the conditional invariance
principle which provide type I error control in these tests. For simplicity, we consider
only two-stage designs, but the methodology can be easily extended to designs
with more stages. In particular, the adaptive combination tests developed in later
chapters use a more general J−stage (J ≥ 2) representation.
Here, the design of the first-stage is fixed at the planning stage, while the
second-stage design can be decided at the interim. After each stage, the observed
data is used to compute the value of the stage-wise statistics, T1 and T2, and the
corresponding p−values, p1 and p2. Note that the form of the first-stage statistic,
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T1, is fixed at the planning stage, while the form of the second stage statistic T2 can
be decided at the interim. At the planning stage, a combination function, C(p1, p2),
monotonically increasing in both arguments, is specified. This combination function
defines how the p−values of the two-stages are combined in the final analysis. In
addition, at the planning stage, we define the acceptance and rejection critical values,
α1,0, α1,1 and α2,1, that satisfy the type I error equation of the test described below.
The study is conducted as follows. After collecting the observations of the
first stage, the p−value p1 is computed and if p1 ≤ α1,1 or p1 ≥ α1,0 the study is
stopped with rejection or acceptance of H0, respectively. If p1 ∈ (α1,1, α1,0), the
study continues to the second stage. The design of the second stage is decided
and the second stage is conducted. After all observations are collected, the study
terminates and the second-stage p−value is computed and combined with p1 using
C(p1, p2). The null hypothesis H0 is then rejected if C(p1, p2) ≤ α2,1, otherwise
accepted. The two-stage combination test can be formally described as follows:
At the interim analysis,
if p1 ≤ α1,1 , stop study and reject H0,
if p1 ≥ α1,0 , stop study and accept H0,
otherwise, continue to stage 2.
At the final analysis,
if C(p1, p2) ≤ α2,1, stop study and reject H0,
otherwise, stop study and accept H0.


(5.3)
The above combination test is said to satisfy the conditional invariance prin-
ciple (CIP) if, despite the dependence of the second stage p−value, p2, on the in-
terim data,X1, the conditional null distribution of p2 given the interim data, p2|X1,
equals a pre-specified null distribution. In other words, the CIP is satisfied, if the
conditional null distribution of p2|X1 is invariant to the design adaptation. Un-
der this requirement, type I error of this combination test is controlled despite the
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adaptations [Brannath et al., 2012; Bretz et al., 2009].
Example: Normally distributed stage-wise statistics
We now illustrate the application of CIP at a combination test with normally dis-
tributed stage-wise test statistics. This example applies to the adaptive tests de-
veloped in later chapters. First suppose that no adaptations are performed. Then,
the test statistics T1 and T˜2, under H0, are standard normally distributed. Thus,
the corresponding p−values, p1 and p˜2, are independent and uniformly distributed
on (0, 1), as in p1, p˜2 ∼ U(0, 1) [George and Mudholkar, 1990]. Suppose now that
an adaptation of the second stage is performed (for example sample size increased)
based on the interim data X1. The second-stage statistic is now changed to T2. If,
despite the adaptation, the conditional null distribution of the modified p−value,
p2|X1, is still uniform, p2|X1 ∼ U(0, 1), the type I error of the combination test is
controlled.
In this example, the type I error equation of the test in (5.3) is
α = α1,1 +
∫ α1,0
α1,1
Pr0
(
C(p1, p2) ≤ α2,1|p1
)
dp1, (5.4)
where the index 0 (as in Pr0(·)) indicates that the above probabilities are computed
under the null hypothesis. If CIP is satisfied and the rejection and acceptance
critical values are chosen at the planning stage to satisfy (5.4), the above equation
holds even if design adaptations are performed at the interim analysis [Bauer and
Ko¨hne, 1994; Brannath et al., 2002; Bretz et al., 2009].
Note that, in this example, CIP implies stochastic independence between the
p−values p1 and p2, under H0. However, for type I error control, a weaker argument
is sufficient. This is that the conditional distribution p2|X1 is stochastically larger
than the uniform distribution of p2 or, formally,
Pr0(p2 ≤ u |X1) ≤ Pr0(p2 ≤ u) = u, u ∈ (0, 1). (5.5)
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The latter distribution of p2 is also described as the conditionally larger than uniform
or p−clud distribution [Brannath et al., 2002].
Combination function
Several combination functions are proposed in the literature. Bauer and Ko¨hne
[1994] suggest the use of Fisher’s product combination function [Fisher, 1970],
C(p1, p2) = p1p2, while Lehmacher and Wassmer [1999] suggest the use of the
weighted inverse normal combination function [Liptak, 1958],
C(p1, p2) = 1− Φ(c1Φ−1(1− p1) + c2Φ−1(1− p2)). (5.6)
Here Φ(·) denotes the cumulative distribution function of the standard normal dis-
tribution and c1, c2 pre-specified weights (c
2
1 + c
2
2 = 1). The latter weights re-
flect the importance of each stage in the test. If the weights c1 =
√
n1/(n1 + n2),
c2 =
√
n2/(n1 + n2) are used and no adaptations are performed, the combination
function in (5.6) is equal to the classical group-sequential statistic for normally dis-
tributed stage-wise test statistics. The latter two combination functions are the
most commonly used in the literature (see Bauer and Einfalt [2006]).
Other combination functions, such as the sum of p−values [Chang, 2007],
as well as variations of Fisher’s product [Brannath et al., 2002] and the inverse
normal [Chi et al., 1999] are also suggested. These combination functions are also
used in meta-analysis (see [Hedges and Olkin, 1985]). Finally, in a development
of combination tests, Brannath et al. [2002] propose a recursive combination test
which allows for the number of interim analyses, the critical values, and the sample
sizes to be chosen adaptively during the experiment.
5.4.2 Conditional error approach
The adaptive linear combination tests developed in this thesis (see chapter 6) are
based on the combination tests in the previous section. However, to obtain a more
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complete picture of adaptive designs, we describe this alternative way of describing
adaptive tests which is based on conditional error functions (CEFs). The idea was
originally developed for two-stage designs by Proschan and Hunsberger [1995] and
for multi-stage designs with a more general principle in Mu¨ller and Scha¨fer [2001];
Mu¨ller and Scha¨ffer [2004]. We restrict this description to two-stage tests, but
generalizations to studies with more stages is straightforward.
The conditional error function A(X1) is the conditional probability, given
the interim data X1, of rejecting the null hypothesis H0, when H0 is true, that is,
A(X1) = Pr0( reject H0|X1), (5.7)
where here the index 0 is used to denote that the above conditional probability is
computed under H0. The conditional error function is set to satisfy
E(A(X1)) =
∫
A(X1)dF0(X1) ≤ α, (5.8)
where F0(X1) is the null cumulative distribution function of the first-stage data.
The tests defined within this framework reject H0 if and only if the second
stage p−value p2 ≤ A(X1). Note that, under this test, the second stage does not
need to be performed if for a given X1, A(X1) = 1 or A(X1) = 0 in which case H0
is respectively rejected or accepted from the first stage.
To control type I error, the CEF is defined at the planning stage and satisfies
(5.8). In addition, the conditional null distribution of p2|X1 should be equal to or
stochastically larger than the uniform distribution (p−clud). It is then straightfor-
ward to see that, even if interim design adaptations are performed, the type I error
rate is
Pr0(p2 ≤ A(X1)) =
∫
Pr0(p2 ≤ A(X1) |X1) dF0(X1) ≤ E(A(X1)) ≤ α, (5.9)
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that is, the type I error is controlled. Note that the equality in the above expression is
implied by the Total Probability Law, while the inequalities by the p−clud property
of p2|X1 and the expression in (5.8).
Combination tests can be re-written in terms of the conditional error function
[Bretz et al., 2009; Posch and Bauer, 1999]. For example, the combination test in
(5.3), with C(p1, p2) = p1p2, can be re-written in terms of the following CEF,
A(p1) =


1, if p1 ≤ α1,1
α2,1/p1, if p1 ∈ (α1,1, α1,0)
0, if p1 ≥ α1,0.
(5.10)
5.5 Types of design modifications
Sequential and adaptive designs are employed for many kinds of design modifica-
tions. One common application is sample size re-calculation. Sample size is a very
important issue especially in medical studies, where ethical and economical concerns
require the study to be conducted safely and efficiently with no human or monetary
resources being wasted. Various authors discuss the subject and provide methods
of re-assessing and modifying, if necessary, sample size at interim analysis within
the framework of group-sequential [Denne and Jennison, 2000; Gould, 2001; Kieser
and Friede, 2000; Stein, 1945; Wittes and Brittain, 1990] and adaptive designs [Chi
et al., 1999; Chuong-Stein et al., 2006; Cui and Wu, 2010; Lehmacher and Wassmer,
1999; Mehta and Patel, 2006; Mehta and Pocock, 2011; Proschan, 2009; Proschan
and Hunsberger, 1995].
Another area which has attracted considerable attention is the response-
adaptive sample allocation. These designs are constructed to allocate subjects to the
different treatment groups based on the observed responses rather than a fixed plan.
Play-the-winner biased allocation rules are being developed [Hu and Rosenberger,
2003; Hu and Zhang, 2004; Wei and Durham, 1978] while Jennison and Turnbull
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[2001] and Zhu and Hu [2010] provide methods for monitoring studies with response-
adaptive allocation using sequential tests methodology.
Adaptive designs are also used for treatment and endpoint selection. That
is, to identify the most effective among a number of different treatments or doses or
to identify the most important among a number of different endpoints. These two
problems are often described as a hypothesis selection or a multiple testing problem
[Hommel, 2001; Koenig et al., 2008; Miller, 2010; Vandemeulebroecke et al., 2010]. In
this setting, adaptive designs are often combined with the closure principle of Marcus
et al. [1976]. A related attractive application of these methods is to combine phase
II and phase III clinical trials in a single study [Bretz et al., 2006; Jennison and
Turnbull, 2007; Kimani et al., 2009; Schmidli et al., 2007; Stallard and Todd, 2011].
Phase II studies are often performed to select the most effective and safe among a
group of treatments or doses. After the best of these treatments is identified, phase
III trials are performed to confirm or disprove the superiority of this treatment
over an established treatment. In seamless phase II/III studies, the phase II study
is treated as the fixed first stage of an adaptive design, with phase III study as
the adaptive second stage. The latter designs have obvious practical advantages
including speeding up the drug development process.
5.5.1 Stage-wise statistic adaptation
In situations where various options for the form of the test statistic exist, as for
example in multiple testing, a test statistic adaptation seems appealing. In this, the
accumulated data are used at each interim analysis to select the subsequent stage-
wise statistics. Despite the fact that many authors advocate the potential for such
adaptations (such as Bauer and Ko¨hne [1994]; Bretz et al. [2009]), there are only a
few papers on the subject [Kieser et al., 2002; Lang et al., 2000; Neuha¨user, 2001].
Lang et al. [2000] propose an adaptive two-stage combination test for dose-finding,
evaluating the global null hypothesis against monotonically ordered alternatives. At
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the first stage, the likelihood-ratio test under the assumption of independent and
monotonically ordered outcomes is used, while at the second stage they construct
a linear combination test with weights equal to the maximum likelihood estimates
under the latter assumption.
Furthermore, Neuha¨user [2001] propose an adaptive two-stage test for si-
multaneous evaluation of location and scale hypothesis, while Kieser et al. [2002]
propose a two-stage design where the first stage data are used to perform a bootstrap
comparison of the power of a selection of test statistics, where the most powerful
test is used at the second stage.
5.6 Discussion: potential and challenges
Since the work of Bauer and Ko¨hne [1994] and Proschan and Hunsberger [1995],
great interest in adaptive designs, especially within the context of clinical trials,
has been expressed in various forms. As Pong and Chow [2010] discuss, this is ad-
dressed by special sessions organised in many professional conferences and meetings,
the large number of publications in the field with special issues published in many
journals (such as Biometrics (Vol. 62, No. 3), Statistics in Medicine (Vol. 25, No.
19), Journal of Biopharmaceutical Statistics (Vol. 15, No. 4 and Vol. 17, No. 6),
Biometrical Journal (Vol. 48, No. 4), and Pharmaceutical Statistics (Vol. 5, No.
2)) and the establishment of working groups and publication of white papers by
various associations (see for example Gallo et al. [2006]) and regulatory authorities
for clinical trials [EMEA, 2007; FDA, 2010].
As is recognized in the latter papers, adaptive designs offer opportunities
for more efficient use of available resources in conducting a study. At the same
time, it is widely understood that several dangers exist if adaptive designs are used
without caution. EMEA [2007]; Gallo et al. [2006] and FDA [2010], which discuss
the use of adaptive designs particularly in confirmatory clinical trials, stress that
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careful planning of the latter trials should not be disregarded when applying an
adaptive design. They also stress that, in this setting, interim analysis and design
modifications should be performed only if absolutely necessary since they introduce
a risk of damaging the integrity of the study. They clarify that the reasons for
allowing for interim adaptations as well as the adaptation rules should be fully
described and justified at the planning stage.
Furthermore, the methodology used by adaptive designs to accommodate
flexibility (for example combination tests) introduces various complexities regard-
ing interpretability and efficiency. Burman and Sonesson [2006] give examples where
adaptive design methodology used naively and without caution can result in out-
comes which are hard to interpret. Jennison and Turnbull [2003, 2006] and Tsiatis
and Mehta [2003] proved that adaptive designs can be substantially less efficient
than similar group-sequential designs. Jennison and Turnbull attribute this loss of
efficiency not only to the use of combination (rather than likelihood-ratio) tests, but
also to the suboptimal adaptation rules and the overreliance on interim estimates.
On the other hand, various authors attempt to improve the integrity and in-
terpretability of adaptive designs. Liu et al. [2002] and Brannath et al. [2012] derive
results that attempt to provide validation of adaptive tests in general situations.
Liu et al. [2002] prove type I error control for any adaptation rule for which the
set of possible adaptations is countable and the rule of adaptation is measurable.
Brannath et al. [2012] show that type I error control of any adaptive design can be
proved, if the conditional distribution of the second-stage data, given the first-stage
data, can be described in terms of a regression model. Posch et al. [2003] provide
adaptive designs that prohibit outcomes that are hard to interpret.
My personal view is that adaptive designs can be useful, particularly to deal
with some difficult situations arising in medical studies. However, it is clear that
adaptive designs require extra caution and, in some cases, extra effort not only
in implementation but also in planning. It should be made clear that the lack of
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knowledge at the planning stage, which makes adaptive designs necessary, comes
with a cost in efficiency. The more information gathered at the planning stage, the
less flexibility will be necessary and therefore the less efficiency cost will be paid.
Therefore, the same effort with non-adaptive designs, if not more, should be made
in careful planning. Furthermore, this cost in efficiency should be carefully studied,
possibly through extensive simulations, at the planning stage. Last but not least, I
believe that more work should be made in order to derive optimal adaptation rules.
The methodology developed in chapter 6 provides an example where power-
optimality, within adaptive designs, is targeted, while type I error control is main-
tained. Furthermore, methodology for studying the efficiency of our adaptive tests
is carefully developed in chapter 7 and used to perform extensive power analysis in
chapter 8. Finally, in our testing procedures, the predictive-power-optimal adapta-
tion rules are specified at the planning stage. This allows the use of our methods in
contexts where pre-specification of the adaptation rule is required, but also allows
further flexibility to be used as appropriate in situations where this is permitted.
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Chapter 6
Adaptive linear combination
tests
6.1 Introduction
In chapter 4, we developed linear combination tests which use a preliminary sample
to derive the tests’ weighting vector. This preliminary sample is collected from
an external pilot study conducted prior to the main study. As we discussed in the
previous chapter, external pilot studies raise various ethical and economical concerns
mainly associated with the non-optimal use of available resources, especially if the
latter are limited and expensive. Adaptive designs provide a solution to these issues,
by turning the pilot study to the first stage of a two- or, generally, multi-stage design,
in which after every stage a test is performed using the obtained data.
In the following, we employ adaptive designs to allow for sequential modi-
fications of the linear combination test statistics based on accumulated data. The
potential of test statistic adaptation methods, as we discussed in the previous chap-
ter, has been advocated by various authors, but only a few papers exist on the
subject. Furthermore, as we mention in chapter 5, various adaptive multiple testing
procedures are developed in the literature. However, these methods target the de-
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tection of one or some few independent local effects and they become conservative
and inefficient in settings, such as the typical neuroimaging studies, where strong
dependencies and large number of outcomes are present.
In our methods, an adaptive testing procedure is employed, where linear com-
bination tests are used as stage-wise statistics. The linear combination statistics are
initially constructed with weighting vector derived from prior information and then
sequentially updated based on the observed data at subsequent interim analyses.
While our tests maintain the two prime targets of adaptive designs, namely flexibil-
ity and type I error control [Brannath et al., 2012], they also target power optimality.
In particular, our procedures are derived to maximize the predictive power of the
test at each interim analysis.
The chapter is organised as follows. We start by formulating the class of
J−stage linear combination z and t tests and then derive power-optimal, with re-
spect to power, tests in this class. We then proceed to derive the proposed adaptive
linear combination tests which are proved: (i) to be optimal with respect to predic-
tive power and (ii) to control the type I error. The chapter is closed with discussion
of the main results and outstanding issues.
6.2 Formulation of J−stage linear combination tests
In the following, we formulate J−stage linear combination z and t tests and define
their error rate functions. We assume that the K−dimensional observation vectors
xij = (xij1, xij2, . . . , xijK)
T of subjects i = 1, 2, . . . , nj , participating in stage j,
j = 1, 2, . . . , J , of the study, are independent and identically distributed Gaussian
random variables
xij ∼ NK (µ,Σ) , (6.1)
with mean µ and covariance matrix the positive definite Σ.
We wish to test the global null hypothesis of no treatment effect against the
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two-sided alternative,
H0 : µ = 0K versus H1 : µ 6= 0K .
As in the single-stage design, the methods which follow equally apply to both the
two-sample setting with common covariance matrix and the setting of paired mul-
tivariate observations. We continue with the one-sample presentation to simplify
notation.
The observation vectors xij , i = 1, 2, . . . , nj , of the subjects participating in
the j−th stage are projected on the non-zero weighting vector wj = (wj1, . . . , wjK)T
and the projection magnitudes form the linear combinations
yij = w
T
j xij, i = 1, 2, . . . , nj, j = 1, 2, . . . , J. (6.2)
Note that the linear combinations yij for subjects i = 1, 2, . . . , nj , j = 1, 2, . . . , J
are independent Gaussian random variables
yij ∼ N(µj, σ2j ), (6.3)
where µj = w
T
j µ, σ
2
j = w
T
j Σwj. Under H0, yij ∼ N(0, σ2j ), i = 1, 2, . . . , nj ,
independent.
The stage-wise z and t statistics for testing H0 against H1 using the random
sample of linear combinations yij, i = 1, . . . , nj, when Σ is either known or unknown
are respectively
zj =
y¯j
σj/
√
nj
, tj =
y¯j
sj/
√
nj
. (6.4)
Here,
y¯j =
1
nj
nj∑
i=1
yij, s
2
j =
1
nj − 1
nj∑
i=1
(yij − y¯j)2 (6.5)
are the sample mean and sample variance of the linear combinations, respectively.
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The two-sided stage-wise p values of the z and t tests are respectively pzj = 2Φ(−|zj |)
and ptj = 2Ψνj(−|tj |).
Under assumption (6.1), the stage-wise z and t statistics, zj, tj , j = 1, . . . , J
are respectively normally and non-centrally t distributed, zj ∼ N(θ¯j, 1) and tj ∼
tnj−1(θ¯j) with location parameter
θ¯j = θj
√
nj, θj =
µj
σj
=
wTj µ√
wTj Σwj
. (6.6)
Under H0, the stage-wise z and t statistics are standard normal and Student’s t
random variables, that is, zj ∼ N(0, 1) and tj ∼ tnj−1 and the p−values pzj and ptj
uniformly distributed in (0, 1), pzj , ptj ∼ U(0, 1), j = 1, 2, . . . , J .
We propose performing the J−stage z and t tests using adaptive combination
tests, which allow for interim design adaptations. As we have described in the pre-
vious chapter, the combination function C(p1, p2, . . . , pj), j = 2, 3, . . . , J is specified
before the start of the study. Here, pj is the p−value of the j−th stage, either pzj
or ptj . In addition, the rejection and acceptance critical values αj,1, j = 1, 2, . . . , J
and αj,0, j = 1, 2, . . . , J − 1 are also pre-selected to satisfy the type I error equation
of the test described next.
After collecting the observations of the first stage, the p−value p1 is computed
and if p1 ≤ α1,1 or p1 ≥ α1,0 the study is stopped with rejection and acceptance
of H0, respectively. If p1 ∈ (α1,1, α1,0), the study continues to the second stage.
The design of the second stage is decided, the second stage is conducted and after
collecting the second stage data, the second stage p−value, p2, is combined with
p1 in C(p1, p2). If C(p1, p2) ≤ α2,1 or C(p1, p2) ≥ α2,0 the study is terminated
and H0 is respectively rejected or accepted. If C(p1, p2) ∈ (α2,1, α2,0), the study
continues to the next stage. The procedure continues in the same way until the
study is terminated early or the final J−th stage is completed. In the latter case,
the study is terminated with either rejection or acceptance of H0 if respectively
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C(p1, p2, . . . , pJ) ≤ αJ,1 or C(p1, p2, . . . , pJ) > αJ,1. The J−stage test is formally
described as follows:
At interim analysis j = 1, 2, . . . , J − 1,
if C(pj) ≤ αj,1 , stop study and reject H0,
if C(pj) ≥ αj,0 , stop study and accept H0,
otherwise, continue to stage j+1.
At the final analysis J,
if C(pJ) ≤ αJ,1, stop study and reject H0,
otherwise, stop study and accept H0.


(6.7)
Here, pj = (p1, p2, . . . , pj)
T is the vector of p−values collected up to stage j, j =
1, 2, . . . , J .
Several combination functions have been proposed in the literature (see sec-
tion 5.4.1 on page 74). The formulation and results which follow use the Fisher’s
product function,
C(pj) =
j∏
l=1
pl, j = 1, 2, . . . , J. (6.8)
However, our results equally apply to other combination functions including the
inverse normal in (5.6) (page 77).
Herein we will refer to the J−stage tests with linear combination stage-wise
z and t test statistics as the J−stage z and t tests, respectively. The power of the
J−stage z or t test is β =∑Jj=1 βj where,
β1 = Pr
(
p1 ≤ α1,1
)
, βj = Pr
(
C(pl) ∈ (αl,1, αl,0) ∀ l < j ; C(pj) ≤ αj,1
)
, (6.9)
are respectively the first stage and j−th stage, j = 2, 3, . . . , J , power functions (β,
βj are either βz, βzj or βt, βtj , respectively).
To control the type I error of the combination test, the rejection and accep-
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tance critical values need to satisfy the type I error equation
α = Pr0
(
p1 ≤ α1,1
)
+
J∑
j=2
Pr0
(
C(pl) ∈ (αl,1, αl,0) ∀ l < j ; C(pj) ≤ αj,1
)
, (6.10)
where the index 0 (as in Pr0(·)) indicates that the above probabilities are computed
under H0. The type I error equation, for the Fisher’s combination function, can be
alternatively written as
α = α1,1 +
J∑
j=2
∫ α1,0
α1,1
∫ α′2,0
α′2,1
· · ·
∫ α′j−1,0
α′j−1,1
α′j,1 dpj−1 . . . dp2dp1, (6.11)
where
α′j,1 = αj,1/p1p2 . . . pj−1, α
′
j,0 = αj,0/p1p2 . . . pj−1 (6.12)
the conditional rejection and acceptance boundaries, respectively, of stage j, j =
2, 3, . . . , J . For the two-stage design the latter reduces to
α = α1,1 +
∫ α1,0
α1,1
α2,1/p1 dp1 = α1,1 + α2,1
(
logα1,0 − logα1,1
)
. (6.13)
Thus, for fixed size α of the test and first stage critical values α1,0, α1,1 the second
stage critical value is
α2,1 =
α− α1,1
logα1,0 − logα1,1 . (6.14)
Here, α1,0 ∈ (α, 1] and often substantially larger than α (for example α1,0 > 0.5) to
avoid inappropriately high probability of early acceptance. Further, α1,1 is chosen
to be in (0, α). The same restrictions are applied for tests with more than two stages
(J > 2).
6.3 Optimal J−stage linear combination tests
In this section, we develop a methodology for optimally deriving the weighting vec-
tors of the stage-wise linear combinations in the J−stage adaptive test. Optimality,
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here, is defined in terms of the power function of these tests as in (6.9).
For this we use a similar approach with the methodology used in chapter 4.
In the latter, lemma 4.3.1 and 4.3.2 (see pp. 51, 52) were used to prove that the
power of the single-stage z and t tests are increasing in the absolute value of the
location parameter, θ, of the z and t statistics. We wish to extend this result to the
J−stage adaptive linear combination z and t tests.
We start by proving the results for the two-stage tests. To reduce technical
details to the minimum, we provide the proofs of the subsequent results regarding
the t tests in Appendix A. However, it might be useful to note here that in these
proofs, the results for the z test are generalised using the equation (4.10) (page 52)
linking the non-central t distribution with the normal distribution.
The first step is to show that the power of the two-stage z and t test is
increasing to the absolute value of θ1. A difficulty in deriving this result arises from
the fact that for some range of values of θ1 an increase in |θ1|, results in increased
chance to reject at the current stage, but also a decreased chance to continue to the
next stage and thus smaller β2. The required result is derived by showing that even
for these range of values of |θ1|, the decrease (in absolute value) in β2 is bounded
above by the increase in β1.
Lemma 6.3.1. Under (6.1), the power of the two-stage z and t test in (6.7) with
combination function as in (6.8) is non-decreasing in the absolute value of θ1 in
(6.6).
Proof. For the first stage power we have that
dβz1
dθ1
=
√
n1
(
φ
(
zα1,1
2
− θ¯1
)
− φ
(
−zα1,1
2
− θ¯1
))
. (6.15)
The second stage power is
βz2 =
∫
Cz1
βc,z2(θ2; z1)φθ1(z1)dz1, (6.16)
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where Cz1 =
(
−zα1,1/2,−zα1,0/2
)
∪
(
zα1,0/2, zα1,1/2
)
the first stage continuation re-
gion and βc,z2(θ2; z1) the second stage conditional power
Pr
(
|z2| ≥ zα′2,1
2
| pz1
)
= 1− Φ
(
zα′2,1
2
− θ¯2
)
+Φ
(
−zα′2,1
2
− θ¯2
)
, (6.17)
where α′2,1 as in (6.12) and θ¯2 as in (6.6). The second stage power in (6.19) can be
written as
βz2 =
∫
C+z1
βc,z2(θ2; z1)
(
φ(z1 − θ¯1) + φ(z1 + θ¯1)
)
dz1,
where C+z1 =
(
zα1,0/2, zα1,1/2
)
. Thus,
dβz2
dθ1
=
∫
C+z1
βc,z2(θ2; z1)
d
(
φ(z1 − θ¯1) + φ(z1 + θ¯1)
)
dθ1
dz1
and using that φ(z1 − θ¯1) = φ(z1 + θ¯1)e2θ¯1z1 ,
d
(
φ(z1 − θ¯1) + φ(z1 + θ¯1)
)
dθ1
=
√
n1
(
(z1 − θ¯1)φ(z1 − θ¯1)− (z1 + θ¯1)φ(z1 + θ¯1)
)
=
√
n1(e
2θ¯1z1 + 1)φ(z1 + θ¯1)(z1 tanh(θ¯1z1)− θ¯1), (6.18)
where tanh(θ¯1z1) =
e2θ¯1z1−1
e2θ¯1z1+1
is the hyperbolic tangent at θ¯1z1. First note that
d tanh
(
θ¯1z1
)
dz1
=
4θ¯1e
2θ¯1z1(
e2θ¯1z1 + 1
)2 ,
which is non-negative for θ1 ≥ 0 and negative for θ1 < 0. Hence,
d
(
z1 tanh θ¯1z1 − θ¯1
)
dz1
is non-negative for θ1 ≥ 0 and negative for θ1 < 0 (z1 ∈ C+z1). Thus, for θ1 ≥ 0, we
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can identify the following three cases:
(1) z1 tanh(θ¯1z1)− θ¯1 ≥ 0, ∀ z1 ∈ C+z1 ,
(2) z1 tanh(θ¯1z1)− θ¯1 ≤ 0, ∀ z1 ∈ C+z1 ,
(3) ∃ z˙1 ∈ C+z1 : z1 tanh(θ¯1z1)− θ¯1 ≤ 0, ∀ z1 ∈ (zα1,0
2
, z˙1),
z1 tanh(θ¯1z1)− θ¯1 > 0, ∀ z1 ∈ (z˙1, zα1,1
2
)
Case (1), by (6.18), implies that
dφ(z1 − θ¯1) + φ(z1 + θ¯1)
dθ1
≥ 0, ∀ z1 ∈ C+z1 .
This in turn implies that βz2 and hence βz is non-decreasing in θ1 for θ1 ≥ 0.
Case (2), by (6.18), implies that
dφ(z1 − θ¯1) + φ(z1 + θ¯1)
dθ1
≤ 0, ∀ z1 ∈ C+z1 .
This in turn implies that
dβz2
dθ1
≥ βc,z2(θ2; zα1,1
2
)
∫ zα1,1
2
zα
1,0
2
dφ(z1 − θ¯1) + φ(z1 + θ¯1)
dθ1
dz1.
Thus, using (6.15), we have that
dβz
dθ1
≥√n1
((
1− βc,z2
(
θ2; zα1,1
2
))(
φ(zα1,1
2
− θ¯1)− φ(zα1,1
2
+ θ¯1)
)
+ βc,z2
(
θ2; zα1,1
2
)(
φ(zα1,0
2
− θ¯1)− φ(zα1,0
2
+ θ¯1)
))
≥ 0.
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Case (3), by (6.18), implies that
d
(
φ(z1 − θ¯1) + φ(z1 + θ¯1)
)
dθ1
≤ 0 ∀ z1 ∈
(
zα1,0
2
, z˙1
)
,
d
(
φ(z1 − θ¯1) + φ(z1 + θ¯1)
)
dθ1
> 0 ∀ z1 ∈
(
z˙1, zα1,1
2
)
.
This in turn implies that
dβz2
dθ1
≥βc,z2(θ2; z˙1)
∫ z˙1
zα1,0
2
d
(
φ(z1 − θ¯1) + φ(z1 + θ¯1)
)
dθ1
dz1
+ βc,z2(θ2; z˙1)
∫ zα1,1
2
z˙1
d
(
φ(z1 − θ¯1) + φ(z1 + θ¯1)
)
dθ1
dz1.
Thus, using (6.15) we can identify the non-negative lower boundary
dβz
dθ1
≥√n1
(
(1− βc,z2 (θ2; z˙1))
(
φ(zα1,1
2
− θ¯1)− φ(zα1,1
2
+ θ¯1)
)
+ βc,z2 (θ2; z˙1)
(
φ(zα1,0
2
− θ¯1)− φ(zα1,0
2
+ θ¯1)
))
≥ 0.
In all three possible cases, the power function of the two-stage z test, βz, is
non-decreasing in θ1 for θ1 ≥ 0. In the same way, we can show that βz is decreasing
in θ1 for θ1 < 0 and the result follows. The result for the t test is provided in
Appendix A.
The second step is to show that power is increasing in the second stage
location parameter.
Lemma 6.3.2. Under (6.1), the power of the two-stage z and t tests in (6.7) with
combination function as in (6.8) are non-decreasing in the absolute value of θ2 in
(6.6).
Proof. The second stage power of the two-stage z test is
βz2 =
∫
Cz1
βc,z2(θ2; z1)φθ1(z1)dz1, (6.19)
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where βc,z2 the second stage conditional power as in (6.17). By similar steps as in
the proof of lemma 4.3.1, we can prove that the derivative of βc,z2 with respect to
θ2 is non-negative for θ2 ≥ 0 and negative for θ2 < 0, and the result follows. The
result for the t test is provided in Appendix A.
The next lemma extends the latter results to the the J−stage z and t tests.
The proof is based on re-writing the stage-wise power functions in a similar form to
the stage-wise power functions of two-stage tests and then use recursively lemmas
6.3.1 and 6.3.2.
Lemma 6.3.3. Under (6.1), the power of the J−stage z and t tests in (6.7) with
combination function as in (6.8) is non-decreasing in the absolute value of θj in
(6.6), j = 1, 2, . . . , J .
Proof. The j−th stage power of the z test can be written as
βzj =
∫
Cz(j−1)
βc,zj(θj ;z(j−1))fθ(j−1)(z(j−1)) dz(j−1),
where fθ(j)(z(j)) is the joint density of the vector of the stage-wise z−statistics up
to stage j, z(j) = (z1, z2, . . . , zj), with parameters θ(j) = (θ1, θ2, . . . , θj). Here,
Cz(j) = Cz1 ∩ Cz2 ∩ · · · ∩ Czj with Czl = (−zα′l,1/2,−zα′l,0/2) ∪ (zα′l,0/2, zα′l,1/2) the
l−th stage continuation region, α′l,1, α′l,0, as in (6.12), l = 1, 2, . . . , j, j = 2, 3, . . . , J
(α′1,1 = α1,1, α
′
1,0 = α1,0).
We can prove that the power of the J−stage test is non-decreasing in |θJ | by
considering the derivative of βc,zJ (θJ ;z(J−1)) as in proof of lemma 6.3.2. Considering
θJ−1, the power of the last two stages, β
(J−1)
z = βzJ−1 + βzJ , can be written as
β(J−1)z =
∫
Cz(j−2)
β(J−1)c,z (θ
(J−1);z(J−2))fθ(J−2)(z(J−2)) dz(J−2),
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where θ(J−l) = (θJ−l, θJ−l+1, . . . , θJ), l = 1, 2, . . . , J − 1, and
β(J−1)c,z (θ
(J−1);z(J−2)) = βc,zJ−1(θJ−1;z(J−2))
+
∫
CzJ−1
βc,zJ (θJ ; zJ−1)fθJ−1(zJ−1)dzJ−1, (6.20)
the conditional power of the last two stages given the value of the test statistics of
the previous stages, z(J−2). Therefore, using the same steps as in lemma 6.3.1, with
the power of the two-stage z test replaced by β
(J−1)
c,z (θ(J−1);z(J−2)) in (6.20), it can
be shown that the power of the J−stage test is increasing in |θJ−1|.
Considering θJ−2, the power of the last three stages, β
(J−2)
z , is
β(J−2)z =
∫
Cz(J−3)
β(J−2)c,z (θ
(J−2);z(J−3))fθ(J−3)(z(J−3)) dz(J−3),
where
β(J−2)c,z (θ
(J−2);z(J−3)) = βc,zJ−2(θJ−2;zJ−3)
+
∫
CzJ−2
β(J−1)c,z (θ
(J−1);z(J−2))fθJ−2(z(J−2)) dz(J−2) (6.21)
and β
(J−1)
c,z (θ(J−1);z(J−2)) as in (6.20). Thus, using the same steps as in lemma
6.3.1 where power of the two-stage test is replaced by β
(J−2)
c,z in (6.21) we have that
the power of the J−stage test is increasing in |θJ−2|.
Proceeding sequentially we can easily see that the power of the last l stages,
β
(J−l)
z , is
β(J−l)z =
∫
CzJ−l−1
β(J−l)c,z (θ
(J−l);z(J−l−1))fθ(J−l−1)(z(J−l−1)) dz(J−l−1),
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where,
β(J−l)c,z (θ
(J−l);z(J−l−1)) = βc,zJ−l(θJ−l;z(J−l−1))
+
∫
CzJ−l
β(J−l+1)c,z (θ
(J−l+1);z(J−l))fθJ−l(zJ−l) dzJ−l
is non-decreasing in |θJ−l|, l = 1, 2, . . . , J − 1.
Regarding the t test, the result follows using the same steps as above but
with the Gaussian distribution replaced by the non-central t distribution and based
on lemmas 6.3.1 and 6.3.2, respectively.
Note that it can be straightforwardly shown that the above results hold for
both one-sided stage-wise tests and for the inverse normal combination function.
Note also that, similarly to the proof for the single-stage test, the result can be
generalized to more general adaptive design settings.
Furthermore, as in the single-stage tests, lemma 6.3.3 implies that in order to
maximize the power of the J−stage linear combination z and t tests with respect to
the weighting vectors wj, it is sufficient to maximize the value of θj, j = 1, 2, . . . , J .
Using this result, we next derive the power-optimal weighting vector.
Theorem 6.3.1. Under (6.1), the power of the J−stage z and t tests in (6.7) with
combination function as in (6.8) are maximized with respect to the weighting vectors
wj, j = 1, 2, . . . , J , if and only if the latter are proportional to ω
∗ = Σ−1µ.
Proof. The proof follows using the same steps as in the proof of theorem 4.3.1 (page
53) with θ replaced by θj and w replaced by wj, j = 1, 2, . . . , J .
The last result provides the optimal, in terms of power, weighting vector for
the J−stage linear combination tests ω∗. The optimal weighting vector ω∗ expresses
the multivariate treatment effect standardized with respect to the covariance ma-
trix Σ. The J−stage linear combination test with weighting vector ω∗ attain the
maximum power for these tests and this result is used in chapter 8.
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However, the optimal vector ω∗ depends on the unknown parameters µ and
Σ and therefore is also unknown. For selecting the weighting vectors, in practice,
we propose using the information for µ and Σ, available at each interim analysis.
The source of this information is the data collected from the stages completed before
each interim analysis, but also prior information extracted from previous studies and
expert clinical opinion. Predictive power allows the incorporation of this information
into our procedures in a natural and plausible way. The weighting vectors are
selected to maximise predictive power, hence they are optimal in terms of the current
knowledge at each interim analysis.
Importantly, as we also explain in the next section, if equation (6.10) is
satisfied, the type I error rate of these tests is controlled.
6.4 The adaptive z+AD and t
+
AD tests
As in z+ and t+ tests, we use the standard Gaussian-inverse-Wishart priors for the
observation mean and covariance matrix,
(µ | Σ,I0) ∼ NK (m0,Σ/n0) , (Σ | I0) ∼ IWK×K
(
ν0,S
−1
0
)
, (6.22)
where m0 represents a prior estimate of the value of µ and n0 corresponds to the
number of observations on which this prior estimate is based on, while ν0 and S0
respectively represent the degrees of freedom and the scale matrix of the inverse-
Wishart prior.
Under this standard Bayesian model (see Gelman et al. [2004]), the posterior
distribution of µ and Σ given the information set Ij = {I0,X(j)}, consisting of
the prior information I0 and the data collected up to the j−th interim analysis
X(j) = [X1X2 . . .Xj ] is
(µ | Σ,Ij) ∼ NK
(
mj,Σ/n(j)
)
, (Σ | Ij) ∼ IWK×K
(
νj ,S
−1
j
)
. (6.23)
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Here,
mj =
n0m0 + n(j)x¯(j)
n0 + n(j)
, (6.24)
and
Sj = S0 + ν(j)Sx(j) +
n0n(j)
n0 + n(j)
(x¯(j) −m0)(x¯(j) −m0)T , (6.25)
where ν(j) = n(j) − 1, νj = ν0 + n(j) with n(j) = n1 + n2 + · · · + nj and
x¯(j) =
j∑
l=1
nl∑
i=1
xil/n(j), Sx(j) =
1
nj − 1
j∑
l=1
nl∑
i=1
(
xil − x¯(j)
) (
xil − x¯(j)
)T
(6.26)
are the sample mean and sample covariance matrix of X(j). Note that, due to
the positive definiteness of the prior estimates S0, the posterior estimates Sj , j =
1, 2, . . . , J , are also positive definite.
We wish to use this information to select the weighting vectors wj optimally.
Optimality here is expressed in terms of predictive power of the test. The predictive
power for the first stage given the prior information set I0 is b1 = Pr (p1 ≤ α1,1 | I0)
and for the j−th stage, j = 2, 3, . . . , J , given the information set Ij−1 is
bj =


1 , Ij−1 such that C(pl) ≤ αl,1 for l ∈ {1, 2, . . . , j − 1},
0 , Ij−1 such that C(pl) ≥ αl,0 for l ∈ {1, 2, . . . , j − 1},
J∑
l=j
Pr
(
C(pl′) ∈ (αl,1′ , αl,0′), l′ < l; C(pl) ≤ αl,1 | Ij−1
)
, otherwise.
(6.27)
The next result presents the weighting vectors that we suggest to use for the stage-
wise linear combination z and t tests.
Theorem 6.4.1. Under (6.1) and (6.22), the j−th stage predictive power, bzj , j =
1, 2, . . . , J , of the J−stage z test in (6.27) is maximized with respect to the weighting
vector wj if and only if wj is proportional to
wz+j
= Σ−1mj−1. (6.28)
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Under (6.1) and (6.22) and for n(j−1) → ∞, the j−th stage predictive power, btj ,
j = 1, 2, . . . , J , of the J−stage t test in (6.27) is maximized with respect to the
weighting vector wj if and only if wj is proportional to
wt+j
= S−1j−1mj−1, (6.29)
where mj, Sj as in (6.24) and (6.25), respectively.
Proof. The z statistic of the j−th stage, j = 1, 2, . . . , J , can be written as
zj = θ¯j + e, e ∼ N(0, 1).
Under (6.1), (6.22), (θj | Ij−1) is normally distributed with mean
θˆj = w
T
j mj−1/σj
and variance (n0+n(j−1))−1. Thus, (zj | Ij−1) ∼ N
(
θˆj
√
nj, 1 + nj/
(
n0 + n(j−1)
))
.
The result is then proved using theorem 6.3.1 and following the same steps as in
4.3.1 where θj is replaced by θˆj.
For the t−test, we wish to compute the asymptotic, n(j−1) →∞, distribution
of tj | Ij−1. By Bayes’ rule, under (6.1) and (6.22), we have that,
(xij | Ij−1) ∼ tK
(
ν0 + n(j−1) −K + 1,mj−1, cSj−1
)
, i = 1, 2, . . . , nj
where c = (n0 + n(j−1) + 1)
(
(n0 + n(j−1))(ν0 + n(j−1) −K + 1)
)−1
. Hence for
n(j−1) →∞,
(xij | Ij−1) ∼ NK (mj−1,Sj−1) .
Using the last result and corollary 7.2.3 in Anderson [1984] we have that
(y¯j |Ij−1) ∼ N
(
wTj mj−1,w
T
j Sj−1wj/nj
)
. (6.30)
99
From the same result we have that
(
Sxj |Ij−1
) ∼WK×K (nj − 1,Sj−1/(nj − 1)) ,
and hence by proposition 3.4.2 in Mardia et al. [1979]
(
s2j
wTj Sj−1wj/(nj − 1)
|Ij−1
)
∼ χ2nj−1, independent of y¯j . (6.31)
From (6.30) and (6.31), it follows that the t statistic in (6.4) can be written as
tj | Ij−1 =
Z + ϑˆj−1
√
nj√
X2/(nj − 1)
,
where Z ∼ N(0, 1) and X2 ∼ χ2nj−1. That is, tj | Ij−1 is approximately non-central
t distributed with non-centrality parameter ϑˆj−1
√
nj−1, where
ϑˆj−1 =
wTj−1mj−1√
wTj−1Sj−1wj−1
and nj − 1 degrees of freedom, as n(j−1) → ∞. By replacing θj with ϑˆj in the
proof of proposition 6.4.1, it follows that, for n(j−1) → ∞, the predictive power
function btj in (6.27) is maximized with respect to the weighting vector, wj, if wj
is proportional to wt+j
in (6.29).
We refer to the J−stage linear combination z and t tests with weighting
vectors wz+j
and wt+j
as the adaptive z+AD and t
+
AD tests, respectively.
We can easily prove that these tests satisfy the conditional invariance prin-
ciple and they control the type I error. We next prove type I error control for the
two-stage adaptive z+AD and t
+
AD tests, while results for J−stage tests follow com-
pletely analogously. The main argument is that the weighting vectors wz+j
| Ij−1
and wt+j
| Ij−1 are fixed and thus, under H0, the conditional distributions of the
stage-wise z+j and t
+
j statistics are standard normal N(0, 1) and Student’s tnj−1
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distributed and the corresponding p−values uniformly distributed, U(0, 1).
Type I error control
For the two-stage z+AD, t
+
AD tests, it is sufficient to show that, under H0, the p values
of the first and second stage, respectively, are
p1, p2 | I0 ∼ U(0, 1), independent,
which implies that, if the critical values α1,0, α1,1, α2,1 satisfy the type I error rate
equation in (6.10), the type I error rate is controlled. For the rest of this section,
all the distributions are computer under H0.
First see that, if the weighting vectors of the z or t statistics in (6.4) are
fixed, their p values are uniformly distributed U(0, 1) [George and Mudholkar, 1990].
Conditional on, respectively, I0 and I1 = {I0,X1} the weighting vectors of the first
and second stage of the adaptive z+AD and t
+
AD tests are fixed and thus,
(p1 | I0) ∼ U(0, 1), (p2 | I1) ∼ U(0, 1). (6.32)
It is then sufficient to show that (p2 | I0) ∼ U(0, 1) since this implies also that (p2 |
I0) andX1 are stochastically independent and thus p1, p2 | I0 are also independent.
Let g(·), f(·), and g˜(·;X1) be the density functions of (p2 | I0), X1 and (p2 | I1),
respectively. Note that, by (6.32), g˜(p2;X1) = 1, p2 ∈ [0, 1] and thus the result
follows from
g(p2) =
∫
g˜(p2;X1)f(X1)dX1 =
∫
f(X1)dX1 = 1, p2 ∈ [0, 1],
which implies that (p2 | I0) ∼ U(0, 1).
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Connections to other linear combination tests
The z+ and t+ tests developed in chapter 4 are special cases of the adaptive z+AD and
t+AD tests. For this, the pilot study is considered as the first stage of the study. The
z+ and t+ tests are thus two-stage tests with (α1,1, α1,0) = (0, 1), that is, no early
stopping is permitted, and C(p2) = p2. The weighting vector used in z
+ and t+
tests are, under this representation, equal to wz+2
and wt+2
, respectively, constructed
based on prior information and first stage (pilot) data.
Furthermore, linear combination z and t tests with fixed weighting vectors,
such as O’Brien’s OLS and GLS (for Σ unknown) tests [O’Brien, 1984], can be
implemented under the adaptive design by setting n0 ≫ nT which effectively sets
the weighting vector equal to the first stage weighting vector wz+1
. Alternatively,
for group sequential linear combination z and t tests with fixed weighting vectors,
one may consider the methodology described in section 5.3.1 (see pp. 72-73).
Two-sided and one-sided p-values
In the proposed z+AD, t
+
AD as well as z
+, t+ tests, the weighting vectors are allowed
to be in any direction the prior information and observed data suggests. Therefore,
they are not necessarily restricted to be positive although this can be attained by ma-
nipulation. This approach is motivated by neuroimaging in which, as we explained
earlier, contrasting effects are often exhibited and are of interest to investigators.
Due to this approach, it is natural to consider two-sided p-values rejecting the
null hypothesis H0 for large absolute values of the z or t statistics regardless of their
sign. This suggests that only the direction of the weighting vector or, equivalently,
the effect structure is of interest and not the sign.
However, since in our methods the sign of the weighting vector in addition
to the direction is chosen, one may consider one-sided p-values in order to improve
power. Specifically, the z+AD and t
+
AD tests described earlier can be implemented
using the p-values pzj = Φ(−zj) or ptj = Ψ(tj), respectively. Power improvement
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will be attained if the sign of the weighting vector is correctly chosen.
In adaptive testing methodology, it is often preferable to use one-sided p-
values since for univariate stage-wise tests this prevents rejections based on effects
with contrasting signs. The issue is more complicated in multivariate testing and if
one wish to prevent such situations should consider one-sided tests (see section 3.3.2).
Primarily due to our motivating application, in this thesis, we mainly consider tests
with two-sided p-values.
6.5 Conclusions
The methodology developed in this chapter provides an important generalisation
of the testing procedures described in chapter 4. The issues arising with external
pilot studies are overcome with a more efficient use of the pilot data. The latter
are here used not only for selecting the weighting vector, but also for testing. This
potentially leads to a considerable improvement to the power performance of the test,
particularly in the case where the first stage weighting vector is close to optimal.
In addition, the tests are further generalised to allow for more than two stages,
with the weighting vector being adapted to observed data at every interim analysis.
Moreover, early stopping of the study, which is particularly important in medical
settings, is permitted in these designs.
The tests control type I error under general conditions and they are optimal
with respect to predictive power. They can be used in situations where a pre-
specification of the adaptation rules is required. In the next chapter, we derive a
power characterisation of linear combination tests, which is then used in chapter
8 to perform an extensive power analysis of these tests, including comparisons to
alternative global tests. The test statistic adaptation is expected to improve power
performance in cases where the initial statistic is far from optimal, while it may lead
to lose of power if the latter is close to optimal.
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Chapter 7
Power characterisation for
linear combination tests
7.1 Introduction
In order to study the performance of a test, we primarily need to explore the relation
between its power function and the parameters defining the statistical model and
the design of the study. Design parameters include the sample size(s), the critical
value(s) of the test and the sample allocation to different observation groups. In
linear combination tests, another key design parameter is the weighting vector of
the linear combinations. This defines the region we decide to search for effects, or,
in other words, the “targeted” region of the test.
The critical values and the sample size(s) of the test are scalar and therefore
it is straightforward to visualize power even across all their possible values (for
example using simulations). Their relation to power can then be relatively easily
described and understood. In univariate settings, this is also the case for the model
parameters. For example, to study the relation between power and treatment effect,
we can plot power versus the standardized effect θ = µ/σ for a fixed sample size.
However, in the multivariate setting, the model parameters and other multi-
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variate design parameters can be high dimensional and therefore it is not practically
feasible to visualize power over all the possible values of these parameters. This
makes our understanding to power behavior very limited. For Hotelling’s T 2 test,
this problem is alleviated since the relation of power to the model parameters µ and
Σ can be summarised by the Mahalanobis distance ∆. The Mahalanobis distance
is scalar and measures the strength of the global treatment effect. Thus, in T 2, the
relation of power to the size of the global effect can be easily studied.
However, such summaries, characterizing the relation of power to model and
design parameters, are not yet identified for the one-sided tests [Follmann, 1996;
Tang et al., 1989b] nor for the O’Brien-type and La¨uter’s linear combination tests
[La¨uter, 1996; O’Brien, 1984]. Power analysis for these tests is then typically re-
stricted to simulations of the power for a limited range of mean and covariance
structures.
As we discuss in earlier chapters, in addition to the strength of the global
effect, an important factor for the power of every multivariate test, including T 2,
is the direction of the effect. For linear combination or other “directional” tests, in
particular, power is substantially affected by the distance between the effect direction
and the targeted direction. Despite that various authors acknowledge this fact (see
for example Follmann [1996]; Logan and Tamhane [2004]; Pocock et al. [1987]; Tang
et al. [1993, 1989b]), a measure of the latter distance is yet to be established.
In the following, we encounter this problem in the context of linear combi-
nation tests and we provide a solution. We first consider the case of J−stage linear
combination z and t tests with fixed weighting vectors which, apart from providing
a method for performing simple power analysis of tests such as O’Brien’s OLS test
(for earlier work see Logan and Tamhane [2004]; Pocock et al. [1987]; Tang et al.
[1993]), also provides the intuition for the results considering the z+AD and t
+
AD tests.
For the remainder of this chapter, the critical values and sample sizes of
the J−stage tests are assumed to be fixed and described by the design vector d =
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(α0,1, α0,2, . . . , α0,J−1, α1,1, α1,2, . . . , α1,J , ν0, n0, n1, . . . , nJ). Our primary interest is
in the model parameters and the weighting vector.
7.2 J−stage z and t tests
To compute the power of the J−stage z and t tests with fixed weighting vectors
wj = w, it is sufficient to know the design vector d, as well as the stage-wise
location parameters θj in (6.6) (page 87). The latter parameters, for fixed wj = w,
j = 1, 2, . . . , J , are also fixed and can be re-expressed as
θ =
wTµ√
wTΣw
=
w˜T ω˜∗
‖w˜‖ = ‖ ω˜
∗ ‖ cos φw, φw = ang(w˜, ω˜∗), (7.1)
where φw denotes the angle, in measured degrees at the origin, between respectively
the standardized selected and optimal weighting vectors
w˜ = Σ1/2w, ω˜∗ = Σ1/2ω∗ = Σ−1/2µ. (7.2)
The standardized optimal weighting vector, ω˜∗, expresses the standardized,
to the covariance matrix, multivariate treatment effect. This standardization elim-
inates the variances and correlations of the local outcomes. The vector ω˜∗ is a
multivariate generalization of the univariate (K = 1) standardized treatment effect
µ/σ.
Considering the weighting vector selection problem, the first equation in (7.1)
implies that a weighting vector that increases the mean and/or decreases the variance
of the linear combination gives higher power. The ambiguity in the latter expression
becomes clearer by the standardization in the second equation which implies that
the weighting vector selection can be expressed as a process of learning the direction
of the standardized optimal weighting vector ω˜∗, that is, the standardized treatment
effect direction.
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The last equation in (7.1) establishes two scalar measures which are sufficient
to determine power. The first is the magnitude of ω˜∗,
‖ω˜∗‖ = (µTΣ−1µ)1/2 = ∆, (7.3)
which is equal to the Mahalanobis distance. As we discussed earlier, Mahalanobis
distance is a global measure of the strength of the treatment effect. The second,
cosφw, with φw = ang(w˜, ω˜
∗), is a measure of angular distance between the selected
weighting vector and the optimal weighting vector. In other words, the angular
distance between the targeted direction and the effect direction.
To summarise, for fixed weighting vectors, the location parameter, θ, is equal
to a measure, ∆, of the strength of the treatment effect scaled down by a measure,
cosφw, of the distance between the effect direction and the targeted direction ex-
pressed by the selected weighting vector. Importantly, as the next theorem states,
the latter measures determine the relation of the model parameters and the weight-
ing vector to power.
Theorem 7.2.1. The design vector d, the Mahalanobis distance ∆ in (7.3) and
the angle φw between the vectors ω˜
∗ and w˜ in (7.2) are sufficient to determine the
power function β of the J−stage linear combination z and t tests with fixed weighting
vectors wj = w.
Proof. By (6.4), (6.6) and (6.9) (pp. 86, 87, 88), the values of the design vector d
and the parameter θj , j = 1, 2, . . . , J are sufficient to compute the power function
of the J−stage z and t tests with wj = w, j = 1, 2, . . . , J . The result then follows
from the last equation in (7.1) and equation (7.3).
It is worth noting that the above results stand for the J−stage linear com-
bination z and t tests (fixed weighing vector), as described in the previous chapter,
but they also apply to the group sequential linear combination zGS and tGS tests,
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as described in section 5.3.1 (page 72). The description derived in the last theorem
is sufficient to compute power and, importantly, is based on easily interpretable
summaries which are scalar (see table 7.1).
Table 7.1: Model parameters, weighting vector and their dimension for the linear
combination z, t, zGS and tGS tests.
parameters dimension
µ,Σ, w
(
K2 + 5K
)
/2
ω˜∗, w˜ 2K
∆, φw 2
This allows us to perform power analysis of the single-stage z, t and group sequential
zGS and tGS tests in a simple way potentially covering the whole design space.
7.3 J−stage z+AD test
The sequential adaptation of the weighting vector increases the complexity within
the relation between power and the design and model parameters. However, follow-
ing similar methodology as above, analogous results can be derived.
For this we use two steps, the first of which involves standardizing the proce-
dure similarly to (7.1), and the second establishing a rotation invariance property of
the power function. The next lemma is a direct consequence of the standardization
step summarizing µ, Σ and m0 to the vectors ω˜
∗ and
w˜z+1
= Σ1/2wz+1
= Σ−1/2m0. (7.4)
Lemma 7.3.1. The design vector d, the standardized optimal weighting vector ω˜∗
in (7.2) and the standardized first-stage weighting vector w˜z+1
in (7.4) are sufficient
to determine the power function βz+AD
.
Proof. By (6.4) and (6.9) (pp. 86, 88), the values of the design vector d and the
parameter θz+j
in (7.5), j = 1, 2, . . . , J , are sufficient to compute the power function
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of the z+AD tests. Furthermore, we can write the location parameter, θz+j
, and the
standardized weighting vector, w˜z+j
= Σ−1/2mj−1, j = 1, 2, . . . , J , of the z+AD test
as
θz+j
=
w˜T
z+j
ω˜∗
‖w˜z+j ‖
, w˜z+j
=
n0w˜z+1
+ n(j−1)w˜x¯(j−1)
n0 + n(j−1)
, (7.5)
where
w˜x¯(j) = Σ
−1/2x¯(j) ∼ NK(ω˜∗, I/n(j)). (7.6)
By equations (7.5) and (7.6), we have that ω˜∗ in (7.2) and w˜z+1 in (7.4) are sufficient
to determine θz∗j , j = 1, 2, . . . , J , and the result follows.
The last lemma and particularly equation (7.5) imply that the adaptive se-
lection of the weighting vectors can be re-expressed as a procedure of adaptive
estimation of the direction of ω˜∗. Furthermore, under this standardization, we can
proceed to the rotation-invariance step which results in the next lemma.
Lemma 7.3.2. The power function βz+AD
is invariant to rotations of the weighting
vector w˜z+1
in (7.5) around the optimal weighting vector ω˜∗ in (7.2).
Proof. Let R be a rotation matrix with rotation axis ω˜∗ (RTR = I, Rω˜∗ = ω˜∗).
We define w˙z+1
= Rw˜z+1
the rotated first stage weighting vector (note that ‖w˙z+1 ‖ =
‖w˜z+1 ‖, ang(ω˜
∗, w˙z+1 ) = ang(ω˜
∗, w˜z+1 )). We can write w˜z+j in (7.5), j = 1, 2, . . . , J ,
as
w˜z+j
= RT w˙z+j
, w˙z+j
=
n0w˙z+1
+ n(j−1)w˙x¯(j−1)
n0 + n(j−1)
, (n(0) = 0)
where w˙x¯(j) = Rw˜x¯(j) and w˜x¯(j) as in (7.6). Therefore, the stage-wise test statistics
z+j , which along with the critical values fully describe the rejection region of the
z+AD test, can be re-written as
z+j =
wT
z+j
x¯j√
wT
z+j
Σwz+j
/nj
=
w˜T
z+j
w˜x¯j
‖w˜z+j ‖/
√
nj
=
w˙T
z+j
Rw˜x¯j
‖w˙z+j ‖/
√
nj
=
w˙T
z+j
w˙x¯j
‖w˙z+j ‖/
√
nj
,
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where w˙x¯j = Rw˜x¯j and w˜x¯j = Σ
−1/2x¯j . Therefore, the rejection region of the
J−stage z+AD test after the rotation is equal to the initial but with the first stage stan-
dardized weighting vector w˜z+1
replaced by w˙z+1
and the standardized observation
vectors w˜xij = Σ
−1/2xij replaced by w˙xij = Rw˜xij , i = 1, 2, . . . , nj , j = 1, 2, . . . , J .
Importantly, w˙xij has the same distribution, NK(ω˜
∗, I), as w˜xij and thus the result
follows.
The result of lemma 7.3.2 can be described, in other words, as that the
change to the rejection region of the z+AD test produced by rotating w˜z+1
around ω˜∗,
that is, replacing w˜z+1
by w˙z+1
= Rw˜z+1
(where R a rotation matrix with axis ω˜⋆),
does not affect power. To see this, first note that the new rejection region, after the
rotation of w˜z+1
, is simply a rotation of the initial rejection region. That is, for each
point say w˜x¯(j) in the initial rejection region, we can find a unique point, say w˙x¯(j) ,
in the rotated rejection region such that w˙x¯(j) = Rw˜x¯(j) . The power is unchanged
by this rotation, because the symmetrical Gaussian distribution of the observations
w˜x¯(j) ∼ NK(ω˜∗, I/n(j)) remains unchanged under the rotation. This implies the
result which is that the likelihood of the rejection region, i.e. the power of the z+AD
test, remains the same after the rotation.
The next theorem is direct consequence of lemmas 7.3.1 and 7.3.2.
Theorem 7.3.1. The design vector d, the Mahalanobis distance ∆ in (7.3) and
the angle φz+1
= ang(ω˜∗, w˜z+1 ) between the vectors ω˜
∗ in (7.2) and w˜z+1 in (7.4) are
sufficient to determine the power function βz+AD
.
Proof. By lemma 7.3.1, the design vector d and the vectors ω˜∗ and w˜z+1 are sufficient
to determine the power function βz+AD
. Further, lemma 7.3.2, by rotation properties,
implies that for any value of w˜z+1
such that φz+1
remains fixed, the power βz+AD
test
is invariant. The result then follows immediately.
The above theorem states that the dependence of the power function on the
model parameters and their prior estimates is described by simply a measure of
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the strength of the treatment effect and a measure of distance between the model
parameters, determinging the effect direction, and their prior estimates, determin-
ing the targeted direction. These easily interpretable measures, which provide a
sufficient description of power, are also scalar (see table 7.2). Therefore this power
characterisation, apart from providing great inside on the behavior of z+ and z+AD
tests, allows us to perform simple power analysis potentially covering the whole
design space.
Table 7.2: Model and prior parameters of the z+ and z+AD tests and their dimension.
parameters dimension
µ,Σ, m0
(
K2 + 5K
)
/2
ω˜∗, w˜z+1 2K
∆, φz+1
2
7.4 J−stage t+AD test
The need to estimate the unknown Σ increases substantially the dimension and the
complexity of the design space. In particular, the sequential estimation of Σ, in
addition to µ, to obtain the weighting vectors wt+j
= S−1j−1mj−1 in (6.29) (page 99),
implies that the power analysis needs to account for both estimation procedures.
For this, we write the weighting vector w˜t+j
= Σ1/2wt+j
, j = 1, 2, . . . , J as
w˜t+j
=D−1j w˜z+j , Dj = Σ
−1/2Sj−1Σ−1/2 (7.7)
and w˜z+j
the j−th standardized weighting vector of the z+AD test in (7.5). Here the
Σ−deviation matrix Dj is a measure of deviation of the estimate Sj−1 in (6.25)
(see page 98) from the parameter Σ. The weighting vector w˜t+j
is then written as
a product of the inverse of the matrix Dj , that accounts for the estimation of Σ,
and the vector w˜z+j
which accounts for the estimation of µ, the latter taking Σ as
known.
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We next follow the same steps as in section 7.3 for deriving the power char-
acterization of the t+AD test. The standardization step results in the next lemma
summarizing µ and Σ and their prior estimates m0 and S0 to the vectors ω˜
∗, w˜z+1
and the matrix D1 that have clear interpretation.
Lemma 7.4.1. The design vector d, the matrix D1 in (7.7) and the vectors ω˜
∗ in
(4.11) and w˜z+1
in (7.5) are sufficient to determine the power function βt+AD
.
Proof. By (6.4) and (6.9), the design vector d and θt+j
in (7.9), j = 1, 2, . . . , J , are
sufficient to compute the power function of the t+AD tests. The location parameter,
θt+j
, of the t+j statistic can be written as
θt+j
=
w˜T
t+j
ω˜∗
‖w˜t+j ‖
=
w˜T
z+j
D−1j ω˜
∗
‖D−1j w˜z+j ‖
, (7.8)
where w˜T
z+j
can be written as the weighted average in (7.5) and the Σ−deviation
matrix Dj as
Dj =D1+ν(j−1)Sw˜x(j−1)+
n0n(j−1)
n0 + n(j−1)
(
w˜x¯(j−1)−w˜z+1
)(
w˜x¯(j−1)−w˜z+1
)T
, (7.9)
where Sw˜
x(j)
=Σ−1/2Sx(j)Σ
−1/2 is the covariance matrix of the sample w˜xil , i =
1, 2, . . . , nl, l = 1, 2, . . . , j. Here, importantly, w˜xil = Σ
−1/2xil ∼ NK(ω˜∗, I). Thus,
we have that ω˜∗ in (7.2), w˜z+1 in (7.4) and D1 in (7.7) are sufficient to determine
θt∗j , j = 1, 2, . . . , J , from which the result follows.
In a similar fashion to the previous section, we next establish the invari-
ance of the power function under certain rotations of the prior estimates. For this,
we define V = [v1 v2 . . . vK ] to be the matrix with the columns being the or-
thonormal eigenvectors v1,v2, . . . ,vK ofD1 and Λ1 = diag(λ1) the diagonal matrix
with diagonal λ1 = (λ11, λ12, . . . , λ1K)
T the vector of the corresponding eigenvalues
(λ11 ≥ λ21 ≥ · · · ≥ λ1K > 0). We can then write D1 = V Λ1V T , w˜z+1 = V cz+1 and
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ω˜∗ = V c∗ where
cz+j ,k
= cos(ang(vk, w˜z+j
)), c∗k = cos (ang (vk, ω˜
∗)) , k = 1, 2, . . . ,K. (7.10)
The rotation invariance property of the t+AD test is described in the next lemma.
Lemma 7.4.2. The power function βt+AD
is invariant to simultaneous rotations of
the vector w˜z+1
in (7.5) and the eigenvectors of the matrix D1 in (7.7) around the
optimal weighting vector ω˜∗ in (7.2).
Proof. Let R be a rotation matrix with rotation axis ω˜∗ and define w˙z+1 = Rw˜z+1 ,
V˙ = RV = [v˙1 v˙2 . . . v˙K ] (note that c
∗
k = cos(ang(ω˜
∗,vk)) = cos(ang(ω˜∗, v˙k)),
cz+1 ,k
= cos(ang(w˜z+1
,vk)) = cos(ang(w˙z+1
, v˙k)), k = 1, 2, . . . ,K). Then note that
we can write w˜z+j
in (7.5) as
w˜z+j
= RT w˙z+j
, w˙z+j
=
n0w˙z+1
+ n(j−1)w˙x¯(j−1)
n0 + n(j−1)
, (n(0) = 0), (7.11)
and Dj in (7.9) as Dj = R
T D˙jR, where
D˙j=D˙1+(n(j−1) − 1)Sw˙x(j−1)+
n0n(j−1)
n0 + n(j−1)
(
w˙x¯(j−1) − w˙z+1
)(
w˙x¯(j−1) − w˙z+1
)T
,
where D˙1 = V˙ Λ1V˙
T and w˙x(j) , Sw˙x(j−1) the sample mean and sample covariance
matrix of the sample w˙x¯ij = Rw˜x¯ij , i = 1, 2, . . . , nj , j = 1, 2, . . . , J . Therefore, the
weighting vector w˜t+j
in (7.7) can be written as
w˜t+j
= RT w˙t+j
, w˙t+j
= D˙−1j w˙z+j
and hence the stage-wise test statistics, t+j (which, along with the critical values,
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fully describe the rejection region of the t+AD test) can be re-written as
t+j =
w˜T
t+j
w˜x¯j
√
nj√
w˜T
t+j
Sw˜xj w˜t+j
=
w˙T
t+j
Rw˜x¯j
√
nj√
w˙T
t+j
RSw˜xjR
T w˙t+j
=
w˙T
t+j
w˙x¯j
√
nj√
w˙T
t+j
Sw˙xj w˙t+j
. (7.12)
Therefore, the rejection region of the t+AD test after the rotation is equal to the
initial but with V replaced by V˙ , w˜z+1
replaced by w˙z+1
and w˜xij replaced by w˙xij .
Importantly, w˙xij , i = 1, 2, . . . , nj , j = 1, 2, . . . , J , have the same distribution,
NK(ω˜
∗, I), as w˜xij and thus the result follows.
The above proof, albeit with the extra complexity, is based on the same idea
with the proof of lemma 7.3.2. The next theorem is a direct consequence of lemmas
7.4.1 and 7.4.2.
Theorem 7.4.1. The design vector d, the vector of eigenvalues λ1 of D1 in (7.7)
and the vectors cz+1
and c∗ in (7.10) are sufficient to determine the power function
βt+AD
.
Proof. By lemma 7.4.1, the design vector d and ω˜∗, w˜z+1 and D1 are sufficient to
determine the power function βt+AD
. Furthermore, lemma 7.4.2, by rotation prop-
erties, implies that for any value of w˜z+1
and D1 such that the vectors c
∗, cz+1 in
(7.10) and λ1 remain fixed, the power of the t
+
AD remains fixed. The result then
follows.
As we can see in table 7.3, the last result reduces the dimension of the design
space of the t+AD test substantially. While the design space, due to the covariance
matrix estimation, still depends on K, it is reduced from order K2 to order K. It
is useful to note that these results apply to the t+ as a special case to the t+AD test.
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Table 7.3: Model and prior parameters of the t+ and t+AD tests and their dimension
parameters dimension
µ,Σ,m0,S0 K
2 + 3K
ω˜∗, w˜z+1 ,D1
K2+5K
2
c∗, cz+1 ,λ1 3K
Furthermore, this reduction provides an understanding of how the selection of the
weighting vector affects power. This becomes clearer if we consider that θt+j
in (7.9)
can be written as
θt+j
=
cT
z+j
Λ−1j c
∗
‖Λ−1j cz+j ‖
, j = 1, 2, . . . , J,
where
cz+j
=
n0cz+1
+ n(j−1)cx¯(j−1)
n0 + n(j−1)
,
and
Λj = Λ1 + ν(j−1)Scx(j−1) +
n0n(j−1)
n0 + n(j−1)
(cx¯(j−1) − cz+1 )(cx¯(j−1) − cz+1 )
T .
Here, cx¯(j) and Scx(j) are the sample mean and sample covariance matrix of the
transformed observation vectors cx(j) = [cx1cx2 . . . cxj ] with cxl , l = 1, 2, . . . , j,
the matrix with columns cxil = V
T
1 w˜xil ∼ NK(c∗, I), i = 1, 2, . . . , nj. The last
expressions show that the distance of the prior estimates m0, S0 to the model
parameters µ, Σ can be expressed by the distances of the vectors cz+1
and λ−11 =
(1/λ11, . . . , 1/λ1K)
T to c∗, the latter directly reflected to power through θt+j (see the
next chapter for more information).
In the special case of the first stage Σ−deviation matrix being proportional
to the identity matrix, that is, D1 ∝ I (λ11 = λ12 = · · · = λ1K), as the next result
shows, the design space can be reduced further.
Theorem 7.4.2. For D1 = c
−1I, the design vector d, the constant c, the Maha-
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lanobis distance ∆ and the angle φz+1
= ang(w˜z+1
, ω˜∗) are sufficient to determine
the power function βt+AD
.
Proof. Let R be a rotation matrix with rotation axis ω˜∗ and define w˙z+1 = Rw˜z+1 .
Then note that we can write w˜z+j
in (7.5) as in (7.11) and Dj in (7.9) as Dj =
RT D˙jR, where
D˙j=c
−1I + (n(j−1) − 1)Sw˙x(j−1)+
n0n(j−1)
n0 + n(j−1)
(
w˙x¯(j−1)−w˙z+1
)(
w˙x¯(j−1)−w˙z+1
)T
.
Therefore, the weighting vector w˜t+j
in (7.7) can be written as
w˜t+j
RT w˙t+j
, w˙t+j
= D˙−1j w˙z+j
and hence the stage-wise test statistics, t+j which, along with the design vector d,
fully describe the rejection region of the t+AD test, can be re-written as in (7.12).
Therefore, for D1 = c
−1I, the rejection region of the t+AD test after the rotation
is equal to the initial but with w˜z+1
replaced by w˙z+1
and w˜xij replaced by w˙xij .
Importantly, w˙xij have the same distribution, NK(ω˜
∗, I), as w˜xij , i = 1, 2, . . . , nj ,
j = 1, 2, . . . , J . The result then follows using the same steps as in the proof of
theorem 7.3.1.
The last theorem proves that, for D1 ∝ I, we can use the fact that the prior
Σ−deviation matrix D1 does not change the directions of w˜z+j ’s, to show that the
relation of βt+AD
to the model parameters and their prior estimates can be described
simply by the scalars ∆ and φz+1
= ang(w˜z+1
, ω˜∗).
7.5 Conclusions
The above results allows us to characterize the power function of linear combination
tests and particularly its relation to the model parameters and the weighting vec-
tor. This power characterization provides a tool for understanding and alleviating
116
to some extent the complexities of multivariate tests and especially directional mul-
tivariate tests. The possibly high dimensional model parameters and the weighting
vector/prior estimates are reduced to low dimensional summaries which are still
sufficient to compute power. Importantly, these summaries have interpretations di-
rectly related to the strength of the treatment effect and the distance between the
targeted direction and the effect direction. They provide a method for performing
simple power analysis, but also understanding the behavior of linear combination
tests.
The methods used to derive the power characterization are also interesting
in their own right. They can be generally described by two steps: standardization
and rotation invariance. The first standardization step is a prevalent technique
for re-expressing statistical models in the standard deviation unit and eliminating
correlations. Here, it allows us to re-express the weighting vector selection, which
involves estimating the unknown model parameters, as a procedure of learning a
single vector, that is, the optimal weighting vector, or, in other words, the effect
direction. The second step of establishing a rotation invariance property for the
power function allows us to identify the measure quantifying the angular distance
between the selected and the optimal weighting vector, reducing further the design
space. In the next chapter, we use these results, and particularly those in theorems
7.3.1, 7.4.1 and 7.4.2 to perform power analysis studies.
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Chapter 8
Power analysis
8.1 Introduction
In this chapter, we study the power behavior of various multivariate global tests. We
mainly focus on the tests developed in this thesis, that is, the z+, t+ and adaptive
z+AD, t
+
AD linear combination tests, but we also examine the class of single-stage and
group sequential linear combination z, t and zGS , tGS tests, with fixed weighting
vectors, as described in sections 3.3.3 and 5.3.1 (pp. 37, 72), respectively. This
includes, as special cases, O’Brien’s OLS and GLS (for Σ known) tests in O’Brien
[1984] and their group sequential extensions as described in Tang et al. [1993, 1989b].
Single-stage and group sequential χ2, χ2GS and Hotelling’s T
2, T 2GS tests, as described
in sections 3.3.1 and 5.3.1 (pp. 31, 72), are also examined, while La¨uter [1996] exact
SS and PC tests are considered for the applications in section 8.4.
In this study, we use the results of previous chapters, and especially chapter
7, which reduces substantially the complexities in performing power analysis of
multivariate global tests and particularly directional tests. As we have seen in the
previous chapter, for determining the power of linear combination tests, the model
parameters and the weighting vector (or the prior estimates used to select it) can be
reduced to two easily interpretable distance measures. The first is the Mahalanobis
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distance, ∆, and expresses the strength of the treatment effect. The second is the
distance of the selected weighting vector to the optimal weighting vector, ω˜∗. The
latter can be seen as the distance of the “targeted” direction and the real effect
direction. For the z, t, zGS and tGS tests, with fixed weighting vector, w˜, this
distance can be measured by the angle
φw = ang(w˜, ω˜
∗), (8.1)
while for the z+, z+AD with first stage weighting vector w˜z+1
using the angle
φz+1
= ang(w˜z+1
, ω˜∗). (8.2)
As we discuss later, this distance can also be studied in a simple way in the t+ and
t+AD tests.
These results provide a method to study complex effect structures, by looking
at simple ones, provided that the latter keep the same values of the above summary
measures as the former. For example, to study the power behavior of any linear
combination test with weighting vector, w˜, having angle, φ, to the optimal, ω˜∗, it is
sufficient to set ω˜∗ = (1, 0, . . . , 0)T and w˜ = (cosφ, sinφ, 0, . . . , 0)T , as this structure
sets ang(w˜, ω˜∗) = φ. Such results, which simplify power analysis considerably, are
used in the empirical studies of the next sections.
For single-stage tests, the main focus of power analysis is on the study of
two measures: power and sample size. For sequential or adaptive tests where early
stopping is permitted, in addition to power and the total or maximum sample size,
nT = n1 + n2 + · · ·+ nJ , it is useful to consider the sample size, n, actually used in
the test. This can be smaller than nT , due to early terminations, and depends on
the observations’ distribution which implies that it is a random variable. A common
approach is then to study the total sample size and expected sample size, E(n), for
a fixed power level.
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In the power analysis to follow, we consider another typical approach where
the total sample size nT is fixed at a certain value and the power of the test along
with the expected sample size are examined. In particular, the expected sample size
is studied using a relative, to the total sample nT , measure, the rate of sample size
reduction (RSSR). RSSR is defined as
RSSR = 100 ×
(
nT − E(n)
nT
)
%. (8.3)
The expected sample size E(n) is approximated by the empirical mean of n across
the simulated replications of the experiment. Similarly, the power of each test is
approximated by the rate of rejection across the number of replications (R = 50000).
RSSR is linearly decreasing with E(n) and thus larger values of E(n) imply
smaller values of RSSR. Furthermore, single-stage tests have RSSR = 0, as in
single-stage tests no early stopping is permitted and thus E(n) = nT . It is also
useful to note that in our examples to follow, the two-stage zGS , tGS tests with
fixed weighting vector, w, have the same RSSR as the two-stage z+AD, t
+
AD tests (for
the same design parameters), since without loss of generality we take w = wz+1
or
w = wt+1
and thus these tests have equal number of early rejections.
To derive the critical values of the group sequential tests we use the gsDesign
package in R software [Anderson, 2013]. In particular, for designs allowing for early
acceptance (αj,0 < 1, j = 1, 2, . . . , J − 1) we use the default Hwang-Shih-DeCani
spending function approach in Hwang et al. [1990], while for designs not allowing
for early acceptance (αj,0 = 1, j = 1, 2, . . . , J − 1) the rejection critical values
are chosen based on the methodology of Wang and Tsiatis [1987] as explained in
Jennison and Turnbull [2000]. For the latter, in our presentations, the values of the
constants CWT and DWT (as in Jennison and Turnbull [2000] notation) which are
used to derive the Wang & Tsiatis stopping boundaries are provided along with the
resulting critical values. Note that critical values derived from both Hwang et al.
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[1990] and Wang and Tsiatis [1987] methodology control the type I error rate of
group sequential zGS tests. For group sequential tGS , χ
2
GS and T
2
GS tests, we use
the “significance level approach” as described in Jennison and Turnbull [2000]. For
this, the p−values of the j−th stage-wise statistics of the latter tests are compared
with the critical values αj,1 = 2(1 − Φ(zαj,1)), where zαj,1 the critical z−value for
the group sequential zGS test. As Jennison and Turnbull [2000] explains, these tests
satisfy the type I error requirement only approximately, but investigations have
shown that this approximation is remarkably accurate. Finally, to make the results
of multi-stage tests more comparable, we set the first stage critical value of the
adaptive z+AD and t
+
AD tests equal to the group sequential tests, while, to ensure
type I error control, the second stage (or later stages) critical values of z+AD and t
+
AD
are selected to satisfy the type I error equation in (6.10) (see page 89).
This chapter proceeds as follows. In section 8.2 we discuss the main out-
comes of an extensive empirical study of the relation between the design and model
parameters to the power behavior of the aforementioned global tests. In section
8.3, we provide a comparison of the power performance of these tests. In section
8.4, we consider the power performance of these global tests in the application to
neuroimaging studies. We close the chapter by a brief discussion of the main results.
8.2 Design and model parameters
In the following, we discuss the main results of an extensive empirical study which
attempts to describe the effect of design and model parameters on power behavior
of various global tests. In each of the next sections, we mainly focus on the effect
of individual design or model parameters on power and RSSR. We start with the
sample size and global effect size.
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Sample and global effect size
Generally, the power of well-behaved tests is expected to increase in the sample
and effect size. As we have explained earlier, the Mahalanobis distance, ∆, is a
measure of the size of the global effect. In particular, ∆ = 0 implies that the null
hypothesis H0 is true and thus the power of exact tests is expected to be equal to
the significance level. As we can see in figure 8.1, for ∆ = 0 all the considered tests
have power equal (at least approximately) to the significance level α = 0.05. This
confirms the analytical proofs of type I error control in these tests.
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Figure 8.1: Power versus Mahalanobis distance ∆ for various tests and angles (as
indicated in the legend) of the weighting vectors w˜z+1
= w˜ to the optimal ω˜⋆. Here
α = 0.05, α0,1 = 1, α1,1 = 0.0085 (DWT = 0.1, CWT = 1.994), K = 10, n0 = 10 and
nT = 25.
Larger values of ∆ and/or nT result in higher values of the location of the
distribution of all the considered test statistics and thus, as we show in figures 8.1
and 8.2, higher power levels are attained. The exceptions are the z, t, zGS and tGS
tests with fixed weighting vectors w˜ orthogonal to ω˜+ (see second row, figure 8.1
and 8.2) for which the location parameter is equal to 0 for any value of ∆ and/or
nT and thus β = α. On the contrary, the power of z
+ and t+ and z+AD, t
+
AD tests
increases with ∆ and/or nT even if w˜z+1
is orthogonal to the optimal ω˜+ due to the
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power gain after the interim adaptation of the weighting vector.
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Figure 8.2: Power versus the total sample size nT for various tests and angles (as
indicated in the legend) of the weighting vectors w˜z+1
= w˜ to the optimal ω˜⋆. Here
α = 0.05, α0,1 = 1, α1,1 = 0.0085 (DWT = 0.1, CWT = 1.994), K = 10, n0 = 10 and
∆ = 0.7.
Furthermore, larger ∆ and/or nT increase the chance to stop early and there-
fore they decrease the expected sample size of adaptive and sequential tests. This is
illustrated by figure 8.3 which shows the increase in the rate of (total) sample size
reduction, RSSR, for the zGS/z
+
AD and χ
2
GS. Note that single-stage tests, as well as
two-stage z and t tests with first stage weighting vector orthogonal to optimal, have
RSSR = 0.
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Figure 8.3: RSSR versus Mahalanobis distance ∆ (left) and the total sample size
nT (right) for various tests and angles (as indicated in the legend) of the weighting
vectors w˜z+1
= w˜ to the optimal ω˜⋆. Here α = 0.05, α0,1 = 1, α1,1 = 0.0085
(DWT = 0.1, CWT = 1.994), K = 10, n0 = 10 and nT = 25 (left), ∆ = 0.7 (right).
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Prior sample size
The prior sample size n0 determines the weight of the prior estimates at the interim
selections of the weighting vector. Larger values of n0 enforce z
+, t+ and z+AD,
t+AD to have more similar power behavior to z, t and zGS and tGS tests with fixed
weighting vector. This is because, for larger n0, the first stage weighting vector,
determined using the prior estimates, has larger weight in computing the weighting
vector of later stages, while, for n0 ≫ nT , the weighting vectors of all stages are
approximately equal to the first stage weighting vector.
As we can see in figure 8.4, for wz+1
close to optimal, power is increasing with
n0, while for wz+1
far from optimal, power is decreasing with n0. Moderate values of
n0, such as n0 = (0.75n1, 1.25n1), make the prior estimates influential, but do not
dominate the accumulated data in selecting the weighting vector. This allows us to
distinguish between z+, t+ and z+AD, t
+
AD test and the z, t and zGS and tGS tests.
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Figure 8.4: Power versus the prior sample size n0 for z
+
AD (left) and z
+ (right) tests
and angles (as indicated in the legend) of the weighting vectors w˜z+1
to the optimal
ω˜⋆. Here α = 0.05, α0,1 = 1, α1,1 = 0.0085 (DWT = 0.1, CWT = 1.994), K = 10,
nT = 30 and ∆ = 0.75.
Critical values
The rejection and acceptance critical values, αj,1, αj,0, j = 1, 2, . . . , J , respectively,
are chosen to satisfy a single constraint: the type I error equation of the test. This
permits for substantial flexibility in selecting the critical values, which can be freely
chosen to reflect, for instance, the investigators priorities on early stopping. In
addition, as we confirm here, the critical values affect the power behavior of the
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tests.
In general, larger values of the rejection critical values αj,1, j = 1, 2, . . . , J ,
increase (decrease) power in cases where the potential power gain at the j−th stage
is larger (smaller) compared to other stages. That is the case when nj is larger
(smaller) or when the j−th stage weighting vector is close to (far from) optimal.
Generally, power is expected to be larger for greater αj,1 in late rather than early
stages as in late stages greater samples are collected. On the other hand, larger
values of αj,1 at early stages increase the chance to terminate the study early and
thus the value of RSSR is expected to increase.
These arguments are supported by the results in table 8.1. Here the power
and RSSR of two-stage χ2GS and zGS , z
+
AD tests, the latter with weighting vectors of
various angles to optimal, are presented. As we can see, power decreases with larger
first stage critical values α1,1 since this result in smaller second stage critical values
α2,1. On the contrary, larger α1,1 increases RSSR since it increases the chance for
early stopping. Moderate values of α1,1 seem to achieve a good compromise between
the benefits of high power and low expected sample size. It may be worth noting
that, as α1,1 increases, the decrease in power and increase in RSSR is larger for more
sample allocated to the first rather than the second stage, as in the former case the
first stage study can potentially attain higher power.
Considering the futility critical values αj,0, j = 1, 2, . . . , J , larger values
increase the chance to proceed to (and thus reject at) subsequent stages, but, on
the other hand, decrease the value of the rejection critical values due to the type I
error restriction. In table 8.2, the power of non-single-stage tests is slightly changed
with α1,0, with an exception being the z
+
AD test with the first stage weighting vector
orthogonal to the optimal for which the power is substantially increased. This is
because of the substantial power increase due to the second stage in which the
weighting vector is no longer orthogonal, but possibly much closer, to the optimal.
However, smaller αj,0 increase RSSR due to the larger chance of early acceptance.
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Table 8.1: Power and RSSR versus the first-stage rejection critical value α1,1 for
various two-stage (J = 2) tests and angles of the weighting vectors w˜z+1
= w˜ to the
optimal ω˜⋆. Here α = 0.05, ∆ = 1, K = 10, nT = 20, n1 = 0.5nT , n0 = 5.
DWT 0.00 0.10 0.25 0.40 0.50 0.75 1.00
α1,1 0.0051 0.0086 0.0153 0.0237 0.0293 0.0419 0.0477
GS α2,1 0.0477 0.0466 0.0414 0.0349 0.0293 0.0155 0.0051
χ2GS β 0.89 0.89 0.88 0.87 0.86 0.81 0.74
RSSR 11.75 14.41 18.10 21.06 22.70 25.58 26.84
zGS 90
◦ β 0.05 0.05 0.05 0.05 0.05 0.05 0.05
RSSR 0.26 0.44 0.82 1.18 1.48 2.14 2.51
45◦ β 0.88 0.88 0.87 0.86 0.85 0.81 0.74
RSSR 14.41 17.49 21.23 24.47 26.17 29.03 30.01
0◦ β 0.99 0.99 0.99 0.99 0.99 0.98 0.97
RSSR 32.17 35.42 38.42 40.77 41.96 43.45 44.01
AD α2,1 0.0085 0.0087 0.0083 0.0070 0.0059 0.0026 0.0008
z+AD 90
◦ β 0.42 0.42 0.42 0.40 0.38 0.29 0.21
RSSR 0.26 0.44 0.82 1.18 1.48 2.14 2.51
45◦ β 0.86 0.86 0.86 0.85 0.85 0.81 0.75
RSSR 14.41 17.49 21.23 24.47 26.17 29.03 30.01
0◦ β 0.96 0.96 0.96 0.96 0.96 0.95 0.93
RSSR 32.17 35.42 38.42 40.77 41.96 43.45 44.01
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Table 8.2: Power and RSSR versus the first-stage futility critical value α1,0 for
various two-stage (J = 2) tests and angles of the weighting vectors w˜z+1
= w˜ to the
optimal ω˜⋆. Here α = 0.05, α1,1 = 0.0148, n0 = 7, K = 10, nT = 20, n1 = 0.5nT ,
∆ = 1.
α1,0 0.60 0.70 0.80 0.90 1.00
GS α2,1 0.0448 0.0438 0.0432 0.0428 0.0420
zGS 90
◦ β 0.05 0.05 0.05 0.05 0.05
RSSR 35.5 33 30.5 28 0.05
45◦ β 0.87 0.87 0.87 0.87 0.88
RSSR 23 22.5 22 22 21
0◦ β 0.99 0.99 0.99 0.99 0.99
RSSR 38.5 38.5 38.5 38.5 38.5
AD α2,1 0.0095 0.0091 0.0088 0.0086 0.0084
z+AD 90
◦ β 0.30 0.33 0.37 0.39 0.42
RSSR 20.71 15.81 10.83 5.77 0.78
45◦ β 0.85 0.86 0.86 0.86 0.86
RSSR 22.71 22.51 21.82 21.47 21.01
0◦ β 0.96 0.96 0.96 0.96 0.96
RSSR 38.47 38.29 38.12 38.45 38.25
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These results indicate that investigators should relate the selection of αj,0 to
the degree of interest on early acceptance of H0 as opposed to final rejection. It
is worth noting here that even if αj,0, j = 1, 2, . . . , J are all set equal to 1, early
stopping of the study either for futility or for other reasons (such as safety), without
declaring rejection of H0, does not inflate the type I error. Suitable thresholds
for futility early stopping can thus be specified, but not taken into account for
computing the type I error. Such procedures are often called non-binding stopping
rules. Bretz et al. [2009] and Jennison and Turnbull [2000] provide methodologies
and discussions on the subject.
Sample allocation
For group sequential and adaptive tests, an important issue is how to allocate the
total sample size, nT , to the different stages. As we have discussed in chapter
5, adaptive designs as well as some group sequential designs allow for sample size
adaptation and thus nT is allowed to change based on the interim results. However,
in this section, to study the effect of different sample allocations on the power of
global tests, we assume that nT is fixed and we consider only two-stage designs. The
sample allocation is described by r1 = n1/nT .
Table 8.3 shows that the changes in the power of zGS and χ
2
GS tests for
different values of r1 are negligible. This is partly due to the moderate value of
α1,1. For very unbalanced α−allocation to stages, for example α1,1 / α, allocating
sample size accordingly provides higher power. On the other hand, table 8.3 shows
that equal sample allocation to stages (r1 = 0.5) can give substantially larger RSSR.
The power of the z+ test is greatly affected by the sample allocation, with
small to moderate allocation ratios attaining substantially greater power levels. This
is because z+ allocates the α rate exclusively to the second stage. In table 8.4,
higher power is observed for r1 = 0.25, with power slightly lower for r1 = 0.5 and
substantially lower for r1 = 0.75.
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Table 8.3: Power and RSSR versus the sample allocation ratio r1 = n1/nT for the
two-stage (J = 2) χ2GS and zGS tests, the latter with different angles of the weighting
vector w˜ to the optimal ω˜⋆. Here α = 0.05, α1,1 = 0.0153 (DWT = 0.388, 0.25,
−0.175), K = 10, ∆ = 0.85, nT = 30.
r1 = 0.25 r1 = 0.5 r1 = 0.75
χ2GS β 0.91 0.91 0.91
RSSR 12.14 20.06 15.45
zGS 90
◦ β 0.05 0.05 0.05
RSSR 1.17 0.79 0.37
45◦ β 0.90 0.90 0.90
RSSR 17.09 23.07 15.81
0◦ β 1.00 1.00 1.00
RSSR 36.09 40.36 22.16
In contrast to z+ and t+, the adaptive z+AD and t
+
AD tests allocate some of
the α rate to the first stage, which greatly affect their power behavior. If the first
stage weighting vector is very close to optimal, an increase in distance to optimality
may occur at later stages due to sampling error, and thus, in contrast to z+ and t+,
allocating greater sample sizes to the first stage may result in slightly greater power
values. On the other hand, similarly to z+ and t+ tests, for first stage weighting
vectors far from the optimal, allocating larger sample to the second stage is more
appropriate as the first stage sample moves the second stage weighting vector closer
to optimal and thus the potential power at the second stage is greater.
The results in table 8.4 show that the highest values of power of the z+AD test
for angles between the first stage and the optimal weighting vector, 0◦, 45◦ and 90◦,
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are respectively attained for r1 = 0.75, 0.75 and 0.25.
Table 8.4: Power and RSSR versus the sample allocation ratio r1 = n1/nT for the
z+ and z+AD tests with different angles of the prior weighting vector w˜z+1
to the
optimal w˜. Here α = 0.05, α1,1 = 0.0153 (DWT = 0.388, 0.25, −0.175), K = 10,
∆ = 0.85, nT = 30. Note that for the z
+ tests RSSR= 0 and that for the two-stage
z+AD test RSSR is not affected by n0.
r1 = 0.25 r1 = 0.5 r1 = 0.75
z+ n0 = 0.25n1 90
◦ β 0.64 0.64 0.42
45◦ β 0.74 0.72 0.47
0◦ β 0.77 0.75 0.49
n0 = 0.75n1 90
◦ β 0.57 0.52 0.32
45◦ β 0.83 0.77 0.49
0◦ β 0.90 0.83 0.55
z+AD n0 = 0.25n1 90
◦ β 0.55 0.53 0.32
45◦ β 0.77 0.87 0.88
0◦ β 0.86 0.96 0.98
n0 = 0.75n1 90
◦ β 0.47 0.41 0.24
45◦ β 0.85 0.90 0.89
0◦ β 0.94 0.98 0.99
90◦ RSSR 1.14 0.71 0.35
45◦ RSSR 17.44 23.02 15.77
0◦ RSSR 36.23 40.21 22.20
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However, most importantly, the loss in power between r1 = 0.5 and the more extreme
allocations, either greater or smaller r1, is small, which makes equally sized stages
overall more appropriate. The latter result is also supported by the results for RSSR,
as the largest values of RSSR are attained for r1 = 0.5 (except for angle 90
◦ where
RSSR is negligible).
It might be useful to note here that, overall, balanced allocations seem to
be appropriate in most cases. The main exceptions are the situations where the
allocation of the α rate to the different stages is very imbalanced (e.g. z+ and t+
tests), in which case it might be preferrable to allocate the sample accordingly.
8.2.1 Impact of Σ unknown
In this section, we consider the impact of Σ being unknown, and thus estimated, on
the performance of the t+AD test. As we have discussed in section 7.4, the location
parameters of the stage-wise t+j statistics are
θt+j
=
w˜T
z+j
D−1j ω˜
∗
‖D−1j w˜z+j ‖
=
cT
z+j
Λ−1j c
∗
‖Λ−1j cz+j ‖
, j = 1, 2, . . . , J,
where Dj = Σ
−1/2Sj−1Σ−1/2, Λj = Diag(λj) the Σ−deviation matrix, with λj
being the vector of eigenvalues of Dj and the vectors cz+j
= V Twz+j
, c∗ = V T ω˜∗,
where V is the matrix of eigenvectors of D1.
We firstly consider the situation where D1 = Σ
−1/2S0Σ−1/2 is proportional
to the identity matrix IK (λ1 ∝ 1K). This situation arises if the prior estimate
S0 is proportional to Σ. For D1 ∝ IK , as we showed in theorem 7.4.2, the power
of t+AD can be studied in a similar way to z
+
AD, that is based on ∆ and the angle
between the vector w˜t+1
= w˜z+1
and the optimal ω˜∗.
It is worth considering the difference in power behavior of t+AD between this
simpler case and the case where D1 6∝ IK . In the former case, the direction of
w˜t+j
is mostly influenced by w˜z+j
and less by Dj . For the first stage, the weighting
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vector w˜t+1
= w˜z+1
while for subsequent stages Dj are expected to be closer to IK
and thus w˜t+j
closer to w˜z+j
. In other words, having a precise (up to a constant)
prior covariance matrix estimate reduces the estimation variability and we generally
expect w˜t+j
to be closer to w˜z+j
.
If D1 6∝ IK (λ1 6∝ 1K), the direction of λ1 is more influential on w˜t+j . To
illustrate this situation with an example, consider the case where the covariance
matrix and its prior estimate S0 are diagonal, that is Σ = Diag
(
σ21, . . . , σ
2
K
)
, S0 =
Diag
(
s201, . . . , s
2
0K
)
. Hence, the matrix D−11 = Diag
(
(σ1/s01)
2, . . . , (σK/s0K)
2
)
which implies that variance underestimation of say the l−th variable results in
σl/s0l > 1. In this case, D
−1
1 gives greater weight to the l−th variable, compared to
D1 ∝ IK , which agrees with the intuition that variables which are expected to be
less variant should receive more weight. Overestimation of the variance, on the other
hand, leads to σl/sl < 1 and thus smaller l−weight, which also seems appropriate
intuitively, since variables expected to be more variant should receive less weight.
This example illustrates that the consequences of D1 6∝ IK or equivalently
λ1 6∝ 1K on power are double-edged. That is, compared to the situation of λ1 ∝ 1K ,
the distance of w˜t+j
to optimal can be larger but also smaller depending on how
close the direction of λ1 is to the optimal direction c
∗. The former situation arises
in situations where, compared with λ1 ∝ 1K , the prior estimate S0 gets w˜z+j more
distant to the optimal (for instance variance underestimation of a variable which
should receive less weight) and the latter in situations where S0 brings w˜z+j
closer
to optimal (for instance variance underestimation of a variable which should receive
more weight).
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Figure 8.5: Power of the t+AD test versus Mahalanobis distance for various c
⋆, cz+1
,λ1.
In the left panel, the vectors c⋆ = cz+1
∝ 1K while in the right panel c⋆ = e1 =
(1, 0, . . . , 0)T and cz+1
∝ 1K which, for λ1 = 1K , give φ = ang(c⋆,Λ−11 cz+1 ) =
ang(c⋆,λ−11 ) = 0
◦ and 72◦, respectively. In both panels, λ1 6∝ 1K are also chosen
to give φ = 25◦, 45◦ and 65◦ (as indicated in the legend). The remaining design
parameters are J = 2, K = 10, α = 0.05, α1,1 = 0.01, α0,1 = 1, nT = 20, r1 = 0.5,
n0 = 0.75n1, ν0 = n0 − 1.
Both situations are illustrated by respectively the left and right panel in
figure 8.5. In the left panel, λ1 ∝ 1K has the same direction with c∗ ∝ 1K and thus
gives higher power than more distant λ1 to c
∗, while in the right panel λ1 ∝ 1K
has direction distant to the direction of c∗ and thus λ1 closer to c∗ can attain
substantially greater power.
It is useful to note that throughout our simulations of t+AD test, the angle
φt+1
= ang(ω˜+, w˜t+1
) is proved to be a robust summary of the angular distance
between the model parameters and their prior estimates. This is not very surprising
because it is a sufficient summary for the first stage power and a good indicator,
albeit not sufficient (see figure 8.6), for the power of subsequent stages.
For the above reasons, but also to reduce complexity, in the comparisons to
follow, we focus on the case of λ1 ∝ 1K for various values of φt+1 . Note that, as we
explain later on, in the simulations presented in the next section the case of λ1 ∝ 1K
resembles the case on the right panel of figure 8.5.
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Figure 8.6: Power of the t+AD test versus Mahalanobis distance for various c
⋆, cz+1
,λ1.
The vector c⋆ = e1 and cz+1
is chosen to give φ = ang(c⋆, cz+1
) = 10◦, 45◦ and 80◦
(as indicated in the legend), while for all values of φ, λ1 is chosen to give the same
φt+1
= ang(c⋆,Λ−11 cz+1 ) = 45
◦. The remaining design parameters are J = 2, K = 10,
α = 0.05, α1,1 = 0.01, α0,1 = 1, nT = 20, r1 = 0.5 and n0 = 0.75n1, ν0 = n0 − 1.
8.3 Comparisons
In this section, we compare various global tests in terms of power performance. We
first compare the tests for Σ known using various illustrations.
In figure 8.7, we present the single-stage z, z+ and χ2 tests. Here, the prior
sample size n0 = 10 (n0 ≈ 0.75n1) which allows the prior estimates to be influential
but not dominating of the pilot estimates. The z+ loses power compared to the z
test for small angles φw = φz+1
(as in (8.1) and (8.2) page 119), mainly due to the
use of the first stage sample only for selecting the weighting vector. On the other
hand, the use of the pilot data to modify the weighting vector at the interim analysis
results in a substantial power gain for φw = φz+1
close to 90◦. Importantly, the z+
test, in contrast to z, can achieve high power levels for sufficient values of nT and/or
∆, even if w˜z+1
is orthogonal to optimal. This property of z+ acts as a benchmark
for the case the unknown direction of ω˜∗ is unexpectedly distant to the anticipated
direction. The χ2 test attains power around the levels of z+ for φz+1
= 45◦.
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Figure 8.7: Power versus Mahalanobis distance ∆ for the χ2, z and z+ tests, the
latter with various angles (as indicated) of the weighting vectors w˜z+1
= w˜ to the
optimal. Here α = 0.05, α0,1 = 1, α1,1 = 0.0085 (DWT = 0.1, CWT = 1.994),
n0 = 10, r1 = 0.25 and nT = 25.
The loss of power in z+ for small angles to the optimal, due to the zero α
spending to the first stage, is reduced with the adaptive z+AD test. On the other
hand, for very large angles, the adaptive z+AD loses small levels of power compared
to z+, due to the spending of α rate to the first stage where little power is attained.
The differences between z+AD and z
+ are smaller for r = 0.25 (see first row figure
8.8), but they increase considerably for r1 = 0.5 (see second row figure 8.8), as the
amount of sample allocated to the first stage is larger. Further, the z+AD permits for
early stopping and thus it has lower expected sample size than the total sample size
used (by construction) in z+.
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Figure 8.8: Power versus Mahalanobis distance ∆ for z+ and z+AD tests and angles
(as indicated in the legend) of the weighting vectors w˜z+1
. Here α = 0.05, α0,1 = 1,
α1,1 = 0.0085 (DWT = 0.1, CWT = 1.994), n0 = 10, r1 = 0.25 (first row), r1 = 0.25
(second row) and nT = 25.
Similarly to the single-stage tests, as shown in figure 8.9, the adaptive z+AD,
compared to zGS , loses power for small angles φw = φz+1
of the first stage weighting
vector to the optimal. This is due to the adaptation of the weighting vector, which
may increase slightly the angle to optimality, due to sampling error, but also due to
the use of adaptive combination tests which are less efficient than the group sequen-
tial tests. On the other hand, z+AD attains large power levels for any first weighting
vector, even if the latter is orthogonal to the optimal, due to the interim adaptation
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which can correct incorrect prior estimates. This is a substantial benchmark to
ensure that, even in the worst case scenario, sufficient power can be attained in any
situation for large enough effect and/or sample sizes.
The group sequential χ2GS tests is approximately equal to the power of the
z+AD test for φz+1
around 45◦. Furthermore, as we can see in table 8.5, the χ2GS test
has RSSR also close to the RSSR values of zGS/z
+
AD tests with φw = φz+1
= 45◦.
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Figure 8.9: Power versus Mahalanobis distance ∆ for various tests and angles of the
weighting vectors w˜z+1
= w˜. Here α = 0.05, α0,1 = 1, α1,1 = 0.0085 (DWT = 0.1,
CWT = 1.994), n0 = 10, r1 = 0.5 and nT = 25.
The fully multivariate χ2 and χ2GS heavily rely on the assumption that Σ is
known. For Σ unknown, the counterparts of χ2 and χ2GS, Hotelling’s T
2 and T 2GS
tests are greatly affected by the lack of knowledge of Σ, especially for small sample
sizes. As we can see in table 8.6, for nT ≤ K = 10 or nT slightly larger than K,
T 2 is respectively inapplicable or very inefficient with power levels lower than the
power of t+ even for angles close to orthogonal.
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Table 8.5: RSSR versus Mahalanobis distance ∆ for the χ2GS and the linear com-
bination zGS and z
+
AD tests, the latter with various angles of the weighting vectors
w˜z+1
= w˜. Here α = 0.05, α0,1 = 1, α1,1 = 0.0085 (DWT = 0.1, CWT = 1.994),
K = 10, n0 = 10, r1 = 0.5 and nT = 25.
∆ 0 0.3 0.6 0.9 1.2 1.5
χ2GS 0.45 0.94 4.38 15.31 31.90 44.61
zGS ,z
+
AD 90
◦ 0.46 0.38 0.48 0.49 0.44 0.27
45◦ 0.50 1.46 6.83 17.57 32.16 42.16
0◦ 0.45 3.01 15.87 34.66 46.00 47.84
Table 8.6: Power versus total sample size nT for the T
2
GS and the linear combination
tGS and t
+
AD tests, the latter with various angles of the weighting vectors w˜z+1
= w˜
to the optimal. Here α = 0.05, α0,1 = 1, α1,1 = 0.0154 (DWT = 0.25, CWT = 2.038),
r1 = 0.25 and ∆ = 1.
nT 10 15 20 25 30 60
T 2 - 0.25 0.53 0.75 0.89 1.00
t 90◦ 0.05 0.05 0.05 0.05 0.05 0.05
45◦ 0.51 0.72 0.85 0.92 0.96 1.00
0◦ 0.80 0.95 0.99 1.00 1.00 1.00
t+ 90◦ 0.11 0.19 0.28 0.37 0.48 0.86
45◦ 0.36 0.56 0.72 0.84 0.90 1.00
0◦ 0.51 0.74 0.87 0.95 0.97 1.00
The group sequential T 2GS is not applicable even for 2nT < K, while, as we
can see in table 8.7, it has power close to the power of linear combination tests of
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large angles (larger than 45◦), even for nT = 30. As sample size becomes consider-
ably bigger than K, the power of T 2 and T 2GS test increases sharply to yield power
levels analogous to the χ2 and χ2GS tests, that is β and RSSR close to t
+/t+AD with
φt+1
= 45◦.
Table 8.7: Power versus total sample size nT for the T
2
GS and the linear combination
tGS and t
+
AD tests, the latter with various angles of the weighting vectors w˜z+1
= w˜
to the optimal. Here α = 0.05, α0,1 = 1, α1,1 = 0.0154 (DWT = 0.25, CWT = 2.038),
r1 = 0.5 and ∆ = 1.
nT 10 15 20 25 30 60
T 2GS - - - 0.73 0.88 1.00
tGS 90
◦ 0.05 0.05 0.05 0.05 0.05 0.05
45◦ 0.49 0.70 0.84 0.91 0.96 1.00
0◦ 0.79 0.94 0.99 1.00 1.00 1.00
t+AD n0 = 1.25n1 90
◦ 0.08 0.12 0.19 0.26 0.33 0.73
45◦ 0.34 0.59 0.77 0.89 0.95 1.00
0◦ 0.55 0.81 0.93 0.98 0.99 1.00
Considering the t+ and t+AD test, it is useful to note here that in the results
presented in this section we consider the case where theΣ−deviation matrixD1 = I
which, using the results of theorem 7.4.2 (see page 115), it can be studied in a similar
way to the case of known Σ. That is, based on ∆ and the angle between the selected
and the optimal weighting vector, φt+1
= φz+1
. For the results in tables 8.6, 8.7 and
8.8, the case of D1 = I can be thought of as representative of λ
−1
1 fairly distant to
c∗ (right panel of figure 8.5), since we take c∗ = e1 resulting in ang(c∗,λ−11 ) = 71
◦,
for K = 10.
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In terms of power performance, first note that the power of the linear com-
bination t, t+ and t+AD tests are also lower than their counterparts z tests (same
design parameters), but not to the extend of the T 2 tests. Moreover, the patterns of
power difference across these tests remain the same. That is, the t+ and t+AD tests
have lower power than t and tGS tests for small angles of the weighting vector to
the optimal, but gain substantial amounts of power for large angles.
Finally, as we can see in table 8.8, for small sample sizes, the T 2GS, if ap-
plicable, attains similar values of RSSR to linear combination tests with weighting
vectors nearly orthogonal to the optimal, but as the sample size becomes substan-
tially larger than K, the values of RSSR of the T 2GS are similar to those of linear
combination tests with much smaller angles to the optimal. Specifically, analogous
results to the χ2 tests are attained.
Table 8.8: RSSR versus total sample size nT for the T
2
GS and the linear combination
tGS and t
+
AD tests, the latter with various angles of the weighting vectors w˜z+1
= w˜
to the optimal. Here α = 0.05, α0,1 = 1, α1,1 = 0.0154 (DWT = 0.25, CWT = 2.038),
r1 = 0.5 and ∆ = 1.
nT 10 15 20 25 30 60
T 2GS - - - 2.33 4.96 36.53
tGS ,t
+
AD 90
◦ 0.72 0.65 0.81 0.70 0.83 0.78
45◦ 4.50 9.52 14.81 20.52 25.59 44.76
0◦ 9.00 20.07 29.40 36.87 42.49 49.85
8.4 Application to neuroimaging studies
In this section, we consider application of various global tests to the neuroimaging
studies introduced in sections 2.3.2 and 2.4.2 (see pp. 15, 20). As we have discussed
earlier, the investigators of both the fMRI and EEG study were interested in evalu-
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ating the null hypothesis of no treatment effect across various locations of the brain.
The tests that we consider here are suitable for the assessment of this global null
hypothesis. Specifically, we apply the Bonferroni global test, Hotelling’s T 2 test,
O’Brien’s OLS t test, La¨uter SS and PC t tests and the t+ and t+AD tests.
Our main target is to assess the performance of these tests in the settings of
these applications. For this, we set the design parameters, α and n, equal to those
of each study and the model parameters, µ and Σ, equal to their sample estimates
extracted from the data of each study. It might be useful to note here that these
studies are performed under a single-stage design. Thus, we set the total sample
size of adaptive tests equal to the sample size of the study, while suitable allocations
of the sample and α rate to the different stages are selected as described in the next
sections. The power of the above tests is derived by simulated replications of the
experiment under the selected parameter values.
8.4.1 Application to the fMRI study
The fMRI study as introduced in section 2.3.2 (page 15) was conducted for drug
development purposes using nT = 13 subjects.
As we have seen in table 2.2 (see page 17), effect sizes differ across ROI
and generally high correlations are observed. The local effects are relatively small,
resulting in low power βBON = 0.19 for the Bonferroni global test. Despite the small
local effects, the Mahalanobis distance ∆ = 2.7657 is relatively large suggesting
strong global effects. Hotelling’s T 2 test has larger, but still relatively low, power,
βT 2 = 0.40, which can be attributed to the sample size being very close to the
number of ROI.
The power of the optimal single-stage linear combination t test has power
βt∗ = 1.00. This suggests that a linear combination test, where the search for effects
is targeted in a specific direction, rather than the whole 11−dimensional space as
in T 2, can attain large power levels. O’Brien’s OLS t test and La¨uter’s SS and PC
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tests, which target on the uniform direction 1K , have very low power βOLS = 0.14,
βSS = 0.13, βPC = 0.14. The reason is that the uniform direction is very distant
to the optimal with angle φw = 84.63
◦. In other words, the low power values are a
result of searching for effects in a direction very distant to the effect direction.
Higher power levels can be obtained if the weighting vector is chosen to be
closer to the optimal. For this, the t+ and t+AD permits the use of prior information
and interim data. We next consider three scenarios with various prior information
being available at the planning stage. Here, two-stage t+AD tests are considered with
critical values set equal to α1,1 = 0.01, α1,0 = 1 and α2,1 = 0.0087 (α = 0.05).
The first scenario considers the case where no prior information is available
and the investigators use the uniform weighting vector at the first stage. That is,
the prior mean estimate is m0 = 1K and the prior covariance matrix estimate S0
has equal variances s0 = 1 and correlations r0 = 0.7, which result in angle of the
first stage weighting vector, w˜t+1
, to the optimal φt+1
= 84.63◦ = φ1K . The prior
sample sizes are set n0 = ν0 = 1, while the sample allocation r1 = 0.5. For these
values, the t+ and t+AD result in a small increase to the power of the OLS, SS and
PC tests, βt+ = 0.26, βt+AD
= 0.23, explained by the decrease in the distance of w˜t+2
,
to the optimal (see figure 8.10) due to the interim adaptation. Despite the small
increase, the latter power values are still very low implying a large chance of type
II error.
The second scenario considers a more informative choice of prior estimates.
This is perhaps more realistic than the first scenario, since most often in neuroimag-
ing studies there is some prior information available about the direction of the effect.
For instance, the knowledge of the ROI to be considered in the study can be use-
ful in prior elicitation. There is substantial work in fMRI and other neuroimaging
modalities about connectivity between ROI (see for example Alexander-Bloch et al.
[2013]) and how to construct correlation matrices based on such results. Another
way to construct correlation matrices is based on the location of ROI. The essence
142
of this method is that ROI which are at closer, in physical distance, locations are
more highly correlated.
Here, we consider a prior covariance estimate constructed using the following
simple model [Ripley, 1981; Worsley et al., 1991]
s0,kk′ = s
2
0 exp(−cdkk′), k, k′ = 1, 2, . . . ,K, (8.4)
with s20 = 1 and c = 0.002 and dkk′ the Euclidean distance between the centroids
of k− and k′−th ROI given in table 8.9. Note that for (bilateral) ROI with left
and right areas, the ROI centroids with the smaller distance (nearest centroids) are
used.
For prior covariance matrix as above and m0 = 1K (n0 = 0, ν0 = 4), the
angle of the first stage weighting vector to the optimal φz∗1 = 84.82
◦ does not change
substantially, compared to the uniform weighting vector, but the improvement of
the direction of the angle due to the interim data is greater (see figure 8.10), which
results in an increase of the power of the t+ and t+AD tests, βt+ = 0.39, βt+AD
= 0.32.
Further power increase can be obtained, by using the available information about the
connectivity between the above regions, but also the nature of the study which can
reveal information about the mean structure. For instance, investigators are often
able to predict which regions can potentially give larger effects based on the nature
of the cognitive task (for example motor task, visual task) given to the subjects
during the scan.
In our third hypothetical scenario, we consider the case where prior infor-
mation suggests the same correlation matrix, but slightly lower activity in the ROI:
AC, GP, T, VS. That is, S0 is same as in the second scenario (ν0 = 4) and the prior
mean estimate m0 = (0.5, 1, 1, 1, 0.5, 1, 1, 1, 0.5, 0.25, 1)
T (n0 = 7). This decreases
the angle φt+1
and slightly the location of the distribution of the angles φt+2
(see
figure 8.10) resulting in a substantial power increase in the first stage of the study,
143
which gives βt+ = 0.42 and βt+AD
= 0.81.
These hypothetical scenarios attempt to describe various settings that are
likely to arise in fMRI studies. In the EEG study considered next, where more
information about the study is available, a more realistic application of our tests is
performed.
Table 8.9: Locations of the ROI centroids of the fMRI study.
ROI x y z
Anterior Cingulate 0.715 19.183 24.387
Amygdala Left -23.039 -4.776 -18.399
Right 23.328 -3.493 -18.399
Caudate Left -12.796 8.697 10.083
Right 13.502 9.555 10.605
DLPFC 0.298 19.685 54.732
Globus Pallidus Left -19.139 -5.314 -1.331
Right 19.854 -4.367 -1.346
Insular Cortex 0.921 2.258 -0.147
Orbitofrontal Cortex -1.289 23.936 -16.046
Putamen Left -24.961 0.365 0.546
Right 25.613 1.601 0.374
Substantia Nigra 9.000 -18.000 -13.000
Thalamus Left -10.200 -19.141 6.541
Right 11.313 -18.126 6.870
Ventral Striatum Left -9.690 11.850 -6.952
Right 9.597 12.678 -6.444
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Figure 8.10: Box-plots of the distribution of the angles, φt+2
, of the second stage
weighting vector, w˜t+2
, to the optimal ω˜∗ at the three considered scenarios and the
angle, φt+1
, of the first stage weighting vector, w˜t+1
, to the optimal.
8.4.2 Application to the EEG study
As we have seen in section 2.4.2 (page 20), the EEG data provided in La¨uter et al.
[1996] represent the differences in the absolute theta power between the recordings
at the beginning and at the end of a six week therapy given to nT = 19 depressive
patients. The K = 9 channels presented in figure 2.5 (page 20) were used.
Similarly to the previous section, we perform power analysis by setting the
design parameters as in the above study, i.e. K = 9, nT = 19, α = 0.05 and the
model parameters equal to their sample estimates µ = x¯, Σ = Sx given in table 2.3
(page 21).
The Bonferroni global test, despite the increase in theta power of all channels,
has low power βBON = 0.38, suggesting small local effects. On the other hand, the
relatively large value of the Mahalanobis distance, ∆ = 1.15, suggests strong global
effects. Hotelling’s T 2 test attains power βT 2 = 0.68, mainly limited by the sample
size nT being relatively close to the number of channels.
Taking into account that the single-stage t test for weighting vector equal to
the optimal has power βt⋆ = 0.9973 we can easily understand that, similarly to the
fMRI study, there is great scope for improvement, using linear combination tests.
However, O’Brien’s OLS and La¨uter’s SS and PC t tests take (very similar) low
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power values, βtOLS = 0.52, βtSS = 0.52, βtPC = 0.51. Here, the uniform weighting
vector of the OLS test, wOLS ∝ 1K , gives angle φw ≈ 71◦ to the optimal.
Since the study was performed, there has been considerable research into
EEG studies on depressive patients. There is now literature (see for example David-
son et al. [2002]; Stewart et al. [2011]) indicating that left-frontal hypoactivation
and right-frontal hyperactivation are present in such subjects. This would indicate
that a non-uniform prior over these frontal regions should be used. Using prior
information based on such evidence, the adaptive t+AD test can attain high power
levels.
For example, the prior estimates given in table 8.10 are in agreement with
the evidence in the literature and further, the prior correlation structure is set to
be roughly coherent to the distances between the channels, that is larger distances
have smaller correlations, with larger correlations set at the highly active frontal
regions (in accordance with the literature, see for example Lopes da Silva [2005]).
Table 8.10: Prior estimates of the means, standard deviations and correlations for
the EEG depression study.
ch.(k) 3 4 5 6 7 8 17 18 19
m0,k 0.5 3.5 1 2 2 2 2 2 2
s0,k 1.5 2.5 1 2 2 2 2 2 2
r0,(3,k) 1
r0,(4,k) 0.8 1
r0,(5,k) 0.8 0.7 1
r0,(6,k) 0.7 0.8 0.7 1
r0,(7,k) 0.5 0.4 0.7 0.55 1
r0,(8,k) 0.4 0.5 0.55 0.7 0.6 1
r0,(17,k) 0.9 0.9 0.75 0.75 0.45 0.45 1
r0,(18,k) 0.45 0.45 0.65 0.65 0.7 0.7 0.5 1
r0,(19,k) 0.75 0.75 0.8 0.8 0.65 0.65 0.8 0.7 1
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This prior estimate gives φt+1
= 37.27◦ which is much smaller than the angle
under the uniform weighting vector. For a two-stage design (J = 2), with balanced
sample allocation, n1 = 10, n2 = 9, and α allocation α1,1 = 0.01, α2,1 = 0.0087, no
early acceptance allowed, α0,1 = 1, prior sample size n0 = 7 = 0.7n1, ν0 = 6 and the
remaining design parameters as the original study, the t+AD test has power βt+AD
=
0.84 with RSSR = 22.3% (E(n) = 15). The t+ test, for n0 = 6, n1 = 6, n2 = 13
(r = 0.3) and the remaining design parameters as above, has power βt+ = 0.64.
8.5 Discussion
In this chapter, we consider an extensive power analysis of various global tests,
mainly focusing on the z+, t+ and adaptive z+AD, t
+
AD tests. In this we used the
results of earlier chapters which allowed for relatively simple power analysis, despite
the great complexities of multivariate tests.
A number of important outcomes are derived. The study of the relation of
power to the sample and effect size confirms that z+, t+, z+AD, t
+
AD tests attain high
power levels for any direction of the first stage weighting vector. Furthermore, our
results indicate that balanced allocations of sample and α rate to the different stages
of group sequential and adaptive designs are, in typical settings, more appropriate.
The results of the impact of unknown Σ to the power of t+AD tests, reveals a few
useful results about the behavior of this test, including that, for power analysis, it is
often sufficient to study the special case of the first stage Σ−deviation matrix being
proportional to the identity matrix.
The comparison of various global tests show that the z+, t+ and adaptive
z+AD, t
+
AD, in a similar way to the fully multivariate χ
2 and T 2 tests, can obtain
high power levels for large enough sample or effect sizes, but they are particularly
useful for small sample sizes, where the latter tests are inapplicable or inefficient.
They lose in power compared to the linear combination z, t and zGS and tGS tests,
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with fixed weighting vector, if the latter are close to the optimal, but they gain
substantial power for distant to optimal weighting vectors.
Finally, the application to neuroimaging studies shows that the properties of
this setting necessitate special consideration in global testing. The typically small
and highly correlated local effects often make the Bonferroni global test inappro-
priate. Moreover, the small sample sizes do not permit the Hotelling’s T 2 test to
achieve high power levels. The developed linear combination tests can improve the
power performance of these classical tests if prior knowledge and observed data set
the targeted direction fairly close to the effect direction.
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Chapter 9
Conclusions and future work
This thesis is devoted to the study of global testing procedures and particularly
linear combination tests within the framework of single stage, group sequential and
adaptive designs.
This work is motivated by the application of global testing in neuroimaging
studies as introduced in chapter 2. Here, we discussed and illustrated through real
examples, the demand for specialized statistical methodology taking into consider-
ation some important characteristics typically observed in this field. First, neural
measures of various brain locations are often highly correlated. Secondly, the treat-
ment effects, if any, are commonly expressed in a dispersed fashion in the sense that
they are locally small but, if combined, globally large. Thirdly, due to the great
amount of literature in the field, the nature of the studies and the spatial charac-
terization of the responses, prior information about the study is typically available.
Finally, due to the high cost of the equipment and the need for trained individuals to
run these studies, sample sizes are typically restricted to small levels. These sample
sizes remain close to the observations’ dimension even if the latter is reduced using
methods such as ROI analysis for fMRI data and frequency analysis for EEG data.
Global hypotheses regarding the treatment effects across various brain loca-
tions are fundamental for neuroimaging studies. In chapter 3, we introduced the
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main available approaches for global testing. We first discussed p−value adjust-
ment methods, which are typically related to multiple testing methods such as the
Bonferroni correction. We saw that these methods are typically simple and do not
require strong modeling assumptions, but they target settings where one or some
few independent local effects are present. In situations, such as our neuroimaging
example studies, where correlations between the responses are relatively high and
the effects are dispersed, these methods become inefficient and multivariate global
tests are more appropriate. This is particularly the case when the multiple outcomes
are biologically related, as in neuroimaging studies.
The fully multivariate χ2 and Hotelling’s T 2 tests were then discussed. We
showed that these methods are efficient for sample sizes, n, substantially larger than
the observation dimension, K, but the χ2 test heavily relies on the knowledge of
the covariance structure and Hotelling’s T 2 becomes respectively inapplicable and
inefficient if n is respectively smaller or larger but close to K. We underlined that
this loss of efficiency, also shown in our application examples, is due to the search for
effects in every direction of the multivariate space and we argue that this loss can be
avoided if prior information about the direction of the effect is available. This can
be practically implemented by linear combination tests where the targeted direction
is selected using the weighting vector. The latter reduces the observation vectors to
scalar linear combinations which are then used to construct z and t test statistics.
The available approaches for linear combination testing were discussed, including
their shortcoming of requiring specific effect structures, such as the uniform, to
attain high power performance.
Taking into consideration the properties of neuroimaging studies and that
the available global testing methodology is often not able to accommodate them, in
chapter 4, we developed the predictive-power-optimal linear combination z+ and t+
tests. We first derived the power-optimal z∗ and t∗ tests maximizing the power of
linear combination z and t tests (for fixed values of the modeling parameters) with
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respect to the weighting vector w. This allowed us to derive some results related to
existing methodology, including the cases where O’Brien’s tests are power-optimal
and a comparison of t∗ with Hotelling’s T 2 test. In the latter, we proved that the
power of the t∗ is always larger than the power of T 2 test. A comparison of the
power of the two tests, reveals the great potential of linear combination tests to
improve power performance over T 2, especially when n is close to K.
As the z∗ and t∗ tests are performed using the optimal but unknown weight-
ing vector ω∗, methodology to obtain the weighting vector using prior information
and pilot data was proposed. The resulting z+ and t+ tests are optimal, within the
class of linear combination tests, with respect to predictive power given the available
information. The z+ and t+ tests, which are analytically proved to control type I
error, satisfy our requirements for application to neuroimaging studies. Firstly, they
incorporate correlations into the multivariate normality assumption which allows us
to capture globally large but dispersed effects. Secondly, they provide a framework
for formally incorporating prior information about the effect structure in selecting
the targeted direction and thirdly, as it becomes more clear in power analysis, they
are appropriate for small sample sizes.
The use of preliminary data obtained from an early pilot study allows for
potentially correcting imprecise directions of the weighting vector, particularly if
the latter is nearly orthogonal to the effect direction. In chapter 5, we introduced
the framework of adaptive designs which allows us to replace this external pilot
study, with an internal pilot study which is then considered as the first stage of a
two-stage or, generally, multi-stage adaptive testing procedure. We discussed how
the concepts of monitoring data acquisition with the possibility for early termination
and interim design modifications give rise to sequential and adaptive designs and
we introduced methodology for performing group sequential and adaptive testing.
Chapter 5 closes with a discussion about the potential and challenges to be overcome
from these designs and particularly adaptive designs. We argued that great effort
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for careful planning should be made in adaptive designs to acquire relevant prior
information to be used in planning the study. We also disputed that, not only
flexibility and type I error control, but also power performance should be targeted
and carefully studied when using adaptive designs. Optimal pre-specified adaptation
rules can be important towards this direction.
In chapter 6, the methodology of adaptive designs was used to perform global
testing. The adaptive J−stage (J ≥ 2) linear combination z+AD and t+AD tests
sequentially adapt the weighting vectors, initially selected using prior information,
based on the information available at each interim analysis. The adaptation rule is
optimal in terms of the predictive power given the results available at each interim
point.
The developed tests, which are analytically proved to control type I error,
have similar properties to z+ and t+, including those related to the application
to neuroimaging studies, but they allow some important additional possibilities.
Firstly, they can be implemented as a multi-stage test with the option of early
stopping in settings where such procedures are considered as more appropriate.
Secondly, the first stage data is not only used for selecting the weighting vector,
which in settings with small sample sizes might be considered as inappropriate, but
also as observations used for testing. This can also be potentially beneficial in terms
of power performance especially in cases where the prior estimates set the targeted
direction relatively close to the effect direction.
In chapter 7, a characterisation of the power function of linear combination
tests was derived. This was useful to understand the behaviour of linear com-
bination tests and explore their power performance by reducing their potentially
high-dimensional design space to a lower dimensional space described by easily in-
terpretable summary measures. In particular, these results showed that the power
of linear combination tests is determined by two measures. The first is the strength
of the treatment effect described by the well-known scalar Mahalanobis distance.
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The second is the distance between the effect direction and the targeted direction,
determined by the weighting vector. For the single-stage z, t and group sequential
zGS and tGS linear combination tests with fixed weighting vectors as well as the z
+
and adaptive z+AD this distance is measured by a scalar measure, the angle of the
selected weighting vector to the optimal. For the t+ and t+AD tests, this distance is
more complex, but methods have been developed which improve our understanding
to the behavior of these tests and reduce substantially the dimension to be consid-
ered in their power analysis.
The results of this power characterisation are used to perform power analysis
of linear combination tests, the main results of which were presented in chapter 8.
Here we studied the power performance of z+, t+ and the adaptive z+AD and t
+
AD
tests as well as the single-stage z, t and χ2, T 2 tests and their group sequential
counterparts zGS , tGS and χ
2
GS , T
2
GS tests. These empirical studies showed that
the above tests attain power 1 for large sample sizes and/or large effect sizes, with
exception to the z, t, zGS and tGS tests with weighting vector fixed orthogonal to
the optimal in which case power is equal to the significance level, α. Furthermore,
the results implied that balanced allocations of the sample size and the α rate to the
different stages of multi-stage tests are, in most cases, more appropriate regarding
power and average sample size.
In terms of comparisons, the z, t and zGS , tGS gain considerable amount of
power compared to z+, t+, z+AD, t
+
AD tests for weighting vectors very close to the
optimal. However, for such small angles the latter tests also achieve good power
performance, while the interim re-assessment of the weighting vector in the latter
tests can substantially reduce large angles of the initial weighting vector to the
optimal. High power levels can therefore be potentially attained with z+, t+, z+AD
and t+AD even if the initial weighting vector is orthogonal to the optimal. The fully
multivariate χ2 and χ2GS tests attain relatively high power levels (in our simulations
close to the power of z+, z+AD with initial weighting vector around 45
◦ from optimal).
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Similar levels are also attained by the T 2 and T 2GS tests for large sample sizes, but for
sample sizes close to the observation dimension their power performance is greatly
affected, taking values close to the t+ and t+AD tests with nearly orthogonal angles
of the initial weighting vector to the optimal.
The application to the real examples of the fMRI drug development study
and the EEG depression study illustrated situations where the existing methodology
for global tests cannot provide acceptable power performance for various different
reasons. It also showed that the developed linear combination tests can provide good
power performance under some conditions. For the small sample sizes presented in
these examples, the selection of the weighting vector is greatly affected by the prior
estimates. However, our application shows that, if prior information is available (a
situation which is not rare in neuroimaging studies), sufficient power levels can be
attained with t+ and especially with the adaptive t+AD test.
While the work presented in the thesis satisfies some of the targets of global
testing, especially within the motivational neuroimaging setting, plenty of questions,
generalisations and extensions remain to be explored. In the following, some of these
areas of future research are discussed.
9.1 Future work
The methodology developed in this thesis, but also, generally, the best part of
existing global testing methodology, is based on the assumption of multivariate
normality. As we discussed in section 3.3 (see page 30), there are various reasons why
this assumption is central in multivariate statistics (for example, the Central Limit
Theorem). Furthermore, normality is the dominant assumption in neuroimaging and
specifically fMRI and EEG. However, multivariate normality in real applications is
always an approximation at best and if substantial departures from normality are
foreseen, a different set of assumptions might be more appropriate.
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Particularly, if sharper peaks than the normal distribution are foreseen, a
distribution such as the double exponential might be preferred [Mangoubi et al.,
2008]. In this case, despite the extra complexities to be encountered in calculating
the test properties, the methodology for deriving the linear combination test statistic
and particularly the weighting vector, is expected to provide similar results. On the
contrary, in situations where multi-modal or skewed distributions are anticipated
[Azzalini and DallaValle, 1996; Ferreira and Steel, 2007], a single weighting vector is
expected to not be sufficient to capture the data variability and describe the effect
direction.
In the latter situation, a generalisation of the present methodology where,
not necessarily a single, but a number of weighting vectors are selected at the interim
analyses of the J−stage adaptive test, might be necessary. Here, an optimization,
in terms of the direction, but also the number of selected weighting vectors, taking
into account data variability and generally the form of the observations’ distribution,
needs to be considered. If the optimization method is effective, these more flexible
procedures should deliver higher efficiency and robustness.
Furthermore, a substantial generalization of the proposed methodology might
be achieved by extending the search for optimal tests beyond the class of linear
combination tests to the wider class of multivariate tests. Bayesian methods and
decision theory can be useful to this end.
The developed methodology has links with hypothesis testing problems oc-
curring in multivariate change-point analysis. Multivariate change-point analysis
targets on detecting location shifts of K−dimensional time-series by testing against
stationarity [Chen and Gupta, 2012]. Similarly to the cross-sectional setting con-
sidered in this thesis, it is often preferable or essential, especially for large K, to
perform these tests by first reducing the multivariate time-series to low-dimensional
summary time-series. An extension of the present methodology may consider new
methods for performing multivariate change-point analysis based on optimal dimen-
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sion reduction operators. In settings, as in neuroimaging, where prior information
is typically available, these dimension reduction operators can be derived using this
information and accumulated data. These methods can potentially improve sub-
stantially the performance of currently available tests such as the one proposed as
part of the methodology developed in Aston and Kirch [2012].
The methods developed so far are mainly suitable for observations of mod-
erate dimension. In many important statistical applications, including genetics and
neuroimaging, the dimension of observations, if not reduced as a preparatory step,
is extremely large. Therefore, it is often preferable to treat the observations as func-
tional. Functional data analysis is particularly attractive in neuroimaging, since it
allows the neural activity of the whole brain to be naturally represented as a single
function [Aston and Kirch, 2012]. An important target of functional data analysis
is testing hypotheses regarding the mean of functional observations [Ramsay and
Silverman, 2005]. In this setting, it is often essential to construct test statistics
using low dimensional summaries of the functional observations. An extension of
the methodology presented in this thesis may explore new methods for performing
dimensionality reductions and hypothesis testing in functional data analysis.
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Appendix A
Proofs of lemma 6.3.1 and 6.3.2
for t tests
We next prove that analogous to the results, regarding the z test, described in
lemmas 6.3.1, 6.3.2 (pp. 90, 93) hold also for the t test. This leads to the proof
of lemma 6.3.3 (page 94) regarding the t test. The methods of the proofs are very
similar to above, but for clarification and to avoid confusion due to the complexity
introduced by the non-centrally t distributed test statistics, the proofs are provided
in complete form.
Proof of lemma 6.3.1 for the t test. For convenience we use in this proof the nota-
tion t˜ = xt/
√
ν1. For the first stage power we have that
dβt1
dθ1
=
∫ ∞
0
√
n1
(
φ
(
t˜ν1,α1,1/2 − θ¯1
)
− φ
(
t˜ν1,α1,1/2 + θ¯1
))
hν1(x)dx. (A.1)
The second stage power can be written as
βt2 =
∫
C+t1
βc,t2(θ2; t1)
(
ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1)
)
dt1,
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where C+t1 =
(
tν1,α0,1/2, tν1,α1,1/2
)
. Thus,
dβt2
dθ1
=
∫
C+t1
βc,t2(θ2; t1)
d
(
ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1)
)
dθ1
dt1. (A.2)
Using (4.10), we can re-write the derivative,
d
(
ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1)
)
dθ1
=
∫ ∞
0
√
n1
((
t˜1 − θ¯1
)
φ
(
t˜1 − θ¯1
)− (t˜1 + θ¯1)φ (t˜1 + θ¯1))hν1(x)dx
=
∫ ∞
0
x
√
n1√
ν1
(
e2θ¯1 t˜1 + 1
)
φ
(
t˜1 + θ¯1
) (
t˜1 tanh
(
θ¯1t˜1
)− θ¯1)hν1(x)dx. (A.3)
First note that
d tanh
(
θ¯1t˜1
)
dt1
=
4θ¯1t˜1e
2θ¯1 t˜1(
e2θ¯1 t˜1 + 1
)2 , (A.4)
which is greater or equal to zero for θ1 ≥ 0 and negative for θ1 < 0. Using the last
result, we can easily see that
d
dt1
(
t˜1 tanh
(
θ¯1t˜1
)− θ¯1)
is non-negative for θ1 ≥ 0 and negative for θ1 < 0 (t1 > 0). Thus, for θ1 ≥ 0, we
can identify the following three cases:
(1) t˜1 tanh
(
θ¯1t˜1
)− θ¯1 ≥ 0, ∀ t1 ∈ C+t1 ,
(2) t˜1 tanh
(
θ¯1t˜1
)− θ¯1 ≤ 0, ∀ t1 ∈ C+t1 ,
(3) ∃ t˙1 ∈ C+t1 : t˜1 tanh
(
θ¯1t˜1
)− θ¯1 ≤ 0, ∀ t1 ∈ (tν1,α0,12 , t˙1),
t˜1 tanh
(
θ¯1t˜1
)− θ¯1 > 0, ∀ t1 ∈ (t˙1, tν1,α1,12 ).
In case (1), by (A.3), we have that
d(ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1))
dθ1
≥ 0, ∀ t1 ∈ C+t1 .
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Therefore, by (A.2), βt2 and hence βt is non-negative for θ1 ≥ 0.
In case (2), by (A.3), we have that
d(ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1))
dθ1
≤ 0, ∀ t1 ∈ C+t1 .
The last result using (A.2) in turn implies that
dβt2
dθ1
≥ βc,t2(θ2; tν1,α1,12 )
∫ t
ν1,
α
1,1
2
t
ν1,
α
0,1
2
d
(
ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1)
)
dθ1
dt1 ≥ 0.
Therefore, using (A.1) we derive that
dβt
dθ1
≥
(
1− βc,t2
(
θ2; tν1,
α1,1
2
))
d
dθ1
(
Ψθ¯1,ν1(−tν1,α1,12 )−Ψθ¯1,ν1(tν1,
α1,1
2
)
)
+ βc,t2
(
θ2; tν1,
α
1,1
2
)
d
dθ1
(
Ψθ¯1,ν1(−tν1,α0,12 )−Ψθ¯1,ν1(tν1,α0,12 ))
)
≥ 0.
In case (3), by (A.3), we have that
d(ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1))
dθ1
≤ 0, ∀ t1 ∈ (tν1,α0,12 , t˙1)
d(ψθ¯1,ν1(t1) + ψθ¯1,ν1(−t1))
dθ1
> 0, ∀ t1 ∈ (t˙1, tν1,α1,12 ).
Thus, using (A.2), we derive that
dβt2(θ1)
dθ1
≥ βc,t2(θ2; t˙1)
∫ t˙1
t
ν1,
α0,1
2
d(ψν1(t1; θ1) + ψν1(−t1; θ1))
dθ1
dt1
+ βc,t2(θ2; t˙1)
∫ t
ν1,
α1,1
2
t˙1
d(ψν1(t1; θ1) + ψν1(−t1; θ1))
dθ1
dt1 ≥ 0.
Hence, using (A.1), we have that
dβt(θ1)
dθ1
≥ (1− βc,t2(θ2; t˙1)) ddθ1
(
Ψν1(−tν1,α1,12 ; θ1)−Ψν1(tν1,
α1,1
2
; θ1)
)
+ βc,t2
(
θ2; t˙1
) d
dθ1
(
Ψν1(−tν1,α0,12 ; θ1)−Ψν1(tν1,α0,12 ; θ1))
)
≥ 0.
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In all three possible cases the power, βt, of the two-stage t test is non-decreasing in
θ1 for θ1 ≥ 0. Similarly, we can prove that βt is decreasing in θ1 for θ1 < 0 and the
result follows.
Proof of lemma 6.3.2 for the t test. The second stage power, βt2 , can be written as
βt2 =
∫
Ct1
βc,t2(θ2; t1)ψθ¯1,ν1(t1)dt1,
where Ct1 =
(
−tν1,α1,1/2,−tν1,α0,1/2
)
∪
(
tν1,α0,1/2, tν1,α1,1/2
)
and the second stage
conditional power
βc,t2(θ2; t1)=Pr
(
|t2| ≥ t
ν2,
α′1,2
2
| pt1
)
=1−Ψθ¯2,ν2
(
t
ν2,
α′1,2
2
)
+Ψθ¯2,ν2
(
−t
ν2,
α′1,2
2
)
.
Using equation (4.10) we derive that
dβc,t2(θ2; t1)
dθ2
=
∫ ∞
0
√
n2
(
φ
(xtν2,α′1,2/2√
ν2
− θ¯2
)
− φ
(xtν2,α′1,2/2√
ν2
+ θ¯2
))
hν2(x)dx,
which is non-negative for θ2 ≥ 0 and negative for θ2 < 0. Therefore, the conditional
power βc,t2 and hence the power of the two-stage t test is non-decreasing in |θ2|.
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